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Table of Abbreviations 
95% CI = 95% confidence interval of the population estimate 
2LL = 2 log likelihood   
AERP = atrial effective refractory period 
AF = atrial fibrillation 
AFCL = atrial fibrillation cycle length 
AFCL4CH = atrial fibrillation cycle length measured in the left atrial free wall from 
the four chamber view 
AFCLRA = atrial fibrillation cycle length from the right atrial dorsal wall at the 
level of the tuberculum intervenosum in a right parasternal view 
AFCLLLA = atrial fibrillation cycle length measured in the left atrial free wall from 
the left parasternal long-axis view 
AIC = Akaike information criterion 
APD = atrial premature depolarization 
APD90 = monophasic action potential at 90% repolarization 
AUC = area under the curve 
AVB = atrioventricular block 
AVB2 = second degree atrioventricular block 
BIC = Bayesian information criterion  
Bid = two times daily 
BPM = beats per minute 
BW = body weight 
Bwt = body weight 
Cl = clearance 
Cmax = maximal plasma concentration 
Cpss = plasma concentration at steady state 
Cpss av = average plasma concentration at steady state 
Cpss max = maximal plasma concentration at steady state 
Cpss min = minimal plasma concentration at steady state 
CV = coefficient of variation 
ECG = electrocardiogram 





ERP = effective refractory period 
F = oral bioavailability 
FFT = fast Fourier transform 
FOCE-ELS = first-order conditional estimation with extended least squares 
FS = fractional shortening 
HF = high frequency band 
HR = heart rate 
HRM = heart rate monitor 
HRV = heart rate variability 
IV =  intravenous 
Ikr = rapid component of the delayed rectifier potassium current 
LC = liquid chromatographic 
LF = low frequency band 
LOD = limit of detection 
LOQ = limit of quantification 
LS = Lomb-Scargle perdiodogram 
LVET  =  left ventricular ejection time 
LVPEP =  left ventricular pre-ejection period 
LVIDd = left ventricular internal diameter at end-diastole 
LVIDs = left ventricular internal diameter at end-systole 
ka = absorption rate constant 
kelα = distribution rate constant 
kelβ = elimination rate constant 
MAP = monophasic action potential 
MS/MS = mass spectrometric system 
NIBP = non-invasive blood pressure 
PCL = pacing cycle length 
PK = pharmacokinetic 
PO = per os 
OR = odds ratio 
QTc = corrected QT interval 
RA = right atrium 
RMSSD = root mean squared successive differences in RR intervals 
 
 
ROC = receiver operating characteristics curve 
RV = right ventricle 
SA node = sinoatrial node 
SD = standard deviation 
SD1 = standard deviation of the Poincaré plot of the RR intervals perpendicular to 
its line of identity 
SD2 = standard deviation of the Poincaré plot of the RR intervals along its line of 
identity 
SDNN = standard deviation of the RR intervals 
SR = sinus rhythm 
SVPD = supraventricular premature depolarization 
T 1/2a = absorption half-life 
T1/2elα = distribution half-life 
T1/2elβ = elimination half-life 
TI = triangular index  
Tid = three times daily 
TINN = triangular interpolation of the RR interval histogram 
Tmax = time to maximal plasma concentration 
TVEC = transvenous electrical cardioversion 
Tvθ = population typical value of the fixed effect parameter 
UPLC = ultra-performance liquid chromatography 
Vc = volume of distribution of the central compartement 
Vp = volume of distribution of the peripheral compartement 
VERP = ventricular effective refractory period 
VLF = very low frequency band 
VPD = ventricular premature depolarization 
VT = ventricular tachycardia  





















































































































13 General Introduction 
Arrhythmias, both physiological and pathological, are fairly common in horses. Atrial ectopic 
beats are often harmless, but predispose to the development of atrial fibrillation (AF), a 
condition with an important impact on athletic performance that may occasionally lead to 
collapse or rarely even sudden death during strenuous exercise. Horses with AF can usually 
be converted into normal sinus rhythm (SR) by means of pharmacological or electrical 
cardioversion but relapse may occur. A rapid diagnosis of AF is important in order to 
maximize treatment success and minimize rider risk and risk for relapse. In some horses, post-
conversion, long-term pharmacologic treatment may be indicated in order to suppress 
premature depolarizations and prevent recurrence of AF while reverse remodeling takes place. 
The first part of this PhD research aims to improve diagnosis of supraventricular arrhythmias, 
with a special focus on atrial premature depolarizations (APD) and AF. In a second part of 
this PhD thesis the pharmacokinetics and electrophysiological effects of the antiarrhythmic 














14 General Introduction 
Atrial Arrhythmia and Atrial Fibrillation: Origin and Clinical Importance 
Atrial Premature Depolarizations 
Atrial premature depolarizations (APDs) are caused by abnormal impulse formation in the 
atrial myocardium, outside of the sinoatrial node. They can be associated with underlying 
external causes such as autonomic imbalance, hypokalemia, certain drugs (catecholamines, 
anesthetics), infections, fever, anemia, hypoxia and colic. Numerous APDs, however, can be 
indicative of cardiac abnormalities, such as myocardial disease, atrial enlargement due to 
atrioventricular valvular disease, endocarditis, or congenital heart disease 
1
. APDs can be 
found in healthy horses with normal performance and may be clinically insignificant 
2
. 
Clinical symptoms, mostly poor performance, are more likely when APDs are frequent at rest, 
associated with runs of atrial tachycardia or structural heart disease 
3
. However, the greatest 





Atrial tachycardia is defined as 4 or more consecutive APDs and may be either sustained or 
nonsustained (paroxysmal). Atrial tachycardia in horses is uncommon and if it occurs,  
underlying structural or myocardial disease should be suspected. If atrial tachycardia occurs 
unrelated to AF treatment, it may be clinically insignificant or may lead to a loss in 
performance, but the most important clinical concern of atrial tachycardia is the potential to 




Atrial flutter is relatively rare in horses. Most often it is found during pharmacological 
treatment of AF with quinidine sulphate as a transitional rhythm between AF and SR 
5
. Atrial 
flutter represents a form of atrial circuit movement or macro-re-entry 
4
. Re-entry is caused by 
abnormal impulse propagation in a region with different electrophysiological properties, such 
as different refractoriness and conduction velocity. It occurs when an impulse is conducted 
through cells with a short refractory period but is blocked by cells with a longer refractory 
period. If such an impulse is conducted over a path of excitable tissue until it can loop back to 




15 General Introduction 
can continue to turn around in the atrium and act as a continuous source of electrical activity. 
The size or path length of the loop is determined by the length of the depolarization wave and 
the amount of excitable tissue in between the ‘head’ and ‘tail’ of the depolarization wave, the 
so called excitable gap 
3
 (Fig.1). During atrial flutter a single re-entry loop continuously turns 
around over a fixed pathway in the atrium. The clinical circumstances, importance and 
assessment of atrial flutter are comparable to those of atrial tachycardia and differentiation 
between atrial flutter and high rate, sustained atrial tachycardia may be difficult or even 
impossible. Atrial flutter is believed to be easier to treat compared to atrial fibrillation.  
 
Figure 1: Schematic drawing of a re-entry loop. After passing of a depolarization wavefront 
(arrow head), the myocardial tissue is brought in a refractory state for a time equal to the 
refractory period (red). After that, the tissue gradually recovers until it has regained full 
excitability (white). A re-entry loop can only propagate as long as a small area of excitable 





AF is the most common clinically important dysrhythmia in horses with a prevalence ranging 
between 0.3% and 2.5% of the population 
6,7
. Horses are predisposed to the development of 
AF compared to other species because of the large size of the atria and because high vagal 
tone results in a relative inhomogeneity of refractoriness within the atrial tissue. Large horses, 
such as draft horses, warmbloods and Standardbreds are predisposed and a genetic heritability 
has been identified in Standardbred horses 
6,7
. AF can be acute or chronic and it can be 
paroxysmal (short period of AF, disappears spontaneously, usually within 24-48 hours), 
persistent (terminates only after treatment) or permanent (resistant to therapy). AF often 
develops in the absence of underlying heart disease – in this case it is termed lone AF – but 
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or acquired cardiac disease. Electrolyte derangements, especially potassium depletion, which 
may occur due to excessive sweating during exercise or administration of furosemide, are also 
thought to predispose for AF development 
1
.  
The anatomical and pathophysiological basis for the development of equine AF is not 
completely understood but different theories have been proposed, including the presence of 
ectopic foci, multiple re-entry waves as a continuous source of electrical activity, the leading 
circle concept and the presence of rotors and spiral waves 
8-14
. A first theory explaining the 
initiation of AF suggests the presence of a rapidly firing focus in the atrium. The high 
frequency of these impulses prevents the organized conduction over the atria, because of 
differences in the refractoriness of the myocardial tissues, leading to a disorganized, 
fibrillatory atrial activity. In human patients it has been shown that ectopic activity usually 
originates from parts of atrial myocardial tissue that extend into the wall of the pulmonary 
veins, the myocardial sleeves 
15
. A second important theory regarding the maintenance of AF 
after initiation is the multiple re-entry wavelet hypothesis 
14
. According to this theory, several 
small re-entrant circuits randomly turn around over the atria. Wavelets may break up at 
anatomical obstacles or may die out due to collision. If a critical number, typically 5 or 6 in a 
human heart, of these re-entry loops circle chaotically through the atria, AF becomes self-
sustained 
3
. The more wavelets coexist in the atria, the more stable AF becomes. Recently, in 
human medicine, there has been increasing interest in spiral waves or rotors, which are 
specific, organized forms of functional re-entry that may be important in order to sustain 
AF
14
. Finally, AF itself induces atrial electrical, structural and functional remodeling which 
are also important factors in the progressive, self-perpetuating and recurrent nature of AF 
16,17
. 
Since, in human patients, atrial changes may become irreversible as time progresses, prompt 
diagnosis of AF is important to maximize treatment outcome and minimize risk for 
recurrence.  
Clinical signs of AF depend on the degree of underlying heart disease and the level of 
exercise expected from the horse. Lone AF in low-performance horses is usually an incidental 
finding without overt clinical signs, but when (sub-) maximal performance is required, 
exercise intolerance and poor performance are observed 
4,18
. In horses with lone AF, cardiac 
output at rest is usually not affected. During exercise, however, when the atrial contraction is 
an important contributor to the ventricular filling, maximal cardiac output is limited. 
Furthermore, horses with AF can reach extremely high heart rates, often exceeding 300 beats 
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lead to R-on-T phenomenon and may occasionally be associated with collapse or rarely even 
lead to sudden death 
4,19,20
. Other symptoms that have been described with AF are epistaxis, 
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Atrial Dysrhythmias and Atrial Fibrillation: Diagnosis 
Auscultation 
APDs can be detected during auscultation as premature beats interrupting an otherwise 
regular underlying rhythm and may or may not be conducted to the ventricles. On 
auscultation, APDs are usually preceded by a short diastolic interval and are followed by an 
either normal or prolonged diastolic interval. However, interlaced beats may not be detected 
on auscultation. 
Both atrial tachycardia and atrial flutter usually lead to an irregularly irregular heart rhythm at 
rest. They are often indistinguishable on auscultation and may mimic AF. Despite the rapid 
and regular atrial rate, the ventricular response rate is often irregular due to variable 
physiological blocking at the level of the atrioventricular node. At increasing heart rates, 
however, 4:1, 3:1, 2:1 or 1:1 atrioventricular conduction may yield a regular heart rate 
3
. 
Auscultation of horses with AF is typically characterized by an irregularly irregular heart 
rhythm with frequent long pauses and early beats. The rhythm remains irregular at increased 
heart rates. The first heart sound (S1) is usually loud while the fourth heart sound (S4) is 
absent. Horses with lone AF usually have normal resting heart rates, but during increased 
sympathetic tone, e.g. due to exercise, stress or pain, heart rates increase excessively. During 
strenuous exercise rates of 300 BPM and more are no exceptions in otherwise healthy horses. 
Loud cardiac murmurs or signs consistent with congestive heart failure are indicative of an 
underlying, probably predisposing, heart disease. Increased resting heart rates (>50 BPM) 
may indicate underlying heart disease, but heart rates of 50-60 BPM can be present in horses 
with no underlying cardiac abnormalities.  
Although auscultation is a valuable diagnostic tool and may allow to make a probability 
diagnosis, some abnormalities sound alike or are even indistinguishable on auscultation. 
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Electrocardiography 
Technique  
Electrocardiography is the technique of recording cardiac electrical activity over a period of 
time using electrodes placed on the skin. It is the golden standard method for diagnosing 
cardiac arrhythmias. The normal conduction process follows a rather fixed pathway through 
the heart starting from the sinus node through the atrial myocardium, over the atrioventricular 
node and via the His and Purkinje fibers towards the ventricular myocardium (Fig.2). As the 
electrical impulse spreads through the heart, the ECG shows successively a P wave (atrial 




Figure 2: Conduction pathway in the equine heart (SA: sino-atrial; AV: atrioventricular). 
 
Equipment 
Performing and interpreting an equine ECG requires specialized equipment and a certain 
amount of expertise. The basic equipment needed for an ECG are electrodes, a recording 
device (Fig.3) and a software program to display the ECG. Specific equine self-adhesive 
electrodes are available containing more contact gel and stronger glue than those used in 
human medicine in order to improve skin contact and to better remain in place (Fig.3). Using 
a small, battery-powered ECG recording device allows to attach the device on the horses back 
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Figure 3: The basic equipment needed to record an equine ECG: electrodes (left) and a 
recording device (right). Afterwards the recordings have to be imported and analyzed in a 
special software program.   
 
Subsequently, the recorded ECG needs to be imported into computer software for automatic 
or manual ECG trace analysis. Manual analysis requires expertise and may be time-
consuming. Automatic analysis by the ECG software is very often prone to error (more in 
horses compared to small animals or human patients), especially for recordings during 
exercise. 
 
              
Figure 4: ECG recording equipment for lunging (left) and ridden (right) exercise. The 
electrodes are protected by a girth during lunging and can be placed under or before the 
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Electrode Configurations  
Several electrode configurations have been described in horses. Usually electrodes are 
positioned along the mean electrical axis, which is directed from the apex of the heart towards 
the base and slightly cranial and to the right. This means that one electrode should be placed 
on the ventral part of the thorax near the cardiac apex and a second electrode should be 
positioned more dorsal, towards the cardiac base somewhere in the region between the lower 
neck and the withers. This base-apex configuration is often used in equine medicine. 
However, no universal method for recording an ECG in horses is available. A number of 
semi-orthogonal lead systems has been evaluated experimentally in horses but are rarely used 
in clinical practice and cannot be applied during exercise 
21,22
. A modified Einthoven’s lead 
system is applicable for ECG studies in resting horses and several modified base-apex leads 
have been described for continuous, ambulatory ECG monitoring or exercise ECG in horses 
22-27
. Recently, a new 12-lead ECG method for horses was described, but the technique still 
needs validation in clinical cases 
28
. Since the electrode position influences morphology, 
amplitude and duration of the different ECG leads, the positioning of the electrodes must be 
taken into account and lead-specific reference values should be used 
24,29
. A combination of 
multiple leads can be displayed in ECG software programs. Each lead measures the cardiac 
depolarization from a different angle, so minor electrical changes can sometimes be identified 
more easily in one lead compared to the other. Therefore using multiple lead recordings is 
advised.  
In horses, ECG is important for assessing heart rate and rhythm. The fact that ECG vector 
analysis is not applicable in horses, makes that the exact electrode positioning is of limited 
importance, as long as the electrodes are positioned along the mean electrical axis of the heart. 
The most commonly used electrode configuration is (a variation on) a classical base-apex 
configuration. In horses, on a base-apex configuration, the P wave is often bifid and the Q 
wave is usually absent, leading to a QRS complex with an rS morphology. The T-wave 
morphology is variable and can be positive, negative or biphasic (Fig.5). At increased heart 
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Figure 5: Normal ECG of a horse in a base-apex electrode configuration. 
 
Of special interest for the diagnosis of APDs is a good visualization of the P wave. Most 
configurations focus on registering ventricular activity and large QRS complexes. This may 
result in suboptimal electrode positioning for P wave registration, since the atrial activation 
has a more cranial to caudal direction compared to the ventricular electrical axis. In addition, 
an increase in heart rate often results in a P wave that is buried in the preceding QRST, so P 
wave morphology is difficult or even impossible to assess during exercise. Compared to a 
base-apex configuration, a significantly higher P wave amplitude has been described with the 
negative electrode on the right side of the withers and the positive electrode 15 cm behind and 
above the left olecranon, as this position is more along the electrical axis of the atrium 
29
.   
 
Diagnosis of Atrial Arrhythmias  
Atrial Premature Depolarizations 
APDs are usually characterized by a premature P wave with normal or abnormal morphology 
that may or may not be followed by a normal QRS-T complex and is followed by a non-
compensatory pause (Fig.6).  
Generally, the electrical activity of the APD will enter the sinus node and reset its timing, 
leading to a non-compensatory pause. This differentiates APDs from ventricular premature 
depolarizations (VPDs). When the ventricle discharges prematurely, the sinus node is not 
affected and will continue firing at its regular time intervals. If the next sinus complex after 
the VPD finds the atrioventricular nodal tissue still refractory (and thus not conducting), this 
results in a compensatory pause. However, in some cases the electrical activity of an atrial 
premature complex probably does not enter the sinus node due to refractoriness of the sinus 
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node will not be reset. In these cases, a compensatory pause will be present and differentiation 
with a VPD may be hampered.  
Whether an APD is conducted through the atrioventricular node, depends on its refractoriness. 
If the atrioventricular nodal tissue is not refractory, the APD will be conducted to the 
ventricle. Since APDs arise from the atrial myocardium, ventricular conduction is generally 
not affected and QRS complex and T wave morphology remain unchanged 
1,4,30,31
. This 
differentiates APDs from VPDs. The latter are not related to a preceding P wave and usually 
have a QRS complex with abnormal morphology, due to abnormal intraventricular 
conduction. However, for some APDs the premature P wave is buried in the preceding T 
wave or QRS complex and thus difficult to identify. In addition, premature atrial impulses can 
also be conducted aberrantly through the ventricle as a result of incomplete repolarization or 
persistent refractoriness of ventricular conducting tissues. This may slightly alter the QRS-T 
complex and can make differentiation with premature depolarizations from a ventricular 
origin challenging.  
 
Figure 6: ECG of an APD (arrow). Note the normal QRS morphology and the non- 
compensatory pause after the APD. 
 
Atrial Tachycardia and Atrial Flutter 
During sustained atrial tachycardia rapid but often regular atrial activity may lead to regular P 
waves especially at a rate between about 120 and 300 BPM 
3
 (Fig.7). In between P waves iso-
electric lines are often present. Atrial flutter, on the other hand, is also characterized by a very 
rapid, abnormal, but regular atrial activity that is often visible as a saw-toothed ECG baseline 
(Fig.8). Each undulation represents a macro-reentry rotation of the depolarization wave, 
usually at an atrial rate between about 170 and 300 BPM 
4
. Isoelectric lines between P waves 
may also be present during atrial flutter, hampering the differentiation between atrial 
tachycardia and atrial flutter. Atrioventricular conduction in both arrhythmias is usually 
variable, resulting in a ventricular rate response that is usually irregular at rest but often 
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atrial-to-ventricular conduction can be observed 
4
. QRS morphology is usually not affected, 
except in cases of incomplete ventricular repolarization. Depending on the atrial rate, the 
origin and the conduction pathway, atrial tachycardia and atrial flutter may lead to the same 
changes on the surface ECG. Exercising the horse usually leads to slightly higher atrial rates 
probably due to the influence of sympathetic tone on impulse formation and/or impulse 
conduction. If strenuous exercise leads to a markedly increased atrial rate, the underlying 
cause is supposed to be atrial tachycardia instead of atrial flutter as the sinus node impulses 
are unlikely to entrain the reentry circuit. However, especially when the atrial rate is high, 
distinguishing correctly between both arrhythmias may be impossible from the surface ECG 
and other electrophysiological techniques, such as multiple intracardiac electrocardiograms or 
3D electroanatomical cardiac mapping may be necessary 
32,33
.  




Figure 8: Base-apex ECG of a horse with atrial flutter. The two vertical green lines indicate 
the flutter cycle length which is the time (ms) between two flutter waves. The first part of the 
ECG (dotted arrow) shows a 2:1 atrioventricular conduction, while conduction is more 
irregular in the remaining part. 
 
Atrial Fibrillation 
The ECG of horses with AF is characterized by the absence of P waves; instead, rapid 
baseline fibrillation “f” waves are present (Fig.9). These f waves may be large or small and 
the number of atrial impulses per minute is difficult to count but often exceeds 300 BPM. 
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morphology. Abnormal QRS complexes, either originating from the ventricle or aberrantly 
conducted, are present in 10-60% of horses with AF during exercise 
1,20
. In otherwise healthy 
horses in AF at rest, vagal tone is usually high and the ventricular rate will be close to normal 
or slightly increased. Ventricular response rate increases with increased sympathetic tone 
(exercise, stress, pain), decreased vagal activity (as with certain antiarrhythmic drugs) or 
underlying heart disease.  
 
Figure 9: ECG of a horse with AF. Note the fibrillation ‘f’ waves instead of normal P waves 
and the irregular RR intervals. 
 
Challenges in the Diagnosis of Atrial Arrhythmias 
Visual ECG screening is time consuming and requires an experienced observer. Sometimes, 
especially for exercise ECGs or in the case of low ECG trace quality, interpretation can be 
challenging, even for an experienced cardiologist. Therefore, after importing ECG recordings 
into ECG analysis software, programs using complex algorithms for the automatic analysis of 
the different waves, are often used. However, most of these algorithms are designed for 
human and small animal medicine and fail to interpret the horse’s ECG correctly. The 
different QRS polarity and especially the large T wave with variable polarity of the equine 
ECG may lead to software confusion. Furthermore, movement artifacts complicating 
automatic ECG analysis are common in horses, especially during exercise. Therefore, the 
visual screening of the horse’s ECG usually remains necessary.  
Both APDs and VPDs are characterized by premature complexes, but a correct differentiation 
is important because of a difference in clinical relevance. While APDs are often harmless and 
not an indication to stop riding the horse, frequent VPDs are a known risk factor for the 
induction of ventricular tachyarrhythmia, which may lead to cardiovascular collapse and even 
sudden death 
4
. VPDs, as opposed to APDs, are the consequence of abnormal impulses arising 
from the ventricular myocardium. This leads to a change in ventricular conduction and 
consequently changes in QRS and T wave morphology and duration 
1,4,31
. However, 
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sometimes be minimal. This can make differentiation from APDs with a hidden P wave 
difficult, especially when QRS morphology following the APD is atypical. Using multiple 
leads and adapted electrode configurations is often helpful. Furthermore, as was explained 
before, differentiation between an APD and a VPD based on the presence of a non-
compensatory or fully compensatory pause, is not always possible since the sinus node may 
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Heart Rate Variability 
Heart rate variability (HRV) describes and quantifies the beat-to-beat variability and the long-
term variation in heart rate 
27
. In order to maintain normal blood pressure, the heart is under 
the influence of both the autonomic nervous system and the neuroendocrine system. 
Therefore, heart rate, even in the resting, healthy horse, is not static but cyclical and beat-to-
beat variation in heart rate occurs. HRV is a measure for the functioning of the autonomic 
nervous system, especially the balance between sympathetic and vagal activity 
27,34
. In SR, 
higher variability represents a healthy heart. In healthy horses, an increase in parasympathetic 
tone or a decrease in sympathetic tone results in a larger beat-to-beat variation and an 
increased HRV. 
Technique 
There are numerous methods and parameters available for describing the variations in heart 
rate. The methods most frequently used are time-domain analysis, frequency-domain analysis 
and non-linear methods. A summary of these methods and their frequently used parameters is 
displayed in Table 1.  
Time-domain parameters are relatively easy to obtain. The most commonly used parameters 
are SDNN, the standard deviation of the RR intervals and RMSSD, the square root of the 
mean squared differences of successive RR intervals. Furthermore, geometrical methods, 
converting these RR intervals into a geometrical pattern and applying formulas to quantify 
these patterns, can be used. Commonly used examples are the Triangular Index; the integral 
of the density distribution (the histogram of the RR intervals) divided by the maximum of the 
density distribution, and the triangular interpolation of the RR interval histogram or TINN, 
which is the baseline width of the distribution measured as a base of a triangle approximating 
the RR interval distribution (Table 1).  
A second method to describe HRV is the frequency-domain or spectral density analysis 
method. Spectral density analysis breaks the HRV into the frequency components that 
compose the overall HRV and thus provides the basic information of how power (i.e. 
variance) distributes as a function of frequency 
35,36
. This technique has been adapted from 
astronomy where the overall power of a star is measured from the different frequencies of the 
light emanating from it. In case of HRV, it is performed by taking a series of numbers along 
the time axis (in this case RR intervals), applying computationally efficient algorithms, 
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band. The most commonly used algorithm is the fast Fourier transform (FFT), alternative 
techniques being the Lomb-Scargle (LS) periodogram or wavelet entropy scales. Normal 
values for the different frequency bands cannot be extrapolated from human medicine or 
between algorithm techniques, so when spectral density analysis is used in horses, care should 
be taken to use normal values designed for horses and specific for the algorithm used 
27
.  
Table 1. Most commonly used methods for heart rate variability analysis. 
Time-domain 
methods 
SDNN Standard deviation of all NN intervals 
SDANN 
Standard deviation of the averages of NN intervals in all 5 min 
segments of the entire recording 
RMSSD 
The square root of the mean  squared differences between 
successive NN intervals 
SDNN 
index 
Mean of the standard deviations of all NN intervals for all 5 
min segments of the entire recording 
NN50 
Number of pairs of adjacent NN intervals differing by more 
than 50 ms in the entire recording 
pNN50 NN50 count divided by the total number of all NN intervals 
Triangular 
Index 
Total number of all NN intervals divided by the height of the 
histogram of all NN intervals measured on a discrete scale 
with bins of 7·8125 ms (128 Hz) 
TINN 
Baseline width of the minimum square difference triangular 





LS or wavelet 
entropy) 
VLF Power in the very low frequency range (0.003 - 0.04 Hz*) 
LF Power in the low frequency range  (0.04 - 0.15 Hz*) 
HF Power in the high frequency range  (0.15 – 0.40 Hz*) 








Standard deviation of the Poincaré plot of the RR intervals 
perpendicular to its line of identity 
SD2 
Standard deviation of the Poincaré plot of the RR intervals 
along its line of identity 
Adapted from Camm and Malik, 1996 
35





A third method for HRV analysis are the non-linear methods. Numerous parameters to 
measure non-linear properties of HRV have been used, including Poincaré sections, low-
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the most commonly used non-linear methods for HRV parameters are SD1 and SD2, the 
standard deviation of the Poincaré plot of the RR intervals perpendicular to and along its line 
of identity, respectively (Fig.10). 
 
 
Figure 10: Poincaré plot of the RR intervals demonstrating the calculated SD1 and SD2.  
 
Use in Human Medicine 
Exercise, Training and High-Level Performance 
Based on several scientific studies, HRV is being increasingly used by professional athletes, 
trainers and everyday sportsmen as a monitoring tool to evaluate athletic training, overtraining 
and fatigue 
37-39
. Training is a stressor with an important impact on HRV and HRV serves as 
an estimate for the recovery of the body. In HRV guided training, the daily amount and type 
of training is based on individual HRV measurements 
37
. It appears to be more effective for 
developing aerobic performance than pre-planned training
 37
. Over the last decades, numerous 
HRV devices and applications have been developed to guide sportsmen to improve their 
performance.  
Marker for Cardiac and Non-Cardiac Disease 
There is an increasing amount of literature concerning HRV in human medicine over the last 
decades (>4,000 publications in the last decade). Data suggest that abnormalities in HRV 
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and hemodynamic 
39
. The most important mechanisms that influence HRV are neurohumoral 
activation and altered sympathovagal interaction. Since these mechanisms are important 
contributors to arrhythmogenesis, atherogenesis and the progression of heart failure, it is not 
surprising that altered HRV measurements predict various causes of cardiac death. More 
specifically, altered (usually lower) HRV has been associated with congestive heart failure, 
cardiomyopathy, arterial hypertension, atherosclerosis, ventricular and supraventricular 
arrhythmias, cardiac arrest and sudden death. It is used as a predictor of risk of mortality for a 




A variety of non-cardiac conditions has also been associated with changes in autonomic tone 
and thus HRV. For instance, decreased HRV is used as an early marker for diabetic 
neuropathy and as a predictor of survival of premature babies in an intensive care unit 
35
. 
Furthermore, HRV, and especially spectral density analysis has proven to be useful as a 
follow-up marker in the treatment of Alzheimer’s Disease, chronic obstructive pulmonary 




There is a growing interest in the use of HRV in the field of psychophysiology. Under 
conditions of stress, acute time pressure, emotional arousal and elevated anxiety, HRV 
decreases, probably due to increased attention or vigilance and increased sympathetic tone 
together with vagal motor inhibition 
43,44
. HRV is also reduced in individuals reporting a 
greater frequency and duration of daily worry and in individuals suffering from post-traumatic 
stress disorder and depression 
40,45
.  
Diagnosis of Arrhythmia 
HRV parameters are expected to be increased with cardiac arrhythmias, especially in the case 
of frequent premature depolarizations and AF, which lead to an increased variation in beat-to-
beat intervals. Higher variability in this case represents more arrhythmias. For this reason, 
HRV is also being used for the detection of several arrhythmias, among which AF, in human 
medicine 
46-50
. Duverney et al.
48
 used wavelet analysis of heart rate intervals in order to detect 
paroxysmal and chronic AF with a high sensitivity and specificity (>90%), whereas Park et 
al.
49
 used three parameters derived from the Poincaré plot of the RR intervals with a 
sensitivity of 91.4% and a specificity of 92.9%. A computer algorithm based on the time-
domain parameters of HRV was developed by Yaghoubi et al.
50
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from SR in 680 ECGs (340 AF en 340 SR) with a sensitivity and specificity around 99%. 
Gilani et al.
46
 studied 146 different HRV parameters to differentiate AF from SR on a 1-
minute ECG recording in 105 AF cases and 96 SR cases. Most parameters could differentiate 
between SR and AF with sensitivity and specificity above 98% and the authors proposed the 
use of commercial monitors with automatic HRV calculations for AF detection. Based on the 
results of these experimental studies, several automatic home monitoring devices using 
algorithms based on HRV parameters, have been marketed especially for AF diagnosis 
47,51
. 
These devices allow rapid arrhythmia detection by the patient, after which confirmation with 
electrocardiography is required.  
Use in Horses  
Exercise, Training and High-Level Performance  
Based on the experience in human training, HRV is becoming a well-known tool in equine 
studies evaluating the effects of different levels of exercise, training and high-level 
performance 
52,53
. Due to the increasing availability of HRV devices and applications for use 
in horses, the use of HRV as a training tool is rapidly gaining popularity, especially in 
endurance horses. However, although the equipment and hardware is often adapted for horses, 
the settings, detections algorithms and HRV calculations are generally set for use in humans 
and not validated for use in the horse.  
Marker for Cardiac and Non-Cardiac Disease 
HRV has been used sporadically to study the autonomic regulation of the horse’s heart 
34,54
 
and has recently been introduced as a prognostic indicator in horses suffering from ischemic 
gastrointestinal disease 
55
. Furthermore, a few studies suggest the use of HRV parameters as 
an indicator of pain in the horse 
56,57
. There are, however, no studies evaluating its prognostic 
or diagnostic use in horses suffering from other diseases.  
Psychophysiology 
The most common use of HRV in equine (and other animal) studies is as a marker for stress 
and anxiety in welfare studies 
34,58-60
. Over the last decade a large number of studies have 
been published using HRV to estimate stress in horses during different handling or exercising 
procedures. In these studies higher HRV is supposed to indicate a lower stress level and a 
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Diagnosis of Arrhythmia 
There are currently no studies available about the potential of HRV to diagnose arrhythmia in 
horses. One study used spectral domain analysis in a horse with AF to estimate the role of the 
autonomic nervous system and the modulation of the intrinsic behavior of the atrioventricular 
node during AF 
61
. This study showed a large increase in frequency-domain analysis HRV 
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Heart Rate Monitors 
A heart rate monitor (HRM) is a device that displays heart rate in real-time and often also 
records heart rates for later study. HRMs for horses are identical to or have been adapted from 
human models and can be used for recordings at rest and during exercise.  
Technique 
HRMs usually consist out of an electrode set and a heart rate sensor (Fig.11). The sensor 
automatically detects the R peaks on the ECG by looking for sharp deflections from the 
baseline. Subsequently, the sensor sends these data in real-time to a device displaying and/or 
recording the heart rate. Special plastic electrodes or an electrode belt which can be placed 
around the chest have been designed for horses (Fig.11). In general, HRMs are affordable, 




         
Figure 11: Heart rate monitors for horses. Special plastic electrodes (left) or an electrode 
belt have been designed for horses.   
 
Use in Horses 
Current Use 
HRMs are increasingly used in sports horses to assess their level of fitness, to adjust workload  
and to monitor training progress. They have long been used in disciplines such as endurance 
and racing, and more recently also in other sports disciplines. Changes in heart rate, maximal 
heart rate and heart rate during recovery can be observed at different levels of exercise and 
training programs are adjusted based on the results.   
In veterinary medicine HRMs are also gaining popularity, both for clinical and for 
experimental purposes. Where studies using HRV formerly were performed with RR intervals 
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Pitfalls 
The most important pitfall of HRMs is correct RR interval detection. Both in humans and in 
horses, a few recent studies objectively assessing the performance of HRMs have shown 
significant differences between results from HRMs and ECG recordings 
63-65
. First, contact 
between the horse’s skin and the electrode has to be sufficient to register electrical activity. 
For equine ECGs, special adhesive electrodes, containing more gel and stronger glue, are 
available, but HRM electrodes are usually non-adhesive and contain no gel nor glue, so skin 
contact may be suboptimal. The performance of different HRM electrodes has not been 
compared in horses. A second problem is heart rate detection by the HRM software program. 
In horses, the T wave can be very pronounced and systems based on detecting R waves by 
looking for sharp deflections from the baseline, can erroneously register T waves. 
Furthermore, movement artifacts are common, especially during exercise, and may also lead 
to erroneous R peak registrations. Most HRMs have not been validated for use in horses, so 
studies assessing the correctness of RR detection with an equine HRM are necessary 
63
.  
Another pitfall in using HRMs is the use of variable artifact correction methods by some 
devices or software programs. Artifact correction omits outliers, i.e. RR intervals that strongly 
differ from other RR intervals or replace them by interpolated values. Although this filtering 
helps to get rid of artifacts, it also blunts the beat-to-beat variation caused by arrhythmias, 
possibly hampering the differentiation between SR and pathological arrhythmias. Different 
software programs may use different artifact correction algorithms. No studies have been 
performed on how this artifact correction influences HRV in horses and it is currently 
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Atrial dysrhythmias and Atrial Fibrillation: Treatment and Prognosis 
Treatment of Atrial Dysrhythmias in horses 
Antiarrhythmic Drugs 
Based on the human Singh-Vaughan Williams classification, antiarrhythmic drugs can be 
divided into categories according to their mode of action (Table 2). Although many 
antiarrhythmic drugs have multiple action mechanisms, they are classified based on the 
primary mechanism of action and the effect on the different phases of the cardiac action 
potential. 
Table 2. Singh-Vaughan Williams classification of antiarrhythmic drugs used in horses.  
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 channel block (slow 
association/dissociation) 
Flecainide   
Arrhythmia, de-
pression, hypotension, 
agitation, sudden death  
Propafenone   
Arrhythmia, 
bronchospasm 
II β- blocker 
Propanolol 
Non-selective (β1 and 
β2), also some class I 
action Weakness, lethargy, 
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 channel blocker Diltiazem   Weakness, lethargy 
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APDs 
Treatment of APDs depends on the underlying cause. Sometimes idiopathic APDs resolve 
following a period of rest and corticosteroid therapy. If APDs are infrequent, treatment is 
often not necessary. In rare cases of rapid supraventricular tachycardia, long-term 
antiarrhythmic therapy may be beneficial to reduce the ventricular response rate 
66-68
. Also in 
case of APDs after cardioversion of AF, long-term antiarrhythmic drug administration may be 
beneficial to attempt reduction in early recurrence of AF and in order to allow for reverse 
electrical remodeling to take place.  
Atrial Tachycardia, Atrial Flutter and AF 
Management strategies for atrial tachycardia, atrial flutter and AF include either no treatment, 
or conversion to normal sinus rhythm, while hardly any information is currently available for 
a ‘rate control’ strategy. Atrial fibrillation has been shown to be often associated with 
abnormal ventricular complexes and R-on-T episodes, both representing a potential risk for 
collapse or even sudden death, while this has so far not been shown for atrial tachycardia and 
atrial flutter. Clinical decision making is influenced by the underlying condition and the 
intended level of activity of the horse.  
Horses with severe cardiac disease or congestive heart failure are not candidates for 
cardioversion because AF recurrence is very likely. For horses in lone AF, however, the 
clinical consequences of AF can be difficult to estimate. Despite general consensus on the 
poor performance caused by AF in high level exercising horses, clinical consequences of AF 
generally abate when exercise demands decrease. Therefore the level of intended activity and 
the owner’s expectations influence clinical decision making. Some horses are able to perform 
well when used for less intense athletic work, while others experience reduced performance 
even at low level exercise. Cardioversion is recommended when performance issues are 
present, when the average maximal heart rate during exercise is greater than 220 BPM at an 
intensity at, or slightly exceeding the horse’s normal activities, or whenever abnormal 
ventricular depolarizations are present 
4
. In horses where treatment is not possible or declined, 
an exercise ECG should be performed to identify potential risk factors for collapse or even 
sudden death, such as extremely high heart rates or abnormal ventricular responses 
4,20
.  
Restoration of SR can be obtained either by electrical or pharmacological cardioversion. Both 
techniques are generally safe and effective with reported success rates ranging between 60 
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influence treatment success are the presence of atrioventricular valvular regurgitation, atrial 
enlargement and primary myocardial disease 
69
. If concurrent congestive heart failure or grave 
other cardiac abnormalities are present or the horse is aged or retired, cardioversion may be 
either of little benefit or unsuccessful. In these cases long-term pharmacological rate control 
therapy may be attempted.  
Pharmacological Cardioversion 
Quinidine sulphate is the standard drug for the pharmacological treatment of equine AF. It is 
effective in many horses and several treatment plans can be followed. Other drugs that have 
been described include flecainide, amiodarone and propafenone (Table 3).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Quinidine 
Quinidine sulphate (22 mg/kg every 2h until adverse reactions or max 4 treatments) remains 
the drug of choice for the pharmacological AF treatment in horses. It is a class Ia 
antiarrhythmic drug that blocks the fast inward sodium channels in the myocardium. It 
prolongs the effective refractory period and, as such, slows down the electrical activity of 
cardiac tissues. However, it can cause dangerous ventricular arrhythmias and has a wide range 
of cardiovascular and noncardiac side-effects, so close monitoring during treatment is 
necessary. Quinidine sulphate is administered via the enteral route, but intravenous treatment 
with quinidine gluconate (1.0- to 1.5 mg/kg every 10  minutes until max 11 mg/kg) has also 
been described. Because of its irritating effect on mucous membranes it has to be 
administered by nasogastric tube. Several treatment protocols have been described, consisting 
of multiple consecutive doses with close clinical and echocardiographic monitoring until 
successful conversion to SR. Cardiovascular adverse effects, such as hypotension, 
proarrhythmia and sudden death may occur, as well as neurological (ataxia, aggression, 
collapse) and gastrointestinal (diarrhea, colic) side effects ranging from mild to lethal. 
Treatment with quinidine is often successful, especially for recent onset AF, and the treatment 
of choice in many veterinary institutes. However, quinidine’s toxicity and its limited 
availability in many countries have stimulated research into alternative therapies.  
Other Drugs 
Amiodarone, a class III antiarrhythmic drug with β-adrenergic properties that increases the 
refractory period by blocking potassium and sodium channels, has a good conversion rate and 
few cardiac side effects in human medicine. In horses, amiodarone has a low oral 
bioavailability (6-33%) 
70
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success rates between 50 and 65% 
71,72
.  Side effects may occur after long-term treatment 
(>56 hours) and include hindlimb weakness, depression and diarrhea 
71,73
. Amiodarone is not 
advised as a first option treatment of AF but can be tried in horses refractory to quinidine 
treatment.  
Flecainide is a class Ic antiarrhythmic drug that slows intracardiac conduction and reduces 
excitability in cardiac tissues due to its potent sodium channel blocking effects. Flecainide 
(0.2mg/kg/min  for 10 minutes) has been used successfully in an experimental acute AF 
model 
74-76
, but showed dangerous, potentially lethal side effects in horses with naturally 
occurring AF 
77
. These side effects included depression, agitation, mild colic, hypotension, 
prolongation of QRS complex and QT intervals and wide-QRS ventricular proarrhythmia 
74,76,77
. Several case reports have described sudden death during both intravenous and oral 
flecainide treatment 
78,79
. Due to a high risk for sudden death, flecainide is currently not 
advised for AF treatment in horses 
16,80
.  
Propafenone, another class Ic antiarrhythmic drug used in humans for cardioversion, was 
studied as an alternative treatment for horses with AF. In 6 horses with AF, intravenous 
propafenone treatment starting with a 2 mg/kg bolus and thereafter 7 µg/kg/min for 2 hours, 
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Table 3: Drugs studied for cardioversion in horses with AF 
Class Drug Route  Dose 
Studied 
population 





1.0- to 1.5 mg/kg 
every 10  minutes 















22 mg/kg every 
2h until adverse 











Ic Flecainide IV 
0.2 mg/kg/min  




























Ic Propafenone IV 
2 mg/kg bolus 
thereafter 7 











III Amiodarone IV 
5 mg/kg/h for 1 h 
followed by 0.83 
mg/kg/h for 23h 










6.52 mg/kg/h for 1 
h followed by 1.1 




50% Colic, diarrhea 
73
 
NGT: nasogastric tube ; Refs:  references 
 
Transvenous Electrical Cardioversion 
Electrical cardioversion appears to be the most viable alternative to quinidine sulphate 
treatment in horses, and is becoming increasingly important because of its high success rate 
(>95%) even in quinidine refractory cases. By means of direct current shock delivery, 
depolarization of the whole atrial myocardium is obtained, thereby terminating the 
arrhythmia
85,86
 (Fig.12). During this procedure one catheter is placed, through the jugular 
vein, in the right atrium while a second catheter is positioned in the left branch of the 
pulmonary artery. Furthermore, a temporary pacing catheter is placed in the right ventricle to 
perform temporary pacing if post-shock asystole due to temporary AV-block should occur 
5
. 
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cardioversion energy is around 160 joule) until restoration of SR 
86
. Apart from occasional 
mild post-anaesthetic myopathy, this technique is safe and has shown to be effective in 98% 




Figure 12: Transvenous electrical cardioversion procedure in a horse.  
Future Prospects 
Despite the high efficacy of current treatment options, recurrence of AF is common. In human 
medicine, recurrence is often due to the presence of ectopic foci originating from the 
myocardial sleeves in the pulmonary veins. Therefore, catheter ablation techniques have been 
developed in order to destroy these foci or prevent them to enter the atria, thereby preventing 
AF recurrence 
9,11,88
. Ablation is performed using radiofrequency or cryo-ablation in order to 
destroy a small amount of myocardial tissue, which leads to conduction block, preventing the 
ectopic beats from entering the atria. In 95% of the human cases, the focus is located within 
the pulmonary vein but other possible sites include right atrium, left atrium, coronary sinus, 
superior vena cava or vein of Marshall 
9
. Success rates in human medicine are relatively high 
but because of the presence of multiple foci or restoration of conduction, several treatment 
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Catheter ablation requires registration of the activation and conduction patterns in the atria for 
an exact determination of the location of the ectopic foci and a very precise positioning of the 
ablation catheter in the heart. In horses, ablation has never been performed. Positioning of the 
catheter would be challenging, because of the large heart and the superposition of lung tissue, 
hampering ultrasonographic guidance or fluoroscopic techniques. Promising research results 
facilitating the development of this technique in horses, have recently been published. One 
study revealed the complex anatomy of the pulmonary veins in horses 
89
 and also intracardiac 
electroanatomical mapping techniques are currently being studied and have been successfully 
used in horses 
33





42 General Introduction 
Recurrence of AF  
Recurrence of AF is relatively common in horses with reported recurrence rates around 35-
45% 
90
. Reported recurrence rates are variable due to differences in horse population, previous 
AF duration, presence of underlying heart disease and follow-up time.  
Risk Factors 
Many risk factors for AF recurrence have been described. Several experimental studies have 
demonstrated extensive atrial remodeling during AF 
16,86,91
 and the likelihood of successful 
conversion decreases and recurrence rates increase with increased AF duration. In one study 
in horses with AF of less than 3 months duration, the recurrence rate was 15%, whereas 65% 
if AF had been present for a longer period 
69
. A recent large multicenter study, however, was 
not able to identify a correlation between AF duration and recurrence 
90
. Atrial size and horse 
breed have also been previously determined as risk factors for AF recurrence 
3,92,93
, but were 
not significantly different in a more recent study 
90
. It is possible that recurrence rates do not 
increase linearly with increased AF duration or increased atrial size, but that a threshold-based 
difference is present. Treatment modality (electrical or pharmacological cardioversion) was 
not related to AF recurrence 
90
. Previous episodes of AF or previous unsuccessful treatment 
attempts, suggesting differences in atrial electrophysiology or the presence of underlying 
atrial myocardial disease, were identified as risk factors for AF recurrence 
90
. Other suggested 
risk factors are mild to moderate mitral valve regurgitation 
90
 and the ratio of the AF cycle 
length to the atrial size 
93
 before cardioversion. After cardioversion, a decrease in active left 
atrial fractional area change, which can be an indicator of atrial remodeling or underlying 
myocardial disease, was also reported as a risk factor for AF recurrence 
69,90
.  
Prevention of AF Recurrence 
In horses, little is known about prevention of AF recurrence and preventive measures are 
based on information from human medicine. 
AF recurrence is also common in humans and prevention is mainly attempted by 
pharmacological antiarrhythmic therapy 
94
. Many patients eventually need prophylactic 
antiarrhythmic drug therapy to maintain SR, suppress symptoms, improve exercise capacity 
and hemodynamic function, and prevent tachycardia-induced cardiomyopathy due to AF. A 
large variety of antiarrhythmic drugs have been studied and are used in human medicine with 
variable results. Recommendations support the use of propafenone, flecainide, dofetilide, 
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disease
94,95
. While amiodarone prevents AF recurrence better than the above antiarrhythmic 
drugs, guidelines advise its use only in cases refractory to other drugs because of its important 
extra cardiac side effects 
101
. In a meta-analysis of 44 randomized controlled trials comparing 
antiarrhythmic drugs against control (placebo or no treatment), the overall likelihood to 




In horses, prevention of AF recurrence is attempted with a combination of management 
changes and antiarrhythmic therapy. After cardioversion a period of rest before resuming 
exercise activities is advised in order to allow for atrial reverse electrical and contractile 
remodeling to take place 
97
. Long-term antiarrhythmic treatment in horses has poorly been 
described. One study described the use of phenytoin, a drug with class 1b antiarrhythmic 
properties, in two horses after successful cardioversion 
98
. Another study did not find a 
statistical difference in AF recurrence in horses treated with KCl supplementation (n=39), 
ACE-inhibitors (n=34), dexamethasone (n=33) or digoxin (n=6) after cardioversion compared 
to untreated horses (n=83) 
90
. Various antiarrhythmic drugs are empirically being used by 
veterinarians after cardioversion but no further studies on the pharmacological prevention of 
AF recurrence in horses, nor studies on their pharmacokinetic properties in horses have been 
published.  
Sotalol 
Before the start of this PhD research, scarce information about sotalol in horses was available. 
An important part of this PhD thesis studies the pharmacological profile and clinical effects of 
sotalol in horses. Sotalol has a straightforward pharmacokinetic profile and a high oral 
bioavailability (F) in humans and small animals. Furthermore, sotalol is used in human 
medicine in patients with various cardiac rhythm disorders as an effective antiarrhythmic and 
anti-fibrillatory agent 
99-102
. Although it can be used for cardioversion of AF patients it is 
mostly used in the prevention of AF recurrence 
101,103
. Guidelines for the management of 
patients with AF recommend sotalol for the prevention of AF recurrence in outpatients in SR 
with little or no heart disease, prone to paroxysmal AF, if the baseline uncorrected QT interval 
is less than 460 ms, serum electrolytes are normal, and risk factors associated with class III 
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In dogs and cats, sotalol is the most commonly used long-term treatment for ventricular 
arrhythmias, but its efficacy in the prevention of recurrence of atrial flutter and AF also has 
been shown 
104-106
.   
Mechanism of Action 
Sotalol, or 4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide, is a water-soluble, 








Sotalol has potent, non-cardioselective β- blocking (class II) effects, blocking both β1- and β2-
adrenoreceptors. β-blockers are competitive antagonists of the endogenous catecholamines, 
such as adrenaline and noradrenaline, on the β-receptors of the sympathetic nervous system. 
β1-adrenergic receptors are located mainly in the heart and in the kidneys, while β2-adrenergic 
receptors are located primarily in the lungs, gastrointestinal tract, liver, uterus, vascular 
smooth muscle, and skeletal muscle. By blocking β1-adrenoreceptors, sotalol prevents the 
activation of the inward calcium channels in the cardiac muscle cells 
108
. This will result in a 
decrease in intracellular Ca
2+
, and a lower excitability of the cell. Important cardiac effects of 
β-blockers are a decrease in heart rate and blood pressure but also a decreased cardiac 
contractility, possibly exacerbating congestive heart failure. Sotalol, however, unlike other, 
selective β-blockers, is devoid of intrinsic sympathomimetic actions and exerts no or very 
little depressant effect on myocardial contractility, because of its additional class III 
antiarrhythmic properties 
109
. Some studies even report positive inotropic effects 
107
. Class III 
antiarrhythmic function primarily results in a lengthening of the cardiac repolarization phase. 
By blocking outward potassium channels, sotalol inhibits the rapidly activating component of 
the delayed rectifier potassium current IKr, thereby slowing the repolarization phase of the 
cardiac tissues and enhancing cardiac contractility 
99,108
. In human electrophysiology studies, 
sotalol prolongs the duration of action potentials recorded in cardiac tissue, increases the 
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However, sotalol-induced prolongation of the QT interval is more pronounced at slow heart 
rates and may not be apparent during exercise-induced tachycardia. This heart rate 
dependence, also referred to as reverse use dependence, has also been reported for other 
agents with class III action, but its clinical importance is unknown 
108
.  
Intravenous sotalol is not available in many countries, but oral tablets, either containing 
sotalol or sotalol hydrochloride, are available for use in humans at concentrations between 40 
and 160 mg per tablet. Sotalol is not registered for use in the horse. However, since no other 
antiarrhythmic drugs are registered for horses, off label use, following the cascade system, is 
allowed. 
Pharmacokinetics and Pharmacodynamics 
Unlike many other antiarrhythmic drugs, pharmacokinetics of sotalol in humans show a good 
oral F,  no drug-drug interactions, no biotransformation and an entire renal excretion (Table 4) 
108
. Sotalol pharmacokinetics conform to a first-order, linear two-compartmental model, in 
which all processes of drug absorption, distribution and elimination occur by first-order 
kinetics 
107
. Higher doses of sotalol are necessary to prolong cardiac repolarization than to 
achieve β-blocking activity. Significant β-blockade in humans occurs at plasma sotalol 
concentrations as low as 0.8 µg/mL, while class-III activity starts from 1.2 µg/mL 
110
. Plasma 
concentrations aimed for in humans are 1-3 µg/mL 
111
. The minimally effective 
antiarrhythmic dose of orally administered sotalol in human medicine is 40-80 mg twice 
daily; the dose can be increased if necessary every 3 to 4 days until a maximum of 640 mg per 
day is reached 
99
.  
Pharmacokinetics of sotalol in dogs are similar to those in humans. Also in dogs sotalol shows 
good oral F, no biotransformation and a complete and unchanged excretion in urine (Table 4) 
112
. In dogs, an oral dose of 5 mg/kg bwt bid, leading to plasma concentrations of 1.1-1.6 
















46 General Introduction 
 
 
Table 4. Pharmacokinetic profile of sotalol in humans and in dogs  after oral 
administration. Data are derived from 
105,107,108,112
 
Parameter Humans Dogs 
Tmax 2.5-4 h 0.5-1.5 h 
Extent of absorption 90%-100% >90% 
Bioavailability  Approximately 100% 85-90% 
Plasma protein binding 0% 0% 
Apparent volume of distribution 2.0 ± 0.4 L/kg 1.5-2.5 L/kg 
Biotransformation 0% <1% 
Metabolites None detected None detected 
Total body clearance  110-400 mL/min   
Renal elimination of unchanged drug >75% >90% 
Plasma elimination half-life  15 (10-20 h) 4.8±1 h 
Therapeutic plasma concentration 
range 
~1-4 µg/mL 0.8 – 1.6 µg/mL* 
Disposition kinetic model First order/2-compartment First order/2-compartment 
Dose proportionality of Cp? Yes (linear) Yes (linear) 
Special features 
Water soluble, little central 
nervous system penetration 
  
Accumulates in patients 
with renal failure, not in 
patients with hepatic 
failure 
  
No pharmacokinetic drug 
interactions 
  
*: Therapeutic Cp range not well established; limited clinical use. Tmax: time to reach maximal 
plasma concentration; Cp: plasma concentration.  
 
Adverse Effects 
The side effects of sotalol are related to either its β-adrenergic antagonism or its capability of 
lengthening the QT interval. Sotalol is a non-cardioselective β-blocker, blocking both β1 and 
β2 receptors. Fatigue, dizziness, dyspnea or worsening of bronchospasm are common side 
effects associated with β2-blocking agents 
99
. Due to its class III effects, the chances of 
exacerbating congestive heart failure, a serious adverse effect of most β1-blockers, are 
significantly reduced with sotalol 
99,108
. The most dangerous adverse effects of sotalol are 
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aggravate preexisting arrhythmias or provoke new arrhythmias, the most notorious one being 
torsade de pointes, a polymorphic ventricular tachycardia. Predisposing factors such as 
hypokalemia, bradycardia or concomitant use of other QT interval prolonging drugs warrant 
close clinical, electrocardiographic and drug monitoring 
99
. In human clinical trials, adverse 
reaction leading to discontinuation of oral sotalol included fatigue (4%), bradycardia (3%), 
dyspnea (3%), proarrhythmia (3%), asthenia (2%) and dizziness (2%) 
108
. Special care should 
be taken when using sotalol in patients suffering from diabetes, renal failure, electrolyte 
disturbances and other drugs prolonging the QT interval.  The use of sotalol is contraindicated 




Although sotalol is frequently used in dogs suffering from ventricular arrhythmias, side 
effects of the therapy are rarely reported. In dogs, proarrhythmia is a rare adverse effect of 
sotalol, although the risk of proarrhythmic events is increased when high dosage is used or 
hypokalemia is present 
105,106,113
. 
Use in the Horse 
Because of its promising pharmacokinetic profile and its demonstrated antiarrhythmic effects 
in humans and small animals, sotalol is being increasingly used by equine veterinarians, at 
different dosages and dose intervals. However, apart from 2 recent reports describing the use 
of sotalol in 2 single cases, no studies on its pharmacokinetics, pharmacodynamics and 
clinical antiarrhythmic properties have been published 
114,115
. Therefore, studies determining a 
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57 Scientific Aims 
The first objective of this dissertation was to improve the diagnosis of atrial rhythm disorders 
both by veterinarians and by horse owners in the field. First, specific ECG characteristics 
associated with atrial premature depolarizations were studied to improve ECG interpretation. 
We hypothesized that an atrial premature depolarization may result in QRS complex and T 
wave morphology alterations, making differentiation between an atrial and a ventricular 
origin challenging. In addition, the use of heart rate variability as a novel diagnostic tool was 
studied. We hypothesized that heart rate variability parameters may allow to distinguish atrial 
fibrillation from sinus rhythm in horses and that heart rate monitors automatically calculating 
these parameters can be used to detect atrial fibrillation in the field. For this first part of the 
dissertation the specific aims were:  
- To describe the QRS complex and T wave morphology following atrial premature 
depolarizations in horses (Chapter 1) 
- To evaluate whether certain heart rate variability parameters differ between horses in 
atrial fibrillation and in sinus rhythm (Chapter 2) 
- To assess whether a heart rate monitor with automatic heart rate variability 
calculations can be used to detect atrial fibrillation in horses (Chapter 3) 
The second major objective was to investigate a new pharmacological treatment for atrial 
arrhythmias in horses by using oral sotalol. The hypothesis was that sotalol influences the 
electrophysiological properties of the heart and results in antiarrhythmic effects in horses. 
First, the pharmacokinetic profile and absolute oral bioavailability of sotalol in horses was 
studied as well as its effect on the surface ECG. Subsequently, the electrophysiological effects 
of different doses of sotalol on the equine heart were studied. Finally, the rate control 
properties of sotalol are evaluated in patients with naturally occurring atrial fibrillation. The 
specific aims of the second part of this dissertation were:  
- To determine the pharmacokinetic profile and absolute oral bioavailability of sotalol in 
healthy horses (Chapter 4) 
- To develop a technique for intracardiac monophasic action potential recording in 
standing horses (Chapter 5) 
- To study the effect of sotalol on the electrophysiological properties of the myocardium 
in healthy horses (Chapter 4 and 6) 
- To assess the effect of sotalol on heart rate, QT interval and atrial fibrillatory rate in 
















































ATRIAL PREMATURE DEPOLARIZATION-INDUCED CHANGES IN QRS AND 
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60 Chapter 1 
Summary 
Background:  The electrocardiographic differentiation between atrial (APDs) and ventricular 
(VPDs) premature depolarizations is important. P wave prematurity and normal QRS and T 
wave morphology generally are used as discriminating criteria for APDs.  
Hypothesis/Objectives: To determine whether P, Q, R, S and T wave amplitude, PQ interval, 
QRS  and P wave duration and P and T wave morphology differ between APDs and sinus 
beats. To determine the relationship between the RR coupling interval and the change in S 
wave amplitude between sinus beats and APDs. 
Methods: Case-control study. From a modified base-apex configuration of 30 horses with 
APDs at rest, sinus beat and APD-associated preceding RR interval, P, PQ and QRS duration 
and P, R, S and T wave amplitudes were measured. Linear mixed models and logistic 
regression were used to determine the effect of APDs on the ECG variables studied.  
Results: In comparison to sinus beats, APDs were associated with a significant (P<0.001) 
change in P amplitude (-0.03±0.01 mV) and increase in S (0.20±0.02 mV) and T (0.08±0.03 
mV) amplitude. PQ (-20.3±5.2 ms) and RR (-519±14 ms) interval and P duration (-21.1±3.0 
ms) decreased (P<0.001). APDs were significantly associated with a singular positive P wave 
(OR: 11.0, CI 6.2-20.0.0, P<0.001) and were more likely to have a monophasic positive T 
wave (OR: 9.2, CI 5.1-16.5, P<0.001). A smaller RR coupling interval was associated with an 
increased relative difference in S amplitude (P<0.01). 
Conclusions: APDs may lead to changes in QRS and T wave morphology. Knowledge of 









61 APD-induced changes in QRS and T wave morphology 
Introduction 
Electrocardiography is of increasing importance in equine medicine. Correct classification of 
different electrocardiographic complexes is important to differentiate clinically relevant 
abnormalities from physiological complexes. Electrocardiographic differentiation between 
ventricular (VPDs) and atrial premature depolarizations (APDs) is important because the 
clinical relevance of both types of premature cardiac complexes is very different.  During 
exercise, VPDs, especially when consecutive, are thought to be a risk factor for the induction 
of ventricular tachyarrhythmia, which can cause an abrupt decrease in blood pressure and may 
even lead to cardiovascular collapse. APDs can occur in normal horses but do, however, 
predispose to the development of atrial fibrillation 
1,2
. Because management and treatment 
options can vary depending on the diagnosis, it is important to correctly differentiate between 
APDs and VPDs. 
Ventricular dysrhythmias are the consequence of abnormal impulses arising somewhere in the 
ventricular myocardium, leading to a different ventricular conduction, and resulting in 
changes in QRS and T wave morphology and duration 
1-3
. However, depending on the site of 
origin, changes in ventricular conduction and morphology can sometimes be minimal 
2
. VPDs 
arise from the ventricular myocardium and result in AV dissociation: they are not associated 
with a preceding P wave and the normal sinus P wave often is not conducted, resulting in a 
compensatory pause 
4
. Atrial dysrhythmias are caused by abnormal impulse formation in the 
atrial myocardium outside of the sinoatrial (SA) node. In the case of APDs, ventricular 
conduction is not affected and QRS complex and T wave morphology remain unchanged 
1,3,5
. 
A premature P wave, with normal or abnormal morphology, usually is present, but can 
sometimes be buried in the preceding QRS or T wave and thus be difficult to visualize. If a P 
wave is not clearly visible, differentiation between a VPD and an APD can be challenging, 
especially when there are only mild changes in QRS and T wave morphology. Using multiple 
lead recordings can be helpful 
6,7
.  Each lead measures the cardiac depolarization from a 
different angle, so minor electrical changes sometimes can be more easily identified in 1 lead 
compared to the other. 
The aim of our study was to report P, QRS and T wave morphology associated with APDs at 
rest in order to improve the interpretation of electrocardiogram recordings. Therefore, the 
amplitude of  P, Q, R, S and T waves and the PQ interval and P and QRS duration of APDs 
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wave morphologies were investigated. Finally, the effect of the RR interval on the relative 
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Material and Methods 
Study design and population 
A case-control study was performed on 30 ECGs of 30 horses with APDs. Per horse, 10 
single APDs were included, whereby for each APD the preceding sinus beat was taken as its 
negative control. All ECGs belonged to horses presented to the Department of Large Animal 
Internal Medicine, Faculty of Veterinary Medicine, Ghent University for cardiac examination. 
All data were used with owner informed consent. Mean age and body weight of the horses 
was 11 ± 5 years and 569 ± 81 kg, respectively. Two stallions, 18 geldings and 10 mares were 
included. Breed was reflective of the hospital population, with 26 warmblood horses, 2 
Arabian horses, 1 French trotter and 1 Belgian draft horse. Nineteen horses had been 
presented for cardiac examination after electrical cardioversion (TVEC) of atrial fibrillation (4 
days [n=14] and 6 weeks [n=5] after TVEC). Two horses were diagnosed with mild to 
moderate mitral regurgitation, 1 horse had an aortacardiac fistula and 1 horse had suffered 
from intoxication with cardiac glycosides. Seven horses had APDs without any other cardiac 
abnormalities. Horses with VPDs were excluded from the study. 
Electrocardiography 
In all 30 horses, an ECG was recorded using a Televet100 recording system
a
. Four self-
adhesive electrodes were placed underneath a girth
b
. The right arm electrode was positioned 
15 cm right of the withers, the left leg electrode caudal to the left elbow on the thorax and the 
left arm electrode 10 cm above the left leg electrode, resulting in a modified base-apex 
configuration 
6,8
. A reference electrode was placed on the left side of the withers. All 
electrodes were connected to the recording device, placed in the girth. The ECG recordings 
were analyzed offline using dedicated software
c
. Standard gain (10 mm/mV) and paper speed 
(25 mm/s) were increased to 20 mm/mV and 200 mm/s to allow accurate analysis. Three 
different leads were displayed simultaneously to improve ECG interpretation (Fig 1). In the 
Televet system, leads 1 and 2 are recorded, whereas lead 3 is calculated, assuming an 
Einthoven triangle. Measurements always were performed in lead 2 (between the right arm [-] 
and left leg [+] electrode). For each horse, the first 10 APDs and their preceding normal sinus 
beats were included. An APD was defined as an individual atrial depolarization, occurring 
prematurely, meaning with an RR coupling interval at least 20% (arbitrary value) shorter than 
the RR interval of the preceding sinus beat. Only APDs followed by a QRS complex were 
included in the study. The ECGs were recorded at rest and heart rate varied between 35 and 
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QRS duration and P (P1 and P2 if present), Q, R, S and T (T1 and T2 if present) wave 
amplitudes were measured (Fig.2).  
Although measurements always were performed in lead 2 of the ECG, 3 different leads were 
recorded to allow for correct interpretation of the electrocardiogram (Fig.1). When P waves 
were difficult to visualize in lead 2 of the ECG, they often were better visualized in lead 1 or 
lead 3, so that a correct diagnosis of APD could be made.  
 
 
Figure 1: Electrocardiogram with 3 lead recording (1, 2, 3) showing an atrial premature 
depolarization (APD). In lead 2 the P wave of the APD is partially buried in the preceding T 
wave and difficult to identify. The S wave amplitude after the APD is increased and also T 
wave morphology has changed. Lead 1 and 3 clearly show the premature P wave. Gain: 20 
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Figure 2: Method of measurement of the different electrocardiographic variables used in the 
present study. For all atrial premature depolarizations and their preceding sinus beat RR and 
PQ interval, QRS duration and P1, P2, Q, R, S and T1 and T2 wave amplitude were 
measured. If a P wave was biphasic or bifid, only the largest amplitude was included in 
statistical analysis. For biphasic T waves, the total T wave amplitude (T), calculated as the 
sum of the absolute amplitudes of the positive and negative T wave (T1, T2) was used for 
statistical analysis.  
 
Data management and statistical analysis 
Statistical analyses were performed using SAS 9.4
d
. In Figure 2, the different measurements 
applied are shown. If the P wave was bifid or biphasic, only the largest amplitude was 
selected. Singular, bifid or biphasic nature of the wave was recorded as a categorical variable. 
For the T wave, if biphasic, the sum of the positive amplitude and the absolute value of the 
negative amplitude were used for statistical analysis. The T wave morphology was recorded 
as a categorical variable with 4 categories: biphasic positive-negative, biphasic negative-
positive, monophasic positive and monophasic negative. 
To determine the effect of an APD on P, Q, R, S and T amplitude and P, PQ and QRS 
duration, a linear mixed model was constructed with horse added as a random factor to 
account for clustering of measurements within a horse (PROC MIXED). A maximum 
likelihood model with Satterthwaite approximation was used. The outcome variables were 
tested for normal distribution (histograms and Q-Q plots) and validity of the final models was 
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Logistic regression was performed to determine associations between P and T wave 
morphology and APDs and RR intervals. A generalized linear model (PROC GLIMMIX) was 
used with binomial distribution and logit link function with Wald’s statistics for type 3 
contrasts. Horse was added as a random factor to account for the clustering of ECG 
recordings within a horse. Post hoc tests were done with Bonferroni corrections for multiple 
comparisons. Model fit was evaluated by the Hosmer-Lemeshow goodness-of-fit test for 
logistic models. In all models, significance was set at P<0.05. 
A mixed model approach (PROC MIXED) was applied to determine the relationship between 
the RR coupling interval of APDs and the change in S wave amplitude. The percentage 
change in S wave amplitude between a normal sinus beat and an APD was calculated as 
follows: S wave amplitude (sinus beat)/ S wave amplitude (APD) x 100. A maximum 
likelihood model with Satterthwaite approximation was used, and horse was added as a 
random effect. The outcome variables were tested for a normal distribution (histograms and 
Q-Q plots) and validity of the final models was checked by inspecting the residuals. In 
addition to the general analysis, in order to better understand the horse effect, the relationship 
between the RR coupling interval and the change in S wave amplitude was visually inspected 
and analyzed by simple linear regression in every individual horse. Validity of the models was 
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Results 
Changes in ECG measurements 
In total, 588 complexes (294 APDs and 294 preceding sinus beat controls) from 30 horses 
were collected. In 2 horses, only 6 and 8 APDs and preceding sinus beats could be measured, 
respectively. In all other horses (n=28) 10 APDs and their preceding sinus beats were 
included. For 96 of 300 APDs (32%) the ectopic P wave could not be accurately measured 
because it was fully or partially buried in the preceding T wave. In all horses, the majority of 
the QRS complexes, both from sinus beats and APDs, had an rS morphology, in 6 horses an S 
morphology was present in 5-35% of the complexes per recording. A Q wave was not visible 
in any of the horses. The S and the T amplitudes of APDs were significantly (P<0.001) 
increased as compared to sinus beats (mean difference±SD 0.20±0.02 mV and 0.08±0.03 mV, 
respectively) and PQ (-20.3±5.2 ms) and RR (-519±14 ms) intervals were decreased as 
compared to sinus beats (P<0.001). Furthermore, the P wave of an APD significantly differed 
from the P wave of a regular sinus beat (amplitude -0.03±0.01 mV, duration -21.1±3.0 ms). 
The R amplitude (P=0.51) and QRS duration (P=0.09) were not significantly different 
between APDs and sinus beats (Table 1).  
Table 1. Changes in ECG morphology in 588 recordings of 30 horses with APDs 
Variable n 
sinus beat  APD 
Estimated 
difference 




mean ± SD 
(range) 











-0.01±0.01 -0.04 - 0.02 0.51 




-0.20±0.02 -0.24 - -0.16 <0.001 




0.08±0.03 0.04 - 0.11 <0.001 




-21.1±3.0 -26.95 - 15.3 <0.001 




-20.3±5.2 -30.4 - -10.2 <0.001 




-519±14 -546 - -492 <0.001 




1.0±0.6 -2.1 - -0.2 0.09 
(ms) (98-164) (98-162) 
Horse was added as a random factor and was significant in each model (P<0.001) 
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The change in morphology was significantly horse-dependent for all variables, especially for 
the S wave amplitude (P<0.0001). In some horses, there was a large increase in the S wave 
amplitude in case of an APD whereas in other horses S wave amplitude hardly changed. The 
horses with the highest and lowest change in S wave amplitude had a mean±SD  increase in S 
amplitude of 44±10% and 3±5%, respectively. 
Changes in P and T wave morphology 
To determine associations between P wave and T wave morphology and APDs, 492 P waves 
(40% APDs, 60% sinus beats) and 588 T waves (50% APDs, 50% sinus beats) could be used. 
The APDs were significantly associated with a singular positive P wave (OR: 11.0, P<0.001) 
and were respectively more and less likely to have single positive (OR: 9.2, P<0.001) or 
single negative (OR: 0.2, P<0.001) T waves (Table 2). The RR interval significantly 
influenced T wave morphology (P<0.05). Within APDs, a monophasic positive T wave was 
associated with a shorter RR interval (mean ±SD: 935±46 ms), whereas monophasic negative 
T waves were associated with the longest mean RR interval (1485±62 ms). Those APDs with 
biphasic negative-positive T waves had a mean RR interval of 1286±42 ms. In normal sinus 
beats, the P wave was most often bifid (79.6%), whereas 62.2% of APDs had a monophasic 
positive P wave. As for the T wave, in normal sinus beats it was most often biphasic negative-
positive (67.3%), with a fairly small percentage monophasic positive (16.7%) or monophasic 
negative (15.3%) T waves. In APDs, however, almost half of the T waves changed polarity 
towards a monophasic positive morphology (41.5%; Table 2). APD morphology was not 
always consistent within the individual horse. The horse effect was significant (P<0.001) for 
P wave morphology, but not for T wave morphology.  
Table 2. Changes in P and T wave morphology associated with APDs  
    Sinus beat APD OR 95% CI P-value 
P wave Bifid 223 (79.6%) 60 (30.0%) Ref.     
Singular 66 (22.7%) 125 (62.2%) 11 6.1-20.0 <0.001 
Biphasic 2 (6.9%) 16 (8.0%) 4 5.7-333.0 <0.001 
Total   291 201   
T wave Biphasic: Pos-neg 2 (0.7%) 0 (0%) Excluded from analysis 
Biphasic: Neg-pos 198 (67.3%) 149 (50.7%) Ref.     
Monophasic: Pos 49 (16.7%) 122 (41.5%) 9.2 5.1-16.5 <0.001 
Monophasic:  Neg 45 (15.3%) 23 (7.8%) 0.2 0.1-0.5 <0.001 
Total   294 294       
Horse effect was significant for P wave morphology (P<0.001) not for T wave morphology 
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Relationship between RR coupling interval and S wave amplitude 
A total of 294 observations could be used to study the relationship between the RR interval 
and S wave amplitude. A significant negative relationship between RR coupling interval of 
the APD and the relative difference in S wave amplitude between a sinus beat and an APD 
was detected (P<0.01). The random horse effect was significant (P<0.001), and therefore 
detailed observations were made in every horse. In only 13% (4/30) of the horses, there was a 
significant (P<0.05) negative relationship between the RR coupling interval and the difference 
in S wave amplitude, and in 1 horse a significant positive relationship (P<0.01) was found. In 




70 Chapter 1 
Discussion 
Our study shows that, besides a change in P wave morphology,  APDs can induce changes in 
QRS complex and T wave morphology. In APDs, the S and T wave amplitude increased and 
PQ and RR interval decreased, whereas R amplitude and QRS duration did not change. The 
APDs were significantly associated with singular positive P waves and were more likely to 
have a single positive T wave.  
In the present study, only conducted APDs for which the RR interval was at least 20% shorter 
than the RR interval of the preceding sinus beat were included. This value is probably 
relatively high, but was arbitrarily chosen because currently no data are available for 
differentiation between APDs and sinus arrhythmia. We chose not to include horses with 
VPDs because in these horses one might argue whether an altered QRS morphology is a 
results of fusion beats. In horses with only APDs, this was very unlikely to occur.  
On visual inspection, the most prominent feature of an APD compared to its preceding sinus 
beat was a more negative S wave and a singular, instead of bifid, P wave. Furthermore, T 
waves often changed polarity in the case of an APD. Another important finding in this study 
was that horse was a strongly significant factor for all observations. This was especially clear 
for the change in S wave amplitude. Among the different horses, the mean increase in S wave 
amplitude for an APD ranged from 3±5% to 44±10%.  
Overall, a significant negative relationship between RR interval and the relative increase in S 
wave amplitude was found, meaning that the shorter the RR coupling interval, the larger the S 
wave amplitude of the APD, when compared with the preceding sinus beat. This relationship, 
however, was strongly horse dependent and can be influenced by differences in vagal tone, 
intraventricular conduction and altered QRS depolarization or repolarization 
9
. The RR 
interval also influenced T-wave morphology. Those APDs with short RR interval were more 
likely to have monophasic positive T waves.   
Current veterinary literature about ECG in horses usually states that, in the case of an APD, P 
wave morphology changes, whereas QRS and T wave morphology remains similar 
1,3,10
. In 
our study, P wave morphology did indeed change. The APDs were more likely to have 
singular positive P waves, instead of the bifid P waves which were seen in most normal sinus 
beats. In the case of an APD, the impulse originates from another location and conducts 
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our study, ECG registration was performed in a modified base-apex configuration because 
this configuration frequently is used in equine practice, especially during exercise and 24-hour 
ECG recording. This modified base-apex configuration produces fewer motion artifacts but 
lower P waves compared with a true base-apex configuration in which the right arm electrode 
is placed in the jugular groove 
8
. Furthermore, although in our study all ECG measurements 
were performed using the second lead, the P wave in our electrode configuration generally 
was best visualized in the first lead of the ECG (between the right arm [-] and the left arm [+] 
electrode). Those P waves buried in preceding T waves were therefore sometimes difficult to 
identify and could not be measured in 32% of the APDs. In these cases, leads 1 and 3 were 
very helpful to identify the APD. Inspecting multiple lead traces is therefore useful for ECG 
interpretation.    
Although it usually is stated that in the case of APDs, ventricular conduction is not affected 
and QRS complex and T wave morphology do not change, our study shows that, in addition  
to changes in P wave morphology, APDs also can lead to changes in QRS complex and T 
wave morphology. The APDs resulted in PQ shortening, increased S wave amplitude and a 
more positive T wave. Similar changes occur during exercise because of  a positive inotropic 
effect and an increase in sympathetic tone 
12,13
.  
Shortly coupled APDs may lead to very premature QRS complexes. For such short RR 
intervals, especially when occurring after a relatively long RR interval, the conduction system 
or parts of it might not be fully recovered yet, resulting in intraventricular conduction block. 
In other species, this conduction block commonly occurs at the right bundle branch and is 
known as Ashman phenomenon. The conduction block results in an aberrant conduction 
whereby part of the myocardium is depolarized from cell to cell. The ECG typically shows 
QRS widening with changes in QRS and T wave morphology. Whether similar mechanisms 
occur in horses is not known, but QRS widening did not occur. The increase in S amplitude 
and the T wave change toward a positive deflection are very similar to what occurs when 
heart rate physiologically increases (e.g. during exercise). Indeed, in 13% of the horses we 
found that, for the APDs, the RR interval and the change in S wave amplitude were inversely 
correlated, meaning that the shorter the RR coupling interval, the larger the difference in S 
wave amplitude between an APD and a sinus beat. In 83% of the horses, the relationship did 
not reach significance but this might be related to the small number of APDs (n=10) per 
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significantly influenced by changes in RR interval with a shorter RR interval leading to a 
more positive T wave. 
A decrease in left ventricular preload has been shown to result in smaller QRS amplitudes, as 
explained by the Brody theory 
14,15
. Premature depolarization results in a shorter diastolic 
interval and consequently a lower left ventricular preload. The increase in S wave amplitude 
found in our study can therefore not be explained by the Brody theory. Respiration also 
influences ECG amplitudes because of alterations in transthoracic impedance and changes in 
cardiac filling 
16,17
. However, this effect is not associated with APD occurrence and therefore 
not likely to have any effect on our results.  
In our study, a modified base-apex lead was used for ECG measurements because this lead 
often is used in clinical situations. The other Einthoven leads also were displayed for better 
interpretation of the ECG. However, one should be aware that most ECG units, such as the 
Televet100, only record lead 1 and 2 whereas lead 3 is calculated assuming an Einthoven 
triangle with the heart in the middle. In horses, these criteria are not fully met which results in 




This study has several limitations. Observers were not blinded to the electrocardiographic 
complexes, so they were aware of whether a cardiac cycle was a normal sinus beat or an APD. 
Blinding the observers would have been difficult to accomplish, because, for measuring the 
RR interval, the previous cycle must be included. As mentioned before, larger P waves could 
have been recorded from a true base-apex ECG. However, the placement of electrodes and 
lead recording were chosen to mimic the clinical situation. Furthermore, there was no control 
group of healthy horses included. A control group of horses without APDs would have 
allowed us to determine the natural variability in electrocardiographic measurements between 
successive normal sinus beats in order to compare those results with the variability between 
an APD and its preceding normal sinus beat. In our study, an APD was defined as an 
individual atrial depolarization with an RR coupling interval at least 20% shorter (arbitrary 
value) than the RR interval of the preceding sinus beat. We chose this relatively large 
difference as a criterion to minimize inclusion of early sinus beats. There is, however, a 
chance that some early sinus beats were included as APDs.   
In conclusion, our study demonstrated that APDs can lead to important changes in ventricular 
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more negative and the T wave often changes polarity from negative or biphasic to a 
monophasic positive T wave. These changes, which are strongly horse dependent, may lead to 
incorrect diagnoses, particularly when P waves are difficult to identify on the ECG. Clinicians 
should be aware of a possible change in QRS complex and T wave morphology not only with 
VPDs but also in the case of an APD in order to avoid mistakes. The use of multiple lead 
recordings can be useful to diagnose certain cardiac arrhythmias. 
 
Footnotes 
a: Televet100, Engel Engineering Services GmbH, Heusenstamm, Germany.  
b: Mainat Vet, Barcelona, Spain. 
c: Televet100 software version 5.1.2, Engel Engineering Services GmbH, Heusenstamm, 
Germany. 
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Summary 
Background: Atrial fibrillation (AF) is the most common pathological arrhythmia in horses. 
After successful treatment, recurrence is common. Heart rate monitors are easily applicable in 
horses and some devices offer basic heart rate variability (HRV) calculations. If HRV can be 
used to distinguish between AF and sinus rhythm (SR), this could become a monitoring tool 
for horses at risk for recurrence of AF.  
Objectives: The purpose of this study was to assess whether in horses AF (before 
cardioversion) and SR (after cardioversion) can be differentiated based upon HRV 
parameters.  
Study Design: Cohort study with internal controls.  
Methods: Six HRV parameters were determined in 20 horses, both in AF and in SR, at rest (2- 
and 5-minute and 1- and 4-hour recordings) and during exercise (walk and trot, 2-minute 
recordings). Time-domain (SDNN, RMSSD and Triangular index), frequency-domain (LF/HF 
ratio) and nonlinear parameters (SD1 and SD2) were used. Statistical analysis was done using 
paired Wilcoxon Signed Rank Tests and  Receiver Operating Curves.  
Results: HRV was higher during AF compared to SR.  Results for the detection of AF were 
good (AUC 0.8-1) for most HRV parameters. RMSSD and SD1 yielded the best results (AUC 
0.9-1). Sensitivity and specificity were high for all parameters at all recordings, but highest 
during exercise. Although AUCs improved with longer recordings, short recordings were also 
good (AUC 0.8-1) for the detection of AF. In horses with frequent second degree 
atrioventricular block, HRV at rest is increased and recordings at walk or trot are 
recommended.  
Main limitations: Animals served as their own controls and there was no long-term follow-up 
to identify AF recurrence. 
Conclusions: AF (before cardioversion) and SR (after cardioversion) could be distinguished 
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Introduction 
Atrial fibrillation (AF) is the most common clinically important arrhythmia in horses. 
Reported prevalence ranges between 0.3 and 2.5% of the population, with an 
overrepresentation in Standardbreds and Warmblood horses 
1-3
. Timely diagnosis and 
treatment are important and definite diagnosis is made with electrocardiography (ECG) 
4
. 
Successful restoration of sinus rhythm (SR) by electrical or pharmacological cardioversion 
can often be attained, but reported recurrence rates range between 16 and 43% 
5-9
. Diagnosis 
of early recurrence cannot always be performed by lay people and may require frequent 
veterinary visits. 
Heart rate variability (HRV) describes and quantifies the beat-to-beat variability and the long-
term variation in heart rate 
10
. Under the influence of both the autonomic nervous system and 
the neuroendocrine system, cyclical and beat-to-beat variations in heart rate are normal in the 
healthy individual. Decrease in parasympathetic tone and increase in sympathetic tone result 
in a decrease in short-term HRV. In human medicine, HRV is often used to predict prognosis 
in various cardiac disease states 
11
. In horses it has been used to study the autonomic 
regulation of the heart and it is frequently used in animal welfare studies, quantifying stress 
and pain 
12-17
. Since arrhythmia, especially AF, leads to an increased variation in beat-to-beat 
intervals, HRV parameters describing short-term (beat-to-beat) variability are expected to be 
increased compared to horses in SR. An increase in HRV in human patients with AF has been 
described and HRV parameters have been used to diagnose arrhythmias 
18-22
. If HRV 
parameters can also be used to differentiate AF from SR in horses, a heart rate monitor or 
smartphone app with automated HRV calculations would be an accessible diagnostic tool for 
both veterinarians and horse owners to monitor their horses for the presence of AF. The 
purpose of the current study was to determine whether HRV parameters at rest, during 
exercise at different paces and at different recording durations, differ between horses in AF 
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Materials and Methods 
Experimental design and population 
In this cohort study, each horse was used as its own internal control. Twenty Warmblood 
horses presented to the Department of Equine Internal Medicine, Faculty of Veterinary 
Sciences, Ghent University, for the treatment of AF using TVEC, were used 
23
. Inclusion 
criteria were electrocardiographic confirmation of AF and successful electrical cardioversion. 
Horses ranged between 5 and 15 years, with a mean±SD age of 10±3 years. Two stallions, 11 
geldings and 7 mares were included. Echocardiography was performed in all horses in AF. A 
resting ECG and a standardized exercise ECG were taken from each horse before (AF) and 5 
days after (SR) TVEC.   
Electrocardiography 
In all 20 horses an ECG was recorded using a Televet100 recording system 
a
. Four self-
adhesive electrodes were placed underneath a girth 
b
. The right arm electrode was positioned 
15 cm right of the withers, the left leg electrode caudal to the left elbow on the thorax and the 
left arm electrode 10 cm above the left leg electrode resulting in a modified base-apex 
configuration 
24,25
. A reference electrode was placed on the left side of the withers. All 
electrodes were connected to the recording device, placed in the girth.  
For resting ECG horses were confined in a stable with access to food and water. All horses 
had been stabled in this environment for at least 1 day in order to minimize environmental 
stress factors. The standardized lunging exercise test consisted of 5 minutes of walk, followed 
by 10 minutes of trot, 2 minutes of walk, 4 minutes of canter, 1 minute of gallop and 10 
minutes of walking. The ECG recordings were analyzed offline using dedicated software 
c
. 
Standard gain (10 mm/mV) and paper speed (25 mm/s) were used. RR intervals were 
automatically calculated by the software program (RR detection Equine), peak detection was 
set on negative (S wave). Three different leads were displayed simultaneously to improve 
ECG interpretation, but S peak detection was always performed in lead 2 (between the right 
arm (-) and left leg (+) electrode). All ECGs were visually inspected and corrected manually 
if necessary. Interference, electrical interruptions or software errors in peak detection were 
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Heart rate variability 
RR intervals were exported into a text file and subsequently imported into commercial 
software for HRV analysis 
d
. Each text file was blinded by giving a random number before 
analysis. For the resting ECG, 15 minutes after starting the ECG recording, a 2-minute, 5-
minute, 1-hour and 4-hour recording were analyzed. For the exercise ECGs, a 2-minute 
recording at walk and trot, starting 2 minutes after the onset of the walking and trotting phase, 
was analyzed. Six HRV parameters were used for further analysis. Three time-domain 
parameters: SDNN (standard deviation of the RR intervals), RMSSD (root mean squared 
successive differences in RR intervals) and Triangular Index (TI) (integral of RR interval 
histogram divided by height of the histogram); 1 frequency-domain parameter: LF/HF ratio 
(the ratio of the low frequency band over the high frequency band); and 2 nonlinear 
parameters: SD1 and SD2 (standard deviation of the Poincaré plot perpendicular to and along 
the line of identity, respectively) (Fig.1) 
11
.  For frequency-domain analyses, frequency values 
for horses were set at 0.001-0.005Hz for the very low frequency band (VLF), 0.005-0.07Hz 
for the low frequency band (LF) and 0.07-0.5Hz for the high frequency band (HF) 
10-12
. There 
were no filters nor artifact corrections applied.  
Data analysis  
Statistical analysis was performed using dedicated software 
e
. Descriptive statistics, quantile-
quantile plots and Shapiro-Wilk tests were used to check for normality of the data. Data were 
not normally distributed. Paired Wilcoxon Signed Rank Tests were used to detect significant 
differences between observations. Significance was set at P <0.05. Receiver operating 
characteristic (ROC) curves were used to study the performance of a parameter as a 
discriminatory variable for the detection of AF. The coordinate points of the ROC curves 
were used to determine the most fitting cut off values for each parameter at each recording. 
Cut off values were chosen to maximize sensitivity whilst retaining good (≥80%) specificity, 
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Results 
Echocardiography revealed mild to moderate mitral (11/15; 3/15), aortic (5/15, 0/15), 
tricuspid (7/15; 3/15) and pulmonary (1/15; 0/15) valve regurgitation in 15 horses and mild 
dilatation of the right (3/3) and left (2/3) ventricle and the right (1/3) and left (1/3) atrium in 3 
of those horses. In 5 horses, no structural or functional echocardiographic abnormalities were 
detected. 
All HRV values were significantly different in SR compared with AF (Table 1). In 11 horses 
in SR at rest, occasional arrhythmias (<1% of RR intervals) such as supraventricular 
premature depolarizations (SVPD) (8/11), second degree atrioventricular block (AVB2) 
(6/11), ventricular premature depolarizations (VPD) (2/11) and ventricular tachycardia (VT) 
(1/11) increased HRV, but not above the cut off values for AF. In 6 horses with frequent 
episodes of sinus arrhythmia, HRV parameters were within the limits of the other horses in 
SR. Where more arrhythmias (1-10% of RR intervals, n=2) were present, HRV values 
increased and sometimes hampered differentiation between SR and AF at rest. In 2 horses 
with very frequent (12% and 18% of the RR intervals) AVB2, HRV values at rest in SR 
approached or even exceeded those in AF. When these horses were exercised, AVB2 














Fig 1: RMSSD of 20 Warmblood 
horses in atrial fibrillation( AF; dotted 
lines) and in sinus rhythm (SR; solid 
lines) during a 2 minute ECG 
recording at rest and walk. Cut off 
RMSSD values for the detection of 
atrial fibrillation (302ms at rest and 
92ms at walk) are represented by the 
horizontal lines. Notice that 2 horses 
(black lines) with frequent second 
degree atrioventricular block in SR 
(black lines) show high RMSSD at 
rest, above the cut off for AF. At walk, 
both horses show an RMSSD below 
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Table 1: Median and range of 6 heart rate variability parameters in 20 warmblood horses in sinus 




Median Min Max Median Min Max 
2 min 
rest 
SDNN (ms) 158 22 901 462 240 1111 0.001 
RMSSD (ms) 89 18 1472 689 325 1745 0.001 
TI 14 4 21 22 13 34 <0.001 
SD1 (ms) 63 13 1051 490 21 1243 0.001 
SD2 (ms) 201 22 741 440 247 475 0.002 
LF/HF ratio 0.93 0.1 24.08 0.19 0.06 1.45 0.001 
5 min 
rest 
SDNN (ms) 154 65 781 469 306 1057 0.001 
RMSSD (ms) 102 29 1215 675 375 1686 0.001 
TI 17 8 40 34 24 45 <0.001 
SD1 (ms) 75 21 862 478 266 1196 0.001 
SD2 (ms) 196 63 838 478 308 902 0.002 
LF/HF ratio 2.4 0.09 70.23 0.16 0.85 0.43 <0.001 
1 hour 
rest 
SDNN (ms) 190 127 768 55 307 1077 <0.001 
RMSSD (ms) 128 47 1057 813 292 1647 <0.001 
TI 29 18 72 58 29 73 <0.001 
SD1 (ms) 91 33 748 575 277 1165 <0.001 
SD2 (ms) 242 156 788 544 327 982 0.001 
LF/HF ratio 2.79 0.17 39.86 0.26 0.13 0.36 <0.001 
4 hours 
rest 
SDNN (ms) 231 130 765 627 279 1148 <0.001 
RMSSD (ms) 153 42 1103 886 366 1804 <0.001 
TI 44 23 80 70 46 88 0.001 
SD1 (ms) 109 30 78 627 259 1276 <0.001 
SD2 (ms) 298 181 749 626 298 1003 <0.001 
LF/HF ratio 2.41 0.2 25.85 0.25 0.19 0.37 <0.001 
2 min 
walk 
SDNN (ms) 79 24 123 186 93 935 <0.001 
RMSSD (ms) 28 7 77 216 106 1195 <0.001 
TI 12 4 19 20 16 29 <0.001 
SD1 (ms) 20 5 55 153 75 850 <0.001 
SD2 (ms) 110 33 172 199 100 1017 <0.001 
LF/HF ratio 7.54 0.39 45.82 0.4 0.08 3.62 <0.001 
2 min 
trot 
SDNN (ms) 19 7 39 70 39 112 <0.001 
RMSSD (ms) 7 3 53 84 48 130 <0.001 
TI 4 2 9 13 8 21 <0.001 
SD1 (ms) 5 2 37 59 34 92 <0.001 
SD2 (ms) 24 8 51 73 43 138 <0.001 
LF/HF ratio 5.35 0.22 24.5 0.26 0.08 0.92 <0.001 
CI: conficence interval, SR: sinus rhythm, AF= atrial fibrillation, SDNN= standard deviation 
of the RR intervals, RMSSD = root mean squared successive differences, TI = Triangular 
Index, SD= standard deviation of the Poincaré plot perpendicular to (1) and along (2) its line 
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Table 2. Area under the Receiver Operating Curves (ROC) with cut off values, sensitivity and specificity 
for 6 heart rate variability parameters in 5 different recording phases for the detection of atrial fibrillation 
(AF) in 20 horses. A value above the cut off indicates AF, except for * where it indicates SR.  
Phase Variable AUC 




















SDNN (ms) 0.89 0.78 1 248 1 0.8 1 0.8 0.56 0.93 
  RMSSD (ms) 0.9 0.79 1 302 1 0.8 1 0.8 0.56 0.93 
Triangular I 0.92 0.84 1 17 0.9 0.67 0.98 0.8 0.56 0.93 
  SD1 (ms) 0.9 0.79 1 215 1 0.8 1 0.8 0.56 0.93 
  SD2 (ms) 0.87 0.75 0.99 283 0.9 0.67 0.98 0.8 0.56 0.93 
LF/HF ratio* 0.83 0.7 0.96 0.41 0.95 0.73 1 0.7 0.45 0.87 
5 min 
rest 
SDNN (ms) 0.89 0.78 1 279 1 0.8 1 0.8 0.56 0.93 
  RMSSD (ms) 0.93 0.83 1 367 1 0.8 1 0.9 0.67 0.98 
Triangular I 0.9 0.8 1 24 1 0.8 1 0.8 0.56 0.93 
  SD1 (ms) 0.93 0.83 1 260 1 0.8 1 0.9 0.67 0.98 
  SD2 (ms) 0.87 0.74 1 299 1 0.8 1 0.8 0.56 0.93 
LF/HF ratio* 0.88 0.76 1 0.38 0.95 0.73 1 0.85 0.61 0.96 
1 hour 
rest 
SDNN (ms) 0.92 0.82 1 305 1 0.8 1 0.8 0.56 0.93 
  RMSSD (ms) 0.94 0.85 1 310 1 0.8 1 0.9 0.67 0.98 
Triangular I 0.88 0.76 0.99 44 0.9 0.67 0.98 0.8 0.56 0.93 
  SD1 (ms) 0.94 0.85 1 219 1 0.8 1 0.9 0.67 0.98 
  SD2 (ms) 0.88 0.76 0.99 430 0.85 0.61 0.96 0.85 0.61 0.96 
LF/HF ratio* 0.96 0.87 1 0.39 1 0.8 1 0.95 0.73 1 
4 hour 
rest 
SDNN (ms) 0.93 0.83 1 350 0.94 0.73 1 0.85 0.61 0.96 
  RMSSD (ms) 0.94 0.85 1 318 1 0.8 1 0.9 0.67 0.98 
Triangular I 0.89 0.78 1 50 0.94 0.73 1 0.75 0.51 0.9 
  SD1 (ms) 0.94 0.85 1 225 1 0.8 1 0.9 0.67 0.98 
  SD2 (ms) 0.91 0.8 1 394 0.94 0.73 1 0.8 0.56 0.93 
LF/HF ratio* 0.96 0.88 1 0.59 1 0.8 1 0.9 0.67 0.98 
2 min 
walk 
SDNN (ms) 0.97 0.93 1 112 0.9 0.67 0.98 0.9 0.67 0.98 
  RMSSD (ms) 1 1 1 92 1 0.8 1 1 0.8 1 
Triangular I 0.96 0.91 1 16 0.9 0.67 0.98 0.9 0.67 0.98 
  SD1 (ms) 1 1 1 65 1 0.8 1 1 0.8 1 
  SD2 (ms) 0.91 0.82 1 148 0.85 0.61 0.96 0.8 0.56 0.93 
LF/HF ratio* 0.96 0.9 1 1.13 0.95 0.73 1 0.9 0.67 0.98 
2 min 
trot 
SDNN (ms) 1 1 1 39 1 0.8 1 1 0.8 1 
  RMSSD (ms) 1 0.98 1 46 1 0.8 1 0.95 0.73 1 
Triangular I 0.99 0.98 1 7.8 1 0.8 1 0.9 0.67 0.98 
  SD1 (ms) 1 0.98 1 33 1 0.8 1 0.95 0.73 1 
  SD2 (ms) 0.99 0.96 1 42 1 0.8 1 0.9 0.67 0.98 
LF/HF ratio* 0.96 0.9 1 0.94 1 0.8 1 0.9 0.67 0.98 
AUC: area under the curve, CI: confidence interval,Lower B: lower bound, Upper B: upper 
bound, SR: sinus rhythm, AF= atrial fibrillation, SDNN= standard deviation of the RR 
intervals, RMSSD = root mean squared successive differences, TI = Triangular Index, SD= 
standard deviation of the Poincaré plot perpendicular to (1) and along (2) its line of identity, 
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Area under the ROC curves and cut off values with their sensitivity and specificity for each 
parameter at each recording duration at rest or during exercise, are summarized in Table 2. 
AUCs were high (>0.8) for all parameters at rest and very high (>0.9) during exercise. 
RMSSD (Fig. 2) and SD1 overall had the highest sensitivity (100%) and specificity (80-
100%). From a 2-minute walk recording, RMSSD and SD1 had an AUC of 1 and 100% 
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Discussion 
The current study demonstrated that AF (before TVEC) and SR (after TVEC) can be 
differentiated based upon HRV parameters. Cut off values with good sensitivity and 
specificity were determined for SDNN, RMSSD, TI, LH/HF ratio, SD1 and SD2 at rest and 
during walking and trotting. At rest, good results with high sensitivity and specificity were 
obtained, even for short recordings. Light exercise (walk and trot), however, led to the most 
reliable cut off values.  
In this study, HRV is not used in its traditional way to study the autonomic control of the 
heart, but to quantify the variation in RR intervals to detect the presence of a certain 
arrhythmia. Ranges of HRV parameters are therefore different and not comparable with 
values published in previous studies using HRV as a tool to study autonomic tone. Higher 
variability represents more arrhythmia. In horses, due to their high parasympathetic tone, 
arrhythmias are common. AF, however, leads to an extremely irregular heart rhythm. The 
variability in heart rate was therefore expected to be higher when horses were in AF compared 
to  SR.  In human medicine several algorithms using HRV parameters are implemented in 
automatic devices detecting AF 
18-22
.  
Apart from AF, other arrhythmias might also increase HRV. We chose to study horses before 
and after TVEC as arrhythmias, such as SVPD, were expected to occur more frequently in the 
post cardioversion period, making the differentiation between AF and SR challenging. The 
presence of occasional (<1% of the RR intervals) arrhythmias did not increase HRV above the 
cut off values for AF but very prevalent arrhythmias might make the differentiation between 
SR and AF more difficult. In this study, frequent AVB2 resulted in increased HRV values but 
AVB2 was abolished at walk or trot. Most HRV parameters are based on beat-to-beat 
variability in RR interval. In AVB2, a blocked beat leads to a major increase in RR interval, 
while other arrhythmias, such as premature beats or sinus arrhythmia, lead to smaller changes, 
with less influence on HRV. In horses with frequent AVB2 or other arrhythmias, care should 
thus be taken when drawing conclusions from recordings at rest and suspicious recordings 
should be repeated while walking or trotting the horse. If HRV remains increased during 
exercise, a pathological arrhythmia is likely to be present. However, more studies are 
necessary to assess the influence of different pathological arrhythmias on HRV.  
Based on the results of a preliminary study investigating 144 different HRV parameters, data 
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devices and internet applications, we used 6 HRV parameters for our study 
11,26
. The simplest 
HRV value to calculate is SDNN. This is a time-domain parameter expressing overall HRV
11
. 
It is easy to use and readily available on various commercial heart rate monitors. Good results 
were obtained for SDNN, especially during exercise. At rest, the presence of frequent AVB2 
can lead to false positives. RMSSD is mainly used to represent short-term HRV (vagal 
influences) 
10,13
. Cut off values for this parameter had a sensitivity of 100% and a specificity 
80-100%, identifying all cases of AF with only a small chance of false positives. RMSSD is 
routinely used and available, which makes it an excellent tool for home monitoring. TI was 
chosen to include a geometrical time-domain parameter and represents overall HRV. It has 
the advantage of being less sensitive to the analytical quality of the RR interval, excludes 
outliers and covers many problems of artifacts 
10
. Its major disadvantage is the need for a 
relatively large number of RR intervals to construct the histogram. In horses, recordings of at 
least 60 minutes are advised to ensure the correct performance of geometric methods for 
studying autonomic tone 
10
. SD1 and SD2 are derived from nonlinear dynamics and based on 
the Poincaré Plot of the RR intervals. While excellent results were obtained for SD1, SD2 
yielded moderate results. Since SD2 mainly represents long-term HRV, and beat-to-beat 
variability is averaged out, it was expected to be less influenced by AF.  The Poincaré plot 
displays the RR intervals against their previous RR interval. Arrhythmias will thus cause a 
dispersion of the plot towards the upper left and lower right area of the graph, increasing SD1 
in particular (Fig.2). Finally, the ratio between LF and HF components was used as a power 
spectral density analysis method of HRV. In contrast to the other parameters, a value lower 
(and not higher) than the cut off value indicates the presence of AF. For short recordings at 
rest moderate sensitivity and specificity was obtained, so longer recordings at rest or 
recordings during exercise are necessary.  
Cut off values determined in this study were chosen to optimize sensitivity whilst retaining 
good specificity. As AF may be associated with potentially dangerous ventricular rhythms 
during exercise and because early diagnosis positively affects treatment outcome, our focus 
was to identify all horses with AF, even if this would include some false positives 
4
. 
Furthermore, if RR identification is correct and no artifacts or electrical interference are 
present on the ECG, false positives will most likely arise from horses with frequent 
arrhythmias. If these horses remain positive during exercise (walk and trot), it is likely that a 
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Fig 2: Poincaré plots of a horse at rest during atrial fibrillation (left) and sinus rhythm 
(right). RR intervals are plotted against their preceding RR interval. SD1 and SD2 are 
calculated as the standard deviation of the Poincaré plot perpendicular to and along the line 
of identity, respectively. Notice the dispersion of the values towards the upper left and lower 
right corner, increasing SD1 in case of atrial fibrillation. In case of sinus rhythm, notice how 
7 second degree atrioventricular blocks, increasing SD1, are visible in the upper left and 
lower right corner of the graph. 
 
This study demonstrated that AF can be distinguished from SR before and after TVEC using 
HRV. Because arrhythmias, especially SVPD, often appear more frequently in the post-
cardioversion period, this differentiation was probably more challenging in the current study 
than if a control group of normal horses had been used. Therefore it seems highly likely that 
HRV monitoring can be used to monitor horses at risk for developing AF, such as horses with 
mitral valve regurgitation, a dilated atrium, SVPD or horses after successful AF treatment. 
However, an important limitation of this study is that we did not include long-term follow-up 
until recurrence. 
Heart rate monitors can automatically generate some basic HRV calculations, mostly SDNN, 
RMSSD and/or SD1. The majority of equine HRV studies have used Holter recordings, but 
equine heart rate monitors have also been used 
14,27,28
. This is an accessible tool for both 
veterinarians and horse owners. In the current study, we used very short recording durations 
(2 and 5 minutes). Our study demonstrated only slight improvements in sensitivity and 
specificity when using longer (1 or 4 hour) recordings. Heart rate monitors have the benefit of 
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automatically detect the R-peak of the ECG. In horses, the T wave can by very pronounced 
and systems based on detecting R peaks by looking for sharp deflections from the baseline, 
can erroneously register T waves. Movement and electrical artifacts are common, especially 
during exercise, and may lead to erroneous R peak registrations.  Most heart rate monitors are 
not validated for the use in horses and significant differences between results from heart rate 
monitors and ECG recordings have been shown 
28
. Further studies are necessary to assess 
whether heart rate monitors can correctly detect RR intervals in horses and whether they can 
differentiate between horses in AF and in SR. 
We did not include exercise at high speed in this study. The exercise tests in SR were 
performed 5 days after TVEC and only low-level exercise was performed. In addition, based 
upon HRV parameters, discriminating between AF and SR at high heart rates is expected to 
be more difficult. In human medicine, HRV after cardioversion is used to predict AF 
recurrence. This was beyond the scope of the current study, but warrants further attention.   
Conclusions 
This study demonstrated that HRV is significantly increased when horses are in AF, 
compared to when they are in SR. HRV could potentially be used as a tool for early detection 
of AF in horses judged to be at risk. ECG would then be required to confirm the diagnosis. 
 
Manufacturers’ Details 
a: Televet100, Engel Engineering Services GmbH, Heusenstamm, Germany.  
b: Mainat Vet, Barcelona, Spain. 
c: Televet100 software version 6.0, Engel Engineering Services GmbH, Heusenstamm, 
Germany. 
d: Kubios 2.2,University of Eastern Finland, Finland  
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Summary 
Background: Heart rate variability (HRV) parameters, and especially RMSSD (root mean 
squared successive differences in RR interval), can be used to diagnose atrial fibrillation (AF) 
in horses. Some heart rate monitors (HRM) offer basic HRV calculations.  
Objectives: To assess whether RMSSD values obtained from a HRM can differentiate AF 
from sinus rhythm (SR) in horses. Furthermore the impact of artifact correction before HRV 
analysis was evaluated.   
Animals: Fourteen horses before and after AF treatment.  
Methods: Prospective clinical trial. Horses were equipped with two HRMs, one using plastic 
electrodes and another using an equine electrode belt, and an ECG. A two-minute recording at 
rest, walk and trot, before and after cardioversion, was obtained. RR intervals were 
determined automatically by the HRM and by equine ECG analysis software, and manually 
from the ECG trace. RMSSD was calculated by the HRM software and by dedicated HRV 
software, using six different artifact filters. Statistical analysis was performed using paired t-
tests, one-way ANOVA and receiver operating curves.   
Results: RR detection using an electrode belt was inconsistent. The HRM with plastic 
electrodes, which applies a low level filter, produced high AUCs (>0.9) and cut off values 
with high sensitivity and specificity for AF detection. Similar results were obtained for the 
ECG, when low level artifact filtering was applied. When no artifact correction was used 
during trotting, an important decrease in AUC (0.75) occurred.  
Conclusion: HRMs with automatic RMSSD calculations can distinguish between AF and SR 
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Introduction 
With a prevalence of 0.3-2.5% of the population, atrial fibrillation (AF) is the most common 
clinically important arrhythmia in horses. Treatment, either by pharmacological or electrical 
cardioversion, is often successful, but recurrence rates are reported to be relatively high (16-
43%) 
1-5
. Most horses with AF have little or no underlying cardiac diseases and clinical signs 
limited to different grades of poor performance. During strenuous exercise horses with AF 
can reach extremely high heart rates which may lead to R-on-T phenomenon and even 
collapse or sudden death 
6-8
. Timely diagnosis and treatment are important. After successful 
AF treatment, home monitoring by means of frequent auscultation or ECG is advised to check 
for AF recurrence. However, this cannot always be performed by lay people, requiring 
frequent veterinary visits or specialized equipment, which is time consuming and expensive.  
Heart rate variability (HRV) describes and quantifies the beat-to-beat variability and the long-
term variation in heart rate 
9
. The heart rate is influenced by both the autonomic nervous 
system and the neuroendocrine system. Cyclical and beat-to-beat variations in heart rate are 
normal in the healthy individual. In horses, HRV has been used to study the autonomic 
regulation of the heart and in animal welfare studies, quantifying stress and pain 
10-12
. Aside 
from its use as indicator of autonomic tone, HRV is used in human medicine to diagnose 
arrhythmias 
13,14
. Since arrhythmia, especially AF, leads to an increased beat-to-beat interval 
variation, HRV parameters describing short-term variability are increased compared to sinus 
rhythm (SR) and algorithms using HRV parameters are implemented in devices detecting 
AF
15-19
. In horses, HRV has already been evaluated for the detection of AF 
20
. In that study, 6 
different HRV variables were calculated from RR intervals of a manually corrected ECG, 
both in AF and in SR. RMSSD, the root mean squared successive differences in RR interval, 
yielded the best results with high sensitivity and specificity to distinguish AF from SR.  
Different types of heart rate monitors (HRM) are increasingly being used in horses and some 
of them offer basic HRV calculations, including RMSSD 
11,21,22
. They might be an accessible 
diagnostic tool for both veterinarians and horse owners to monitor horses for AF. Most 
HRMs, however, have not been validated for use in horses and significant differences 
between their RR registration and RR intervals from ECG recordings have been shown 
23
. 
Therefore the purpose of this study was to assess whether AF and SR can be differentiated in 
horses based upon RMSSD generated by a HRM and to compare this technique with manual 
ECG interpretation as golden standard. Furthermore the impact of artifact correction before 
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Materials and Methods 
Study design and study population 
Prospective clinical trial. Fourteen warmblood horses were presented to the Faculty of 
Veterinary Medicine, Ghent University for the treatment of AF. All horses were warmblood 
horses with a mean±SD age, bodyweight and height at the withers of 12±6 years, 544±62kg 
and 167±13cm. The study population consisted of 5 mares, 8 geldings and 1 stallion. All 
horses were included in the study with informed owner consent and cared for according to the 
principles outlined in the NIH Guide for the Care and Use of Laboratory Animals. Each horse 
was subjected to a recording at rest and a standardized exercise test including 5 minutes of 
walk and 10 minutes of trot, both in AF (before cardioversion) and in SR (5 days after 
cardioversion).  
Electrodes and heart rate detection 
Four different systems of heart rate detection (electrodes + RR detection) were compared 





 was manually analyzed using a commercial ECG software program 
b
 to 
obtain RR intervals (ECGMan). The same surface ECG was subsequently automatically 
analyzed by the commercial ECG software program 
b
 (ECGAut). Furthermore, a commercial 
plastic electrode set 
c
 and an equine heart rate electrode belt 
d
, each with their own heart rate 
sensor for RR detection 
e
, were attached according to the manufacturer’s instructions 
(HRMElec and HRMBelt).  
Because subjective assessment of heart rate detection suggested inconsistency, a preliminary 
evaluation of the different heart rate detection methods was conducted after examination of 
the first 8 horses. All RR interval files obtained by the different heart rate detection methods 
(ECGMan, ECGAut, HRMElec and HRMBelt) were imported into a software program for HRV 
analysis 
f 
and time-matched 2 minute recordings at rest and during walk and trot, were 
analyzed. Due to inconsistent results using the electrode belt, this technique was not further 
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Table 1. Four different methods for heart rate detection and heart rate variability calculations in 14 
warmblood horses. Due to inconsistent results, heart rate detection using the equine heart rate 
electrode belt was not continued after the first 8 horses and all belt data were further omitted from the 
study.  




Manual RR detection 
(Televet 100) 




Automatic RR detection 
(Televet 100) 
Kubios HRV Analysis 
HRMElec 
Plastic heart rate 
electrodes (Polar) 
Heart rate sensor Equine 
H7 (Polar) 
Polar Flow software 
HRMBelt 
Equine heart rate 
electrode belt (Polar) 




Heart rate variability and artifact correction methods 
From all 14 horses, RR intervals from both ECGMan and ECGAut were imported in Kubios 
Software 
f
 for HRV analysis, while RR data from HRMElec were imported into its own 
commercial software program 
g
 (Table 1). Subsequently, a time-matched 2-minute recording 
at rest, walk and trot, both in AF and SR, was selected for calculation of RMSSD. Each 
recording was obtained 2 minutes after a change in gait, in order to exclude movement 
artifacts and stress reactions from the gait change.   
Furthermore, for the ECGAut method, using the Kubios HRV software program 
f
, 5 different 
levels of artifact correction were applied. The artifact correction algorithm of this program 
compares every RR interval value against the average RR interval of the 2-minute recording. 
The average is obtained by median filtering of the RR interval time series, and is therefore not 
affected by single outliers in RR interval time series. RR intervals that differ from the local 
average more than a specified threshold value, are identified as artifacts and corrected by 
replacing the corrupted RR intervals by interpolated RR values. The threshold values used in 
this study were 0.45s (very low artifact correction), 0.35s (low), 0.25s (moderate), 0.15s 
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Statistical analysis 
Statistical analysis was performed using dedicated software 
h
. Descriptive statistics, quantile-
quantile plots and Shapiro-Wilk tests were used to check for normality of data.  
To evaluate the RR detection methods, mean differences in RMSSD and its standard 
deviations (SD) between the evaluated method and the golden standard were calculated and 
student paired t-tests were used to assess significant differences between the evaluated 
method and the golden standard. Significance was set at P <0.05. 
One-way ANOVA was used to detect significant differences in RMSSD between horses in 
AF and SR at different paces using the different detection methods and artifact correction 
levels. Receiver operating characteristic (ROC) curves were used to study the performance of 
each method and each artifact correction level as a discriminatory variable for the detection of 
AF. The coordinate points of the ROC curves were used to determine the most fitting cut off 
values for each parameter at each recording. Cut off values were chosen to maximize 
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Results 
Electrodes and heart rate detection 
Since RMSSD was calculated using the same software program for each RR detection 
method, differences in RMSSD were caused by differences in RR intervals and therefore by 
differences in RR detection. A graphical comparison between golden standard RMSSD from 
manually analyzed ECG and the 4 different methods for heart rate detection in the first 8 
horses is presented in Fig.1. RMSSD values using HRMBelt were significantly different 
(P<0.05) from the golden standard method (ECGMan) at all paces, both in AF and in SR, 
except for the recording at rest in SR (P=0.2). Mean differences between the ECGMan and 
ECGAut, HRMElec and HRMBelt were ranging, for the different paces, between -38ms and -
41ms, -22ms and -43ms and between +7ms and -20ms,  respectively. SD of the mean 
differences between RMSSD obtained from ECGMan and HRMBelt were large (range 171 – 
241 ms), indicating inconsistent heart rate detection with the belt. Therefore, the use of the 
belt was not continued and all belt data were omitted from the study.   
Heart rate detection using the other methods was not significantly different from the golden 
standard (P>0.05) and SD of the mean differences in RMSSD for ECGAut and HRMElec were 

















Fig. 1. Graphical comparison of 
RMSSD obtained by 4 different heart 
rate detection methods in 8 horses in 
atrial fibrillation.  
ECGMan= a manually analyzed ECG 
(Televet 100) with adhesive electrodes 
which served as golden standard. 
ECGAut= an automatically analyzed 
ECG (Televet 100) with adhesive 
electrodes. HRMElec= heart rate 
monitor (Polar Equine H7) using two 
plastic electrodes. HRMBelt= a heart 
rate monitor (Polar Equine H7) using 
an equine heart rate electrode belt. 
Kubios HRV software was used to 
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Distinguishing AF from SR and effect of artifact correction level 
Mean values for RMSSD are displayed in Table 2. RMSSD values were significantly 
different (P<0.001) between horses in SR and horses in AF, except when a very high level of 
artifact correction was used and at trot if no artifact correction was applied.  
AUCs, cut off values and their sensitivity and specificity for the use of RMSSD as a 
discriminatory variable for the detection of atrial fibrillation are displayed in Table 3. ECGAut, 
without artifact correction, led to reliable results at rest and at walk (AUC 0.96), but there was 
an important decrease in AUCs during trotting exercise (AUC: 0.75). Low level artifact 
correction during trotting exercise, led to a clear improvement in AUC (=1) and cut off values 
with very high sensitivity and specificity. High levels of artifact correction resulted in an 
important drop in AUCs, especially at rest. Using the Polar Flow software
g
 in combination 
with a plastic electrode set
c
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Table 2. Mean ± SD RMSSD values of 14 horses before (in atrial fibrillation (AF)) and 
after cardioversion (in sinus rhythm (SR)). 
Pace Method Artifact correction 
RMSSD SR RMSSD AF 
P-value 
Mean SD Mean SD 
Rest 
ECGMan none 107.21 86.99 725.71 339.3 < 0.001* 
ECGAut none 164.29 150.84 725.79 340.37 < 0.001* 
ECGAut Kubios very low 82.86 44.37 232.71 31.32 < 0.001* 
ECGAut Kubios low 80.07 42.42 195.5 18.62 < 0.001* 
ECGAut Kubios moderate 71.36 36.46 147.79 18.17 < 0.001* 
ECGAut Kubios high 57.71 22.52 80.07 14.47 0.006* 
ECGAut Kubios very high 31.5 10.18 32.07 21.72 0.93 
HRMElec Polar Flow 86.14 38.66 216.93 76.35 < 0.001* 
Walk 
ECGMan None 55.29 45.49 252.71 106.47 < 0.001* 
ECGAut None 90.5 58.61 262.86 96.33 < 0.001* 
ECGAut Kubios very low 42.36 26.68 182.79 31.18 < 0.001* 
ECGAut Kubios low 38.29 24.87 164.79 30.12 < 0.001* 
ECGAut Kubios moderate 35.64 19.96 134.07 18.58 < 0.001* 
ECGAut Kubios high 30.36 15.09 82.29 10.12 < 0.001* 
ECGAut Kubios very high 22.14 9.64 31.5 10.9 0.29 
HRMElec Polar Flow 37.21 22.22 115.71 30.34 < 0.001* 
Trot 
ECGMan None 11 4.17 92.07 25.81 < 0.001* 
ECGAut None 84.69 66.76 142.71 91.01 0.08 
ECGAut Kubios very low 23.92 16.88 97 32.13 < 0.001* 
ECGAut Kubios low 20.23 13.64 84.14 21.9 < 0.001* 
ECGAut Kubios moderate 16.46 8.45 75.14 20.44 < 0.001* 
ECGAut Kubios high 14.62 6.29 56.29 13.99 < 0.001* 
ECGAut Kubios very high 11.77 6.48 23.57 9.69 0.02* 
HRMElec Polar Flow 8.31 3.79 42.27 22 < 0.001* 
Two-minute recordings at rest, walk and trot were analyzed using 4 different methods of RR detection 
and HRV analysis. The manually analyzed ECG (ECGMan) with HRV analysis using Kubios HRV 
Software was considered the golden standard method. HRMElec= Polar heart rate monitor (Equine 
H7) with plastic electrodes and Polar Flow Software. ECGAut= ECG with automatic RR interval 
detection (Televet 100) and Kubios HRV software with 5 different artifact correction levels. The 
artifact correction algorithm identifies every RR interval that differs from the average RR interval of 
the 2-minute recording more than a specified threshold value as artifacts and replaces the corrupted 
RR interval by interpolated RR values. The threshold values used in this study were 0.45s (very low 
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Table 3. Area under the curve (AUC), cut off values and their sensitivity and specificity 
and 95% confidence intervals (95% CI) for the use of RMSSD as a discriminatory 
variable for the detection of atrial fibrillation in 14 warmblood horses. 
Pace Method Artifact correction AUC cut off 
sensitivity specificity 
  95% CI   95% CI 
Rest 
ECGMan none 0.99 215 1 0.77-1 1 0.77-1 
ECGAut none 0.96 383 0.93 0.66-1 0.93 0.66-1 
ECGAut Kubios very low 1 188 1 0.77-1 1 0.77-1 
ECGAut Kubios low 0.99 131 1 0.66-1 0.93 0.66-1 
ECGAut Kubios moderate 0.96 111 1 0.77-1 0.93 0.66-1 
ECGAut Kubios high 0.8 65 0.93 0.66-1 0.69 0.42-0.92 
ECGAut Kubios very high 0.38 24 0.5 0.23-0.77 0.38 0.13-0.65 
HRMElec Polar Flow 0.92 136 0.86 0.57-0.98 0.86 0.57-0.98 
Walk 
ECGMan None 0.97 121 0.93 0.66-1 0.93 0.66-1 
ECGAut None 0.96 164 0.93 0.66-1 0.86 0.57-0.98 
ECGAut Kubios very low 1 119 1 0.77-1 1 0.77-1 
ECGAut Kubios low 1 111 1 0.77-1 1 0.77-1 
ECGAut Kubios moderate 1 92 1 0.77-1 1 0.77-1 
ECGAut Kubios high 0.99 57 1 0.77-1 0.93 0.66-1 
ECGAut Kubios very high 0.74 22 0.78 0.49-0.95 0.57 0.29-0.82 
HRMElec Polar Flow 0.97 70 0.93 0.66-1 0.93 0.66-1 
Trot 
ECGMan None 1 36 1 0.77-1 1 0.77-1 
ECGAut None 0.75 90 0.86 0.57-0.98 0.72 0.42-0.91 
ECGAut Kubios very low 1 51 1 0.77-1 0.93 0.66-1 
ECGAut Kubios low 1 42 1 0.77-1 0.93 0.66-1 
ECGAut Kubios moderate 1 40 1 0.77-1 1 0.77-1 
ECGAut Kubios high 1 33 1 0.77-1 1 0.77-1 
ECGAut Kubios very high 0.93 15 0.93 0.66-1 0.93 0.66-1 
HRMElec Polar Flow 1 21 1 0.77-1 1 0.77-1 
Two-minute recordings at rest, walk and trot were analyzed using 4 different methods of RR detection 
and HRV analysis. The manually analyzed ECG (ECGMan) with HRV analysis using Kubios HRV 
Software was considered the golden standard method. HRMElec= Polar heart rate monitor (Equine 
H7) with plastic electrodes and Polar Flow Software. ECGAut= ECG with automatic RR interval 
detection (Televet 100) and Kubios HRV software with 5 different artifact correction levels. The 
artifact correction algorithm identifies every RR interval that differs from the average RR interval of 
the 2-minute recording more than a specified threshold value as artifacts and replaces the corrupted 
RR interval by interpolated RR values. The threshold values used in this study were 0.45s (very low 
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Discussion 
The ultimate goal of this study was to find an easily applicable tool for AF detection. In this 
study, AF could be differentiated from SR based upon RMSSD using a commercially 
available HRM. Investigation of different artifact filtering levels learned that high levels of 
artifact correction decreased test sensitivity and specificity, while low levels of artifact 
correction significantly improved sensitivity and specificity, especially during trotting 
exercise.  
In this study RMSSD was chosen as the HRV parameter to detect AF. RMSSD is a time-
domain HRV parameter and especially useful in assessing short-term HRV 
9,24
. In a previous 
study, using 6 different HRV parameters for AF detection in horses, RMSSD yielded the best 
results with cut off values with high sensitivity and specificity, identifying all cases of AF 
with only a small chance of false positives 
20
. Furthermore, RMSSD is a well-known and 
frequently used HRV parameter, available on a variety of HRMs, HRV software programs 
and mobile applications, which makes it a suitable tool for home monitoring. However, if 
RMSSD calculations are not available, SDNN (the standard deviation of the RR intervals) and 
SD1 (nonlinear parameter, derived from Point Caré plot), other frequently used HRV 
parameters and inter-related with RMSSD, might also be useful to detect AF 
20
.  
Several methods to record heart rate were used in this study. Manual analysis of an ECG trace 
using adhesive electrodes 
a
 and calculation of RMSSD by specialized software 
f
 was used as 
golden standard. However, this requires specialized equipment, expertise for ECG 
interpretation and data handling (exporting, importing), which is time consuming and 
expensive. Automatic analysis of the ECG trace by dedicated software 
b
 reduces analysis 
time, but also introduces error. HRMs are increasingly being used by both veterinarians and 
horse owners, because they are relatively cheap and easy to use. They automatically detect 
heart rate and some devices also generate HRV calculations, including RMSSD. Previous 
studies, however, have demonstrated significant differences between HRMs and ECG 
recordings and many HRMs have not been thoroughly validated in horses 
23
. In our study 2 
different electrode systems for heart rate monitoring, were evaluated 
12,21-23
. Heart rate 
detection using a commercially available equine heart rate electrode belt 
d
 was not reliable in 
our study, probably due to frequent movement artifacts, loss of contact and T wave detection, 
especially during exercise. Heart rate detection using a plastic electrode set 
c
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For the data obtained by the HRM, we used Polar Flow commercial software 
g
 for HRV 
analysis. There are, however, numerous other, often cheaper, software programs and mobile 
phone applications available automatically importing RR data from HRMs via Bluetooth, 
displaying them in real time and immediately generating some basic HRV calculations. These 
applications might be useful candidates for home monitoring of horses at risk for AF 
recurrence but need to be validated.  
Different HRV software programs might apply a different artifact correction method. The 
second goal of this study was to assess the effect of artifact correction levels on RMSSD as a 
discriminatory parameter for the AF detection. Artifact filters omit outliers, i.e. RR intervals 
that strongly differ from other RR intervals, and/ or replace them by interpolated values. 
Although this filtering helps to delete artifacts, it will also blunt the large beat-to-beat 
variation which is typical for AF. Low level artifact correction resulted in improved 
sensitivity and specificity approaching 100% at all paces. Furthermore, in horses in SR at rest, 
second degree atrioventricular block (AVB) was a common finding with a large impact on 
HRV. Low level artifact correction omitted AVB from the analysis, leading to better 
differentiation with horses in AF. The Polar Flow software
g
 also uses an algorithm for artifact 
correction, which cannot be adapted. Unfortunately the authors were not able to obtain the 
details of this algorithm, but comparison with Kubios artifact correction
f
 indicated that the 
Polar correction algorithm is of a low to moderate level.  Other HRV software or applications 
often allow manual adaptation of the applied artifact correction. Care should be taken when 
using unknown algorithms, filters or artifact correction.  
In human medicine, artifact correction algorithms are also used in AF detection devices
16,17,25
. 




Cut off values determined in this study were chosen to optimize sensitivity whilst maintaining 
a good specificity. Because early diagnosis positively affects outcome and AF may be 
associated with dangerous ventricular tachyarrhythmias, our focus was to identify all horses 
with AF, even if this would include some false positives. False positives, however, will most 
likely arise from either incorrect RR registration, electrical interference and movement 
artifacts, or from horses with frequent arrhythmias other than AF. If these horses remain 
positive at consecutive HRM sessions and during walk and trot, further electrocardiographic 
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Despite the relatively small study population, differences in HRV between SR and AF were 
large, leading to reliable cut off values. Also, power calculations based upon RMSSD 
differences between horses in AF and in SR from a previous study, indicated sufficient power 
to detect significant differences with 5-7 horses
20
.  An important limitation of the study was 
its self-control design. We used horses before and after cardioversion because arrhythmias, 
especially atrial premature depolarizations, often appear more frequently in the post-
cardioversion period. This probably made differentiation more challenging than if a control 
group of normal horses had been used. Since our goal was to diagnose AF recurrence after 
successful treatment, comparing AF to SR in the immediate post-cardioversion period, when 
the chances of relapse are the highest, most closely resembled the clinical situation in which 
this technique would be used.  
We conclude that in horses, AF can be differentiated from SR using RMSSD values obtained 
from automatically analysed ECGs but also from an equine HRM. One should be aware that 
heart rate detection technique as well as level of artifact correction are important.  
Footnotes:  
a Skintact, Leonhard Lang GmbH, Innsbruck, Austria 
b Televet 100 software version 5.1.2, Engel Engineering Services GmbH, Heusenstamm, 
Germany 
c Polar equine heart rate electrode set, Polar Electro Benelux, Dendermonde, Belgium 
d Polar equine heart rate electrode belt, Polar Electro Benelux, Dendermonde, Belgium 
e Polar heart rate sensor H7, Polar Electro Benelux, Dendermonde, Belgium 
f Kubios Heart Rate Variability Analysis Software, Varsitie 22, 70150 Kuopio, Finland 
g Polar Flow Software, Polar Electro Benelux, Dendermonde, Belgium 
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Summary 
Arrhythmias are common in horses. Some, such as frequent atrial or ventricular premature 
beats, may require long-term antiarrhythmic therapy. In humans and small animals, sotalol is 
often used for chronic oral antiarrhythmic therapy. Sotalol prolongs repolarization and the 
effective refractory period in all cardiac tissues. No information on sotalol pharmacokinetics 
or pharmacodynamics in horses is available and the aim of this study was to evaluate the 
pharmacokinetics of intravenously (IV) and orally (PO) administered sotalol and the effects 
on surface electrocardiogram and left ventricular systolic function. Six healthy horses were 
given 1 mg sotalol/kg bodyweight either IV or PO.  Blood samples to determine plasma 
sotalol concentrations were taken before and at several time points after drug administration. 
Electrocardiography and echocardiography were performed at different time points before and 
after IV sotalol administration.  
Mean peak plasma concentrations after IV and PO administration of sotalol were 1624 ng/mL 
and 317 ng/mL, respectively. The oral bioavailability was intermediate (48%) with maximal 
absorption after 0.94 h, a moderate distribution and a mean elimination half-life of 15.24 h. 
After IV administration, there was a significant increase in QT interval, but no significant 
changes in other electrocardiographic and echocardiographic parameters. Transient 
transpiration was observed after IV administration, but no adverse effects were noted after a 
single oral dose of 1 mg/kg in any of the horses. It was concluded that sotalol has an 
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Introduction 
In horses, supraventricular and ventricular arrhythmias can be associated with a wide range of 
cardiac and non-cardiac diseases. Frequent ventricular premature beats carry a risk of 
ventricular tachyarrhythmia and even ventricular fibrillation and sometimes requires long-
term, antiarrhythmic therapy 
1
. A high number of atrial premature beats may require treatment 
as atrial premature beats increase the risk of atrial fibrillation developing 
1,2
. In the first few 
days to weeks after cardioversion of atrial fibrillation, reverse remodeling takes place. During 




In human medicine, long-term oral antiarrhythmic treatment is often prescribed to reduce the 
chances to relapse into atrial fibrillation 
6,7
. Sotalol, a potent, non-cardioselective β-adrenergic 
blocking agent with class III antiarrhythmic action, has been shown to have an efficacy 
equivalent to propafenone and quinidine in preventing atrial fibrillation recurrence, but is 
significantly better tolerated by human patients 
8-10
.  In dogs, sotalol is used to prevent 
recurrence of atrial flutter and atrial fibrillation 
11,12
. Unlike many other antiarrhythmic drugs, 
sotalol has a good oral bioavailability (F) (90%) in humans, no major interaction with other 
drugs, no metabolism and is solely cleared through the urine 
13
. The most important side 
effects of sotalol are related to its β-blocking actions and the risk of torsade de pointes (a form 
of polymorphic ventricular tachycardia). Most antiarrhythmic drugs currently used in horses 
have a low F, are difficult for long-term administration or are very expensive. The present 
study investigates the pharmacokinetics of sotalol in horses and its effect on the surface 
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Materials and methods 
Study design 
Six healthy Standardbred horses, with a mean ± standard deviation (SD) age, bodyweight 
(BW) and height at the withers of  17±3 years, 527±46 kg and 156±23 cm, respectively, 
belonging to the teaching herd of the Faculty of Veterinary Medicine, Ghent University, were 
used. The experimental protocol was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine at Ghent University (case number EC 2012/149, date of approval 23 
November 2012).  
The horses received sotalol at an intravenous (IV) and oral (PO) dose of 1 mg/kg BW in a 
two-way cross-over design, with a wash-out period of 40 days. For the IV study, horses 
received 1 mg/kg sotalol (Sotalol Carino, Carinopharm) as a constant rate infusion over a 
period of 10 min. For the PO administration, after being withheld from food for 12 h, horses 
received 1 mg/kg of crushed sotalol tablets (Sotalol Sandoz) in 2 L of tap water by means of 
nasogastric intubation.  
Blood was withdrawn in heparinized polyethylene tubes just before and at 5, 15, 30, 45, 60, 
90, 120, 150, 180, 210, 240, 300, 360, 480, 600 and 720 min after administration, and every 
12 h after that, until 72 h after administration. Blood samples were immediately centrifuged 
for 10 min at 4000 g and plasma was frozen at -18 °C until drug assay. Clinical signs, heart 
rate (HR) and respiratory rates were recorded just before each blood sampling. The horses 
receiving IV sotalol were under continuous ECG surveillance until 12 h after drug 
administration. Echocardiography was performed before, and at 60 and 180 min after sotalol 
administration.  
Plasma analysis 
Quantitation of sotalol in the plasma samples was performed using a liquid chromatographic 
(LC) tandem mass spectrometric (MS/MS) method, developed and validated in house. To 250 
µL of plasma, 25 µL of the internal standard (IS) working solution (1 µg/mL, atenolol) were 
added and the sample was vortex mixed for 15 s. Subsequently, the sample clean-up consisted 
of a protein precipitation step using 750 µL of acetonitrile. After a vortex mixing (15 s) and 
centrifugation step (10 min, 7800 g), the supernatant was evaporated to dryness using a 
nitrogen stream (40 °C). The dry residue was re-dissolved in 250 µL ultra-performance liquid 
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filter (Millex-GN, Merck). The filtrate was transferred to an autosampler vial and a 5 µL 
aliquot was injected onto the LC-MS/MS system.  
The LC system consisted of an UPLC Acquity Binary Solvent Manager and Sample Manager 
with temperature controlled tray and column oven (Waters). Chromatographic separation was 
achieved on an Acquity UPLC BEH C18 column in combination with an Acquity BEH C18 
Vanguard pre-column (Waters). The mobile phases used consisted of 20 mM ammonium 
formate in UPLC-grade water (A) and UPLC-grade acetonitrile (B). A gradient elution was 
performed (0-2 min: 97% A, 2-5 min: linear gradient to 20% A, 5-6 min: 20% A, 6-6.5 min: 
linear gradient to 97% A, 6.5-10 min: 97% A) at a flow-rate of 0.3 mL/min. The LC column 
effluent was interfaced to a Quattro Premier XE triple quadrupole mass spectrometer with an 
electrospray ionisation source operating in the positive mode (Waters). Instrument parameters 
were optimized for both analytes (sotalol and IS) and the following multiple reaction 
monitoring transitions were selected: sotalol: mass to charge ratio (m/z) = 273.01 > 255.01 
(quantifier ion) and 212.96 (qualifier ion); IS: m/z = 267.06 > 144.96.   
The method was validated in house by a set of parameters that were in compliance with the 
recommendations as defined by the European Community 
1
, international guidelines 
2
 and in 
literature 
14
. The following parameters were evaluated: linearity (2-2000 ng/mL), within-run 
and between-run accuracy and precision, limit of quantification (LOQ, 2 ng/mL), limit of 
detection (LOD 0.26 ng/mL), specificity and carry-over. The validation protocol and the 
acceptance criteria used were previously described by De Baere et al. 
15
.   
Pharmacokinetic analysis  
Two-compartmental pharmacokinetic analysis was performed with dedicated software 
(WinNonlin 6.3 Pharsight). The most important pharmacokinetic parameters were calculated: 
maximal plasma concentration (Cmax), plasma concentration at time 0 (C0), time to maximal 
plasma concentration (Tmax), area under the plasma concentration-time curve from time 0 to 
infinite (AUC0-inf), absorption rate constant (ka), absorption half-life (T1/2a), distribution rate 
                                                 
 
1
 August 12, 2002. Commission Decision 2002/657/EC implementing Council Directive 96/23/EC concerning 
the performances of analytical methods and the interpretation of results. In: L221. Official Journal of the 
European Communities. 
2
 February 2011. Guidance for Industry, Studies to evaluate the metabolism and residue kinetics of veterinary 
drugs in food producing animals: validation of analytical methods used in residue depletion studies. In: VICH 
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constant (kelα), distribution half-life (T1/2elα), elimination rate constant (kelβ), elimination half-
life (T1/2elβ), clearance (Cl), volume of distribution in the central (Vc) and peripheral (Vp) 
compartment. The F was calculated for each horse according to the formula: 
F (%) = AUC0-inf PO / AUC0-inf IV x 100 
where Cl, Vc and Vp after oral administration were calculated by multiplying the output 
generated by the modelling software, namely Cl/F, Vc/F and Vp/F, with the F for each 
individual horse. 
Based on the data derived from the single PO administration study, plasma concentrations 
were predicted for multiple dosing of sotalol: 1, 2 and 3 mg/kg twice daily for 4 days. 
Maximal and minimal plasma concentrations at steady state (Cpss max and Cpss min) were 
derived from the dosing interval between 72 h and 84 h. The average plasma concentration at 
steady state (Cpss av) was calculated as follows: 
Cpss av = AUC72 h-t / τ 
with t the next time point of administration, 84 h, and τ the dose interval, 12 h. 
Electrocardiography 
An ECG was recorded using a Televet100 recording system (Engel Engineering Services). A 
modified base-apex configuration as described by Verheyen et al. 
16
 was used. The ECG 
recordings were analysed offline (Televet100 software version 5.0, Engel Engineering 
Services) by a blinded observer. The duration of the QRS complex and the P wave, and the 
RR, PQ and QT intervals were measured for 20 cycles before and at 15, 30, 60, 120, 180 and 
360 min after sotalol administration. All values were also corrected using the Fridericia 




All horses were examined with a HR < 45 beats/min, using an ultrasound unit (GE Vivid 7 
Dimension, GE Healthcare) with phased-array transducer (3S, GE Healthcare). A base-apex 
ECG was recorded simultaneously. All examinations were recorded digitally and analysed 
offline (EchoPAC software version BT12, GE Healthcare) by a blinded observer. 
Echocardiographic recordings and measurements were obtained as described elsewhere 
17, 18
. 
In brief, systolic function was assessed by calculating fractional shortening from left 




115 Pharmacokinetics of sotalol in horses 
((LVIDd–LVIDs)*100)/LVIDd) on a right parasternal short axis view M-mode at the chordal 
level. From a right parasternal left ventricular outflow tract view M-mode of the aortic valve, 
left ventricular pre-ejection period (LVPEP) was measured from the onset of the QRS 
complex to the opening of the aortic valve and left ventricular ejection time (LVET) from the 
opening to closure of the aortic valve. Pre-ejection period to ejection time ratio 
(LVPEP/LVET) was calculated to reduce the influence of HR on systolic time intervals. For 
each cycle the instantaneous HR was recorded. Three consecutive cycles were measured to 
calculate a mean value at each time point (0, 60 and 180 min) for each horse.  
Statistical analysis.  
Statistical analysis was performed using dedicated software (SPSS 21 for Windows, IBM). 
Pharmacokinetic parameters are reported as mean values ± SD. Linear mixed models with 
post hoc Dunnett’s comparison with baseline values were used to assess the relationship 
between ECG measurements and between echocardiographic measurements at different time 
points before and after the administration of sotalol. Differences were considered statistically 
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Results 
Pharmacokinetics 
Pharmacokinetic variables and plasma concentrations of sotalol after IV and PO 
administration are summarized in Table 1 and Fig. 1, respectively. In Fig. 2, the predicted 
steady state concentrations at a dose of 1, 2 and 3 mg/kg PO twice daily in fasted horses are 
shown. Table 2 summarizes the predicted AUC, Cpss av, Cpss max  and Cpss min.  
Table 1. Main pharmacokinetic parameters of sotalol 
hydrochloride after oral (PO) and intravenous (IV) 
administration (1 mg/kg BW) to fasted horses (n = 6). Values are 
presented as mean ± standard deviation. 
Parameter PO IV 
Cmax (PO) or C0 (IV) (ng/mL) 316.53 ± 56.59 1624.39 ± 297.37 
Tmax (h) 0.94 ± 0.31 / 
AUC0-inf (h.µg/mL) 3.38 ± 0.88 7.18 ± 1.10 
ka (h
-1
) 2.21 ± 1.46 / 
T1/2a (h) 0.50 ± 0.23 / 
Cl (L/h/kg) 0.15 ± 0.02 0.15 ± 0.03 
kel α (h
-1
) 1.10 ± 0.15 2.37 ± 0.39 
kel β (h
-1
) 0.05 ± 0.01 0.08 ± 0.01 
T1/2el α (h) 0.66 ± 0.11 0.31 ± 0.05 
T1/2el β (h) 15.24 ± 1.76 8.66 ± 0.70 
Vc (L/kg) 0.74 ± 0.11 0.66 ± 0.15 
Vp (L/kg) 1.89 ± 0.14 1.02 ± 0.01 
F (%) 47.84 ± 12.43 / 
Cmax, maximal plasma concentration; C0, plasma concentration at time 0; Tmax, time to 
maximal plasma concentration; AUC0-inf, area under the plasma concentration-time curve 
from time 0 to infinite; ka, absorption rate constant; T1/2a, absorption half-life; Cl, clearance; 
kel α, distribution rate constant; kel β, elimination rate constant; T1/2el α, distribution half-life; 
T1/2el β, elimination half-life; Vc, volume of distribution in the central compartment; Vp, 
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Fig. 1: Mean plasma concentrations ± standard deviations of sotalol after a single 




Fig. 2: Predicted steady state plasma sotalol concentrations based on the study results when 
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Table 2. Predicted area under the plasma concentration-time curve (AUC) for 
one dosing interval at steady state (72-84 h) and average, maximum and 
minimum plasma concentration of sotalol at steady state after oral 
administration of 1, 2 or 3mg sotalol/kg bodyweight two (bid) times a day to 
fasted horses (n = 6).  
  1 mg/kg bid 2 mg/kg bid 3 mg/kg bid 
AUC72-80/84 h  (h.ng/mL) 3212.52 ± 859.96 6392.48 ± 1695.80 
9673.13 ± 
3284.22 
Cpss av (ng/mL) 267.71 ± 71.66 532.71 ± 141.32 806.09 ± 273.69 
Cpss max (ng/mL) 498.11 ± 96.10 992.75 ± 189.72 1498.09 ± 344.00 
Cpss min (ng/mL) 178.09 ± 56.60 349.06 ± 115.02 548.88 ± 250.84 
AUC: area under the curve, Cpss av: sotalol plasma concentration at steady state; Cpss max: 
maximal sotalol plasmaconcentration, Cpss min: minimal sotalol plasma concentration. 
 
Electrocardiography 
Electrocardiographic variables at baseline and at different time points after IV STL 
administration are summarized in Table 3. Compared to baseline, mean QT interval was 
significantly increased at 15 (mean increase ± SD: 35 ± 27 ms, 6.0%, P = 0.026), 30 (37 ± 24 
ms, 6.2%, P = 0.018) and 60 (35 ± 25 ms, 5.6%, P = 0.039) min after STL administration. No 
significant difference was found for the corrected QT interval (QTc), although QTc at 15 min 
after STL administration was increased by 37 ± 18 ms (7.8%, P = 0.051). There were no 
significant differences in P wave and QRS duration or in RR and PQ interval, between 
baseline and any time point after IV STL administration, neither with nor without correction. 
 
Echocardiography 
Echocardiographic variables at baseline and at 60 and 180 min after IV STL administration 
are summarized in Table 3. There were no significant differences in FS, LVPEP, LVET and 
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Table 3. Summary of electro- and echocardiographic data (mean±SD) of 6 horses recieving 1mg/kg 
BW sotalol hydrochloride intravenously.  














P 163 17 157 14 159 16 158 20 168 15 164 16 ms 
PQ 359 52 361 47 367 48 371 56 385 54 381 50 ms 
QRS 141 9 136 11 136 7 136 11 141 10 141 9 ms 
QT 593*†ˠ 28 628* 23 630† 24 626ˠ 34 616 59 619 37 ms 
RR 1984 26 188 14 1885 14 1927 27 2019 22 2146 23 ms 
Pc 130 14 127 16 129 13 126 18 133 11 127 12 ms 
PQc 286 40 292 38 297 35 298 37 305 45 296 41 ms 
QRSc 113 7 111 8 110 6 110 10 111 7 109 8 ms 








FS 36 8 NA NA NA NA 37 5 37 5 NA NA % 
LVPEP 13 2 NA NA NA NA 13 2 14 3 NA NA ms 
LVET 47 3 NA NA NA NA 48 1 49 3 NA NA ms 
LVPEP/LVET 27 5 NA NA NA NA 26 4 29 7 NA NA   
C=corrected interval using the Fridericia correction; FS: fractional shortening; LVPEP= left 
ventricular pre-ejection period; LVET= left ventricular ejection time; NA= not available.  *, 
† and ˠ indicate significant differences: there is a significant difference between values with 
the same superscript. *: p= 0.026, †: p= 0.018, ˠ: p=0.039. 
 
 Tolerability 
After IV administration sweating (n = 3) and mild colic signs (n = 1) were observed. Oral 




120 Chapter 4 
Discussion 
In contrast to most available antiarrhythmic drugs, sotalol has a simple pharmacokinetic 
profile in humans. In our study in horses, the decline in sotalol plasma concentrations after IV 
or PO administration follows a two compartment pharmacokinetic model, as is the case in 
humans and small animals. In the present study, the absorption rate of sotalol in horses, was 
slower compared to dogs (T1/2a = 11-17 min) and similar to that in humans (Tmax = 1-4 h). 
Also F in horses was lower than in humans and dogs (F = 75-90%) 
19-21
.  
For many drugs the absorption after oral administration is lower in horses than in other 
monogastric species. This can be attributed to the herbivorous diet of horses which causes 
them to maintain some fermentative bacteria in the stomach flora, possibly interfering with 
drug absorption. Quinidine, administered by nasogastric tube, has a similar F (48±21%) 
compared to sotalol 
22
. Phenytoin has a medium F of 35±8% in the horse and amiodarone (F = 
6-33%) and propranolol (F = 1-32%) are poorly available 
23-25
. In the present study, horses 
were fasted before receiving oral sotalol. Further work is needed to better understand the 
influence of feeding on F of sotalol. Animal studies indicate that sotalol distributes into a 
number of tissues including the liver, heart and kidney 
26,27
. In our study, after PO 
administration, tissue distribution of sotalol was moderate and slightly lower than in humans 
(Vd = 1.2-2.4 L/kg) 
21
. The elimination half-life and clearance of sotalol in horses were 
similar to those published in humans (T1/2elβ = 10-20 h, Cl = 0.15 L/h/kg), but slower than 
those described in small animals (T1/2elβ = 4 h) 
13
.  
The pharmacological effects of sotalol are strongly related to its plasma concentrations. β-
blockade in humans occurs at concentrations between 0.8 and 1 µg/mL, while class-III 
activity starts from 1.2 µg/mL 
21,28
. Therapeutic concentrations used in human medicine lie 
therefore between 0.8 and 4 µg/mL, depending on the clinical indication 
13
. In small animals, 
an oral dose of 5 mg/kg twice daily, leading to plasma concentrations of 1.1 -1.6 µg/mL, 
results in β-blockade, class-III activity and QT prolongation 
29
. As displayed in Fig. 2 and 
Table 2, 2 and 3 mg/kg twice daily in fasted horses resulted in a predicted average plasma 
concentration approximating the therapeutic concentration used in human medicine. However, 
further studies are necessary to establish the efficacy and safety of these dosing protocols in 
horses.  
The class-III action potential prolonging effect of sotalol is important for its antiarrhythmic 
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prolongation, however, has been associated with torsade de pointes, a life-threatening 
ventricular tachyarrhythmia. In human medicine, the dose-effect relationship between oral 
sotalol and QT prolongation has been widely studied 
30-32
. In our study in horses, a single IV 
dose of 1 mg/kg caused a small QT prolongation. After correction of the QT interval for HR, 
results were close to significant with an increase in QTc interval of 37±18 ms. In this study, 
the Fridericia formula was used to diminish the influence of HR on QT interval. However, 
there is no general consensus on which formula to use and all are subject to possible under- 
and overcorrection. It is therefore possible that a different correction formula would have 
been more appropriate. 
Several studies on IV dosed sotalol in humans and in dogs revealed negative chronotropic and 
limited negative inotropic effects, because of the β-blocking action counterbalancing the 
class-III activity of the drug 
33,34
. Similar as in human studies, in our study FS, LVEP, LVET 
and LVEP/LVET were unchanged 
35-37
.  
Sotalol toxicity is associated with proarrhythmia. Generally adverse effects of sotalol 
administration occur after overdosing or in association with electrolyte disturbances or renal 
failure, but on rare occasions sotalol can induce ventricular arrhythmia even at therapeutic 
dosages 
38,39
. The risk of initiating torsade de pointes can be attributed to its propensity to 
lengthen the QT interval, rather than its β-blocking action. Avoiding hypokalaemia, excessive 
QT prolongation and bradycardia is important to prevent ventricular tachycardia 
13,39
. 
Underlying renal disease and the use of diuretics may require dose adjustments 
28,40
. In human 
medicine, if high concentrations are required, effects on QT interval are monitored with 
prolongations of more than 20% being an indication to reduce the dose 
41
. In our study, a 
small prolongation in QTc interval (7.8%) was noted after 1 mg/kg sotalol IV. Adverse effects 
noted after IV administration of sotalol in our study were local sweating and mild colic. Also 
in human medicine, abdominal discomfort and sweating have been reported as  side effects of 
sotalol and other beta-blocking agents.   
The main limitation of our study is its low power. Because of the small study population, 
conclusions should be drawn carefully. A larger study population would better allow the 
identification of small changes in electrocardiographic and echocardiographic measurements.  
The inclusion of a control group would have enabled us to eliminate environmental 
influences. Urine was not collected during the entire study period in order to clarify the 
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models had to be used to draw conclusions about steady state concentrations with different 
dosing protocols. These models are subject to variability and are less reliable than clinical 
studies on animals. Also, sotalol was given to fasted horses in this study. More studies are 
needed to correctly asses the influence of feeding on the F.   
Conclusions 
Sotalol seems promising because of its oral bioavailability and its ease of administration. The 
IV administration of 1 mg/kg resulted in relatively high plasma concentrations. There was a 
small QT prolongation, with no significant changes in other electrocardiographic 
measurements, or in echocardiographic assessment of left ventricular function. Further studies 
are needed to assess the effect of feeding on plasma concentrations and to study the effects of 
higher plasma concentrations on electrocardiographic and echocardiographic parameters, in 
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Summary 
Reasons for performing the study: In human medicine, monophasic action potential (MAP) 
analysis and determination of local refractory periods by contact electrode technique gives 
highly accurate information about cardiac electrophysiological properties. It is used to 
investigate dysrhythmias and the impact of drugs on the myocardium. Precise measurement of 
total MAP duration is difficult, therefore the MAP duration is usually determined at a 
repolarization level of 90% (APD90). 
Objectives: To determine the feasibility, amplitude and APD90 of right cardiac MAP 
recordings and to measure local refractory period in standing non-sedated healthy horses by 
using a contact electrode. 
Study design: prospective study. 
Methods: In 6 healthy Warmblood horses, on two different days, an 8F quadripolar contact 
catheter was passed through a jugular introducer sheath and placed under ultrasound guidance 
at the level of the tuberculum intervenosum or right atrial free wall (RA), and in the right 
ventricular apex (RV) to record the MAP. The MAP amplitude and APD90 were measured at 
a resting heart rate of 30-42 BPM and at pacing cycle lengths (PCL) of 1000 and 600ms. The 
effective refractory period (ERP) was determined at PCL of 1000 and 600ms. 
Results: The overall mean (±SD) APD90(rest), APD90(1000) and APD90(600) were 
263±39ms, 262±41ms, 236±47ms for the RA and 472±26ms, 412±34ms, 331±45ms for the 
RV. The mean ERP1000 and ERP600 were 273±24ms and 256±22ms for the RA and 
386±40ms and 293±30ms for the RV. The day-to-day variability for the amplitude, APD90 
and ERP measurements were high, low to moderate and low, respectively. 
Conclusions: RA and RV MAP duration and ERP can be obtained by a contact electrode in 
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Introduction 
Electrocardiography (ECG) is the most commonly used technique for recording electrical 
activity of the myocardium. However, it does not provide precise information regarding the 
dispersion of repolarization or after-depolarizations since an ECG represents the summation 
of electrical activity of many myocardial cells from a relatively large region of the heart 
1
. The 
local electrical activity of the in situ beating heart can be assessed by monophasic action 
potentials (MAP). This waveform can be obtained by slight pressure of a contact electrode on 
the heart muscle and is a result of membrane potential discharges (depolarization) and slow 
recharges (repolarization). MAP is useful for investigation of the electrophysiology of 
different arrhythmias and  the impact of drugs on the heart 
2-4
. In humans and animals, MAP 
recordings by contact electrode can give highly accurate information about local atrial or 
ventricular activation time and the entire duration of myocardial repolarization 
2,5-10
. The 
underlying principles concerning MAP recordings are described elsewhere 
1,11,12
. 
This paper describes the technique and the day-to-day variability of right cardiac MAP 
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Materials and methods 
The experimental protocol was approved by the Ethical Committee of the Faculty of 
Veterinary Medicine and the Faculty of Bioscience Engineering at Ghent University (case 
number EC 2015/85, date of approval 9
th
 of September, 2015). 
The study population consisted of 6 healthy warmblood horses (3 geldings, 3 mares) aged 
10±5 years, with a body weight of 531±70 kg and a height at the withers of 160±6 cm. 
Cardiovascular or other diseases were excluded based on a physical examination, a complete 
blood exam, an echocardiographic examination, a 30-minute resting ECG and a 20-minute 
standardized exercise ECG. All horses underwent the procedure on 2 different days with at 
least 2 weeks interval. In each horse an 8.5F introducer sheath (Introflex)
a
 was placed using 
the Seldinger technique in the lower third of the jugular vein. An 8F quadripolar contact 
catheter with separated recording and pacing electrodes (EasyMap MAP)
b
 [7-8] was 
introduced via the introducer sheath. The catheter was placed under ultrasonograpic guidance 
at the level of the tuberculum intervenosum (n=9) or the right atrial free wall (RA) (n=3) and 
in the right ventricular apex (RV) (n=12). The catheter tip was pressed softly against the 
endocardium. MAPs were recorded after placement of the catheter in a position that provided 
continuous recordings with a stable amplitude of >2 mV in the RA and >3mV in the RV, a 
stable baseline, a sharp positive phase and an upward convex plateau phase 
11
. MAP signal 
and a surface ECG (base-apex) were recorded simultaneously using a multichannel recorder 
(PowerLab 8/35)
c
 with amplifier (Bio Amp and Quad Bridge Amp)
c
 and digitized on a 
computer. Measurements were performed off-line using the cardiac action potential peak 
analysis module of a specialized semi-automatic data analysis software program (LabChart 
8)
c
. The minimum peak height detection was set at 1.5 mV and an automatic resting 
membrane potential detection was used. The MAP signals were amplified using a low-pass 
filter with settings between 20-50 Hz because it reduces noise which results in a smoother 
signal. Each MAP curve was checked separately and only MAPs where the automatic resting 
membrane potential was automatically set at the level of true baseline were used. In every 
horse, 15 cardiac cycles were analysed per chamber and per day. The APD90 was 
automatically measured by the software as the duration between the upstroke and 90% 
repolarization. The amplitude was measured as the height from baseline to the crest of the 
plateau phase. First, measurements were made in sinus rhythm at rest at a cardiac rate 
between 30-42 BPM. Subsequently, to have a more stable rhythm and to follow the impact of 
heart frequency on action potential characteristics, the pacing electrodes of the MAP catheter 
were connected to a pacemaker programmer
d
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length 1000 and 600ms to record MAPs at each pacing rate. Finally, atrial and ventricular 
effective refractory periods (ERP) were determined as previously described 
13,14
. In brief, after 
pacing for two minutes with a fixed pacing interval (S1-S1), an extra stimulus (S2), at two 
times threshold amplitude, was introduced with a coupling interval (S1-S2) below the 
expected refractory period. The coupling interval was then increased in steps of 8 ms until 
capture of the extra stimulus occurred (the atrial or ventricular S2 was followed by a P wave 
or QRS complex on the surface ECG, respectively). The longest S1-S2 interval without 
capture was taken as the effective refractory period. ERP was always determined five times to 
obtain a mean value. After the procedure, all catheters were removed under ultrasound 
guidance.  
Data analysis 
Statistical analyses were performed using dedicated software
e
. Mean and standard deviation 
(SD) were calculated from pooled measurements of all examinations for each horse. 
Measurement variability was obtained by comparing the results of the measurements from 
day 1 and day 2 in a one-way repeated measures analysis of variance with the horse as the 
unit of repeated measure. The numerical values for the reported coefficients of variation (CV) 
were calculated by dividing the square root of the mean square error (MSE) by the grand 
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Results 
Right atrial (Fig.1A) and right ventricular (Fig.1B) MAP recordings of sufficient quality 
could be obtained and analysed in non-sedated standing horses. However, horse movements 
occasionally resulted in loss of contact requiring MAP catheter repositioning. The total 
recording time per horse and per day ranged between 35-165 minutes. Catheter positioning 
was occasionally associated with self-limiting atrial or ventricular depolarizations which 
terminated after slight catheter tip movements. During atrial ERP measurements, a short 
episode of self-limiting atrial tachycardia was occasionally found and one horse showed a 20-
minute paroxysm of atrial fibrillation. Ventricular ERP measurements were never associated 
with tachyarrhythmias. No complications were observed after the procedure. Typical right 
atrial and ventricular MAP recordings are shown in Figure 1. The results of the two different 
days and the overall mean±SD are shown in Table 1. The day-to-day variabilities for the 
amplitude, APD90 and ERP measurements were high, low to moderate and low, respectively 
(Fig.2 and 3). A difference of up to 100ms was observed during VERP1000 measurement in 
one horse.   
Table 1: Mean ±SD and coefficient of variation (CV) of monophasic action potential 
amplitude and duration at 90% repolarization (APD90) and effective refractory periods 
(ERP) measured at rest and at a pacing cycle length of 1000 and 600ms in the right atrium 
and right ventricle in 6 horses. 
Parameter 
RIGHT ATRIUM RIGHT VENTRICLE 
mean±SD   mean±SD   
Day 1 Day 2 Overall CV % Day 1 Day 2 Overall CV % 
amplitude (rest)(mV) 6.9±1.9 4.4±1.9 5.7±2.3 35.6 8.7±2.6 8.1±4.7 8.4±3.6 42.7 
amplitude(1000)(mV) 6.0±2.0 4.0±1.0 5.0±2.0 44 9.0±4.0 8.0±5.0 9.0±4.0 58.1 
amplitude(600)(mV) 6.0±1.0 6.0±2.0 6.0±2.0 37.3 9.0±3.0 8.0±5.0 9.0±4.0 64.2 
APD90(rest)(ms) 282±41 244±29 263±39 9.1 477±31 467±21 472±26 6.7 
APD90(1000)(ms) 281±47 243±23 262±41 12.3 418±28 406±41 412±34 10 
APD90(600)(ms) 242±17 231±67 236±47 21.6 324±36 338±56 331±45 8.8 
ERP1000 (ms) 269±18 277±31 273±24 7.9 401±34 370±43 386±40 11.8 











 Figure 1: Electrocardiogram (red) and monophasic action potential recording (green) from 
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Figure 2: Day-to-day variability of the amplitude of the monophasic action potential in the 
right atrium and right ventricle of 6 warmblood horses. 
 
Figure 3: Day-to-day variability of the monophasic action potential duration at 90% 
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Discussion 
The present paper describes the technique to determine right atrial and right ventricular 
repolarization and refractoriness in the standing non-sedated horse. In humans, dogs, cats and 
pigs, MAP recordings play an important role in the investigation of myocardial 
electrophysiology under physiological, pathological and pharmacological conditions and have 
a low risk 
3,15-19
. However, complications such as sustained dysrhythmias, movement artefacts 
or pericardial effusion have been reported 
20
. In our study, complications were limited to a 
few short episodes of ectopic rhythms and one short episode of atrial fibrillation during ERP 
measurement. The ERP values in our study were comparable with previously reported 
results
14
. The coefficient of variation of the ERP measurements ranged between 7 and 12% 
but in one horse the difference in VERP1000 measurement on 2 different days was >100ms. 
As observed in awake dogs, neck and body movements of the horse occasionally resulted in 
dislocation of the catheter and loss of tip pressure, increasing recording time and 
measurement variability 
20
. Due to a more fixed catheter position in the apex, dislodgement of 
the catheter tip was less frequently observed in ventricular MAP recordings. Probably, some 
spatial repolarization differences also contributed to the measurement variability 
11,14
. MAP 
duration and amplitude can be variable due to angle differences of the catheter tip relative to 
the myocardium, the catheter location and varying endocardial contact pressures in the 
beating heart 
11,20
. Prolonged good quality MAP recordings from the same endocardial site 
(up to 1 hour), as described for awake dogs, could not be achieved in our horses 
20
. Mild 
sedation or the use of another type of catheter could have facilitated the procedure in our 
study. In humans and sedated dogs, the MAP amplitude of the atrium and ventricle ranges 
between 5 and 50mV due to a variability in contact pressure but also due to tissue type and 
species 
11,18,21
. The difference in amplitude between the atrium and the ventricle can partly be 
explained by differences in thickness of the endocardial tissue beneath the tip of the 
catheter
18
. The reason for the species- and tissue-related difference in MAP amplitude is still 
not clear 
20
. Intracellular recordings have amplitudes of approximately 120 mV regardless of 
species or tissue . The MAP amplitude in our horses ranged between 2 and 10 mV for the 
atrium and between 3 and 16 mV for the ventricle, which could be related to endocardial 
properties. The large size of the equine heart seems to be a large disadvantage and has 
probably also contributed to a less stable catheter position. The most frequently used filters 
during MAP measurements are the low-pass filter and the high-pass filter. The guidelines of 
the program we used, recommends the use of a low-pass filter since it lets low frequencies 
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MAP signal. The use of a high pass filter allows high frequencies to pass and removes any 
steady component or slow fluctuations from the signal. This setting is used to stabilize 
baseline. In this study we have chosen a low pass filter to have smoother MAP signals. In 
addition, each MAP signal was checked to evaluate if the automatic resting membrane 
potential was really automatically set at the level of baseline. 
Despite ultrasonographic guidance, altered catheter location, changes in contact pressure by 
the beating heart and horse movements contributed to the variability. Further research is 
necessary to identify whether repeating the measurements in a higher number of horses, 
harder pressure on the catheter tip, measurement under general anaesthesia or using another 
type of catheter (for example with a spring-steel stylet that is inserted into the myocardium) 
results in a lower variability in horses 
11
. Also the influence of spatial differences within right 
atrium and right ventricle, and between the left and right heart should be investigated.  
The present study describes the feasibility and measurement variability of MAP recording and 
refractory period measurement with a quadripolar contact catheter in the standing non-sedated 
horse. Further research is necessary to evaluate whether this MAP recording technique can be 
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Summary 
Background: Arrhythmias in horses may require long-term antiarrhythmic therapy. 
Unfortunately, oral antiarrhythmic drugs for use in horses are currently scarce. In human 
patients and small animals, sotalol, a β-blocker with class III antiarrhythmic properties, is 
often used for long-term treatment.  
Objectives: To determine the pharmacokinetics of sotalol at multiple oral dosages in unfasted 
horses, as well as the effects on electro- and echocardiographic measurements, right atrial and 
ventricular monophasic action potential (MAP) and effective refractory period (ERP).  
Study design: Prospective, placebo controlled, double-blinded experimental study. 
Materials and Methods: 6 healthy, unfasted warmblood horses were given either 0, 2, 3 or 4 
mg/kg body weight sotalol orally (PO) twice daily (bid) for 9 days in a randomised cross-over 
design with a wash-out period of 4 weeks. Echocardiography and surface electrocardiography 
were performed and plasma concentrations of sotalol and right atrial and right ventricular 
MAPs and ERPs were determined at steady state conditions. Statistical analysis was 
performed using a repeated measures univariate analysis with post hoc Bonferroni 
corrections.  
Results: Calculated mean steady state plasma concentrations determined by non-linear mixed 
effect modeling were 287 (range 234-339), 409 (359-458) and 543 (439-646) ng/mL for 2, 3 
and 4 mg/kg sotalol PO bid, respectively. Sotalol significantly increased the QT interval and 
ERPs, but, despite increasing plasma concentrations, higher dosages did not result in a 
progressive increase in QT interval or ERPs. Echocardiographic and other 
electrocardiographic measurements did not change significantly. MAP durations at 90% 
repolarization were not significantly different during sotalol treatment. Besides transient local 
sweating, no side effects were noted.  
Main limitations:  Small study population and variable location of MAP catheter.  
Conclusions: Sotalol at a dose of 2, 3 and 4 mg/kg body weight PO bid increases the QT 
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Introduction  
Arrhythmias, both physiological and pathological, are relatively common in horses. While 
physiological arrhythmias are mostly caused by high vagal tone, pathological arrhythmias can 
be associated with a wide range of both cardiac and non-cardiac diseases. Aside from treating 
the underlying disease, long-term antiarrhythmic therapy may be indicated. So far, a limited 
number of oral antiarrhythmic drugs are available for long-term use in horses because of low 
oral bioavailability, important side effects, high costs and a lack of knowledge and data 
supporting their use 
1-3
. In human medicine, sotalol, a potent β-blocking agent with additional 
class III antiarrhythmic properties, is frequently used for long-term oral antiarrhythmic 
therapy. Sotalol blocks both β1 and β2 receptors and has potassium channel blocking activity. 
By blocking outward potassium channels, sotalol inhibits the delayed rectifier potassium 
current, thereby slowing the repolarization phase of the cardiac tissues. Because of its dual 
action, it is often preferred over other β-blockers as treatment for ventricular tachycardia, 
symptomatic atrial fibrillation or atrial flutter, or to reduce the chances to relapse into atrial 
fibrillation 
4,5
. In dogs, sotalol has also been used experimentally to prevent recurrence of 
atrial flutter and atrial fibrillation 
4,6,7
. Due to its class III antiarrhythmic effects, sotalol 
lengthens the QT interval, monophasic action potentials (MAPs) and effective refractory 
periods (ERPs) in human and small animal cardiac tissues. Adverse reactions to sotalol are 
almost entirely accounted for by events related to β-blocker activity and QT prolongation, 
specifically torsade de pointes. The pharmacokinetic properties of a single dose of 1 mg/kg 
body weight (BW) of sotalol have been studied in horses, demonstrating a moderate absolute 
oral bioavailability of 48% in the fasted horse 
8
. The purpose of the current study was to 
determine the pharmacokinetics and electrophysiological effects of 2, 3 and 4 mg/kg BW 
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Materials and Methods 
Study design 
Six healthy warmblood horses, 3 mares and 3 geldings, with a mean ± standard deviation 
(SD) age, BW and height at the withers of 11±5 years, 532±70 kg and 160±6 cm, were used. 
All horses belonged to the teaching herd of the Faculty of Veterinary Medicine. The 
experimental protocol was approved by the Ethical Committee of the Faculty of Veterinary 
Medicine, Ghent University, Belgium (case number EC 2015/85). 
In a randomized cross-over design, the horses received 0, 2, 3 and 4 mg/kg BW sotalol orally 
twice daily for 9 days, with a dose interval τ of 12 h. A washout period of 4 weeks was 
included before starting a new study period. Sotalol was administered as 80mg tablets (Sotalol 
Sandoz)
a
 given uncrushed in 100 g of concentrates (Fibermix)
b
. Tablets could be divided in 
half to approximate correct dosage, leading to a dose (range 1000-2000mg) accuracy of 20mg 
(=1-2%). Horses receiving 0 mg/kg BW were given a sham tablet. Horses were housed in 
straw-bedded boxes and given 4-5 kg of hay, twice daily, 30 min after the medication, for ad 
libitum consumption during the day. Each morning during the study period, body temperature, 
heart rate (HR) and respiratory rates were recorded. On day 8 of each study period, non-
invasive blood pressure (NIBP) measurements, echocardiography and electrocardiography 
were performed between 2 and 3 hours (h) after administration of medication and blood 
samples were taken for determination of sotalol plasma concentrations. More specifically, 
blood was withdrawn in heparinized polyethylene tubes just before (0 h) and at 1, 1.5, 2, 3 
and 4 h after sotalol administration in the morning. On day 9 of each study period, ERPs and 
MAPs were recorded between 2 and 3 h after administration of medication and again blood 
samples were taken for determination of sotalol plasma concentrations at the same time points 
as on day 8. Observers conducting the clinical examinations, echocardiography, 
electrocardiography, NIBP, ERP and MAP recordings and data analysis were blinded to the 
dose of sotalol used.  
Sotalol plasma analysis  
Blood samples were immediately centrifuged for 10 minutes at 4000g and plasma was frozen 
at −18 °C until analysis. Sotalol plasma concentrations were measured using a validated liquid 
chromatography-tandem mass spectrometry method, as described before 
8
. Observers 
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Pharmacokinetic analysis 
Plasma concentration–time data were analyzed for each dose with a nonlinear mixed-effects 
modeling approach using first-order conditional estimation with extended least squares 
(FOCE-ELS) as an estimation method in Phoenix NLME
®c
. The structural pharmacokinetic 
model was a one-compartmental with first order absorption and elimination.  
 
dAa/dt = -Ka . Aa 
dA1/dt = Ka . Aa – Cl . C 
 
Where dAa/dt and dA1/dt are the decrease of amount of sotalol in the intestinal tract and in 
plasma, respectively, Aa and A1 are the amount of drug in the intestinal tract and in the 
plasma, respectively, ka is the absorption rate constant, Cl is the total body clearance and C is 
the plasma concentration. 
Interindividual variability was expressed using an exponential error model according to the 
equation: 
Pi = θP . e
η
Pi 
where Pi is the parameter value in the ith patient, θP is the typical value of the parameter in the 
population, and ηPi is a random variable in the ith patient with a mean of 0 and a variance of 
ω². Interindividual variability is reported as ω. Residual variability (ε), with a mean of zero 
and a variance of σ², was evaluated within the best structural pharmacokinetic model. The 
best residual error model was multiplicative: 
Cobs = Cpred . (1+ε) 
where Cobs is the observed concentration for the individual and Cpred is the model predicted 
concentration plus the error value (ε). 
Structural and error model selection was guided by visual inspection of goodness-of-fit plots 
(observed vs. predicted plasma concentrations, weighted residuals vs. predicted 
concentrations, and weighted residuals vs. time), -2 log likelihood (-2LL), Akaike information 
criterion (AIC) and Bayesian information criterion (BIC) as well as precision of the parameter 
estimates. The models were chosen based on the smaller values of -2LL, AIC and BIC, better 
precision of estimates, and superior goodness-of-fit plots. 
BW was evaluated as covariate (continuous variable). A stepwise forward-backward process 
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using a -2LL test. A decrease in -2LL with a p-value <0.01 was considered significant for 
addition and p<0.001 for exclusion of the covariate. 
Electrocardiography 
A 30-minute ECG was performed on the stabled horses in undisturbed rest on day 8 of the 
study between 2 and 3 hours after sotalol administration using a Televet100 recording 
system
d
. A modified base-apex configuration as described by Verheyen et al. (lead II) was 
used 
9
. The ECG recordings were analyzed offline using dedicated software (Televet100 
software version 6.0)
d
. QRS complex and P wave duration, and RR, PQ and QT intervals 
were measured for 10 non-consecutive cycles at least 10 minutes after the start of the 
recording. All measurements were performed on cycles with RR intervals between 1450 (42 
beats/minute) and 1650ms (37 beats/minute) to minimize influence of heart rate.  
Echocardiography 





. A modified base-apex ECG was recorded simultaneously. All 
examinations were recorded digitally and analyzed offline by a blinded observer (EchoPAC 
software version BT12)
e
. Fractional shortening, left ventricular pre-ejection period, left 
ventricular pre-ejection time and pre-ejection period to ejection time ratio were measured as 
described elsewhere at a heart rate (HR) between 32 and 40 beats/min 
8,10
. For each horse, 
three consecutive cycles were measured to calculate a mean value for each study period. 
Blood pressure  
NIBP was measured using a non-invasive, oscillometric blood pressure monitor (Cardell 
9401)
f
 with an average cuff width-to-tail circumference ratio according to the manufacturers 
guidelines 
11
. For each horse, 10 consecutive blood pressure measurements (mean arterial 
pressure) were determined to calculate a mean value for each study period.  
Effective refractory period and monophasic action potential recordings 
Under ultrasound guidance, a contact electrode MAP catheter
g
 was inserted through the right 
jugular vein into the right atrium and right ventricle. ERP measurements were performed at 
twice baseline pacing
h
 threshold and of 0.5 ms pulse duration 
12
. ERP was measured by 
delivering 10 basic stimuli (S1) with a fixed pacing interval (S1-S1) followed by an extra 
stimulus (S2) with a coupling interval below the expected refractory period. The S1-S2 
coupling interval was then increased with 8 ms increments until capture of the extra stimulus 
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potential
12-14
. Five consecutive ERP measurements were recorded at 1000 (63 BPM) and 600 
ms (100 BPM) basic pacing cycle length. Measurements were performed with the catheter in 
the right atrium (AERP) at the level of the tuberculum intervenosum or at the free wall, and in 
the right ventricle (VERP) at the level of the apex. Subsequently, right atrial and ventricular 
MAPs were recorded (Powerlab)
i
  at 1200 (50 BPM) and 600 ms (100 BPM) basic pacing 
cycle length as described by De Clercq et al 
15
. In each horse, 20 action potential durations at 
90% repolarization (APD90) were measured off-line semi-automatically (Labchart 8)
i
 by a 
blinded observer to obtain a mean value for each study period.  
Statistical analyses 
Descriptive statistics (SPSS Statistics 24)
j
, visual inspection, the Kolmogorov-Smirnov and 
Shapiro-Wilk tests were used to explore the normality of the data. Univariate analysis with 
horse as the unit of repeated measures and post hoc Bonferroni correction for multiple 
comparisons was performed to determine significant differences between different sotalol 
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Results 
Clinical parameters and adverse effects 
The sotalol tablets were well ingested by all horses. No changes in clinical parameters (heart 
rate, respiratory rate and rectal temperature) were observed during the study period (results 
not shown), but clinical parameters were only assessed once daily (8 am). Local sweating in 
the region of the head, neck and chest, was sometimes present, independent of the dose or 
plasma concentration of sotalol, at 1 to 4 hours after sotalol dosing. No other adverse effects 
were noted.  
Pharmacokinetics 
The main population pharmacokinetic (PK) parameters following either 0, 2, 3 or 4 mg/kg 
BW sotalol PO twice daily for 9 days are presented in Table 1 and Figure 1. Calculated mean  
steady state plasma concentrations (Cpss) increased proportionally with the dose and were 287 
(range 234-339), 409 (359-458) and 543 (439-646) ng/mL for 2, 3 and 4 mg/kg BW  sotalol 
PO bid, respectively. Individual peak plasma concentrations were variable between and within 
horses, ranging from 188-711 ng/mL, 448-1016 ng/mL and 542-2324 ng/mL following 2, 3 
and 4 mg/kg BW, respectively. BW was not included in the final model since it did not 
significantly improve the model fit. Visual evaluation of the population model can be found in 
Figure 2. Assuming that the PK remains linear over the range, an average Cpss of 1118 ng/mL 
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Table 1. Population pharmacokinetic parameters of sotalol from 6 warmblood horses receiving 
either of 2, 3 and 4mg/kg BW PO bid for 9 days 
Dose (mg/kg) θ tvθ 95% CI CV (%) ω 
2 
Vd/F (L/kg) 8.95 3.83 - 14.06 28.63 0.407 
Cl/F (L/h.kg) 0.58 0.48 – 0.69 9.1 0.095 
Ka (h
-1
) 1.21 0.08 – 2.34 46.91 < 0.001 
T1/2a (h) 0.57 0.04 – 1.11 46.91 / 
Tmax (h) 2.56 1.01-4.11 30.37 / 
AUC0-τ (ng.h/mL) 3438.74 2813.65 – 4063.83 9.1 / 
Cpss (ng/mL) 286.56 234.47 – 338.65 9.1 / 
Ke (h
-1
) 0.07 0.03 - 0.10 24.53 / 
T1/2el (h) 10.66 5.44 – 15.89 24.53 / 
Res. Error 0.23 0.14 – 0.33 20.07 / 
3 
Vd/F (L/kg) 9.92 5.87 – 13.97 20.43 0.235 
Cl/F (L/h.kg) 0.61 0.54 – 0.69 6.08 0.028 
Ka (h
-1
) 2.61 0.26 – 4.97 45.12 <0.001 
T1/2a (h) 0.27 0.03 – 0.50 45.12 / 
Tmax (h) 1.47 0.50 – 2.43 32.91 / 
AUC0-τ (ng.h/mL) 4903.36 4308.05 – 5498.67 6.08 / 
Cpss (ng/mL) 408.61 359.00 – 458.22 6.08 / 
Ke (h
-1
) 0.06 0.04 – 0.09 21.16 / 
T1/2el (h) 11.24 6.49 – 15.99 21.16 / 
Res. Error 0.23 0.17 – 0.29 13.46 / 
4 
Vd/F (L/kg) 9.54 59.56 – 13.12 18.8 0.469 
Cl/F (L/h.kg) 0.61 0.50 – 0.73 9.54 0.117 
Ka (h
-1
) 1.37 0.04 – 2.70 48.64 <0.001 
T1/2a (h) 0.51 0.01 – 1.00 48.64 / 
Tmax (h) 2.34 0.78 – 3.91 33.37 / 
AUC0-τ (ng.h/mL) 6514.37 5272.62 – 7756.12 9.54 / 
Cpss (ng/mL) 542.86 439.39 – 646.34 9.54 / 
Ke (h
-1
) 0.06 0.04 – 0.08 15.52 / 
T1/2el (h) 10.77 7.43 – 14.11 15.52 / 
Res. Error 0.22 0.17 – 0.26 10.77 / 
Ɵ: fixed effect parameter; tvθ: population typical value of the fixed effect parameter; 95% CI: 
95% confidence interval of the population estimate; CV%: coefficient of variation; ω: 
variance of the interindividual variability; Vd/F: volume of distribution uncorrected for oral 
bioavailability; Cl/F: total body clearance uncorrected for oral bioavailability; Ka: 
absorption rate constant; T1/2a: absorption half-life; Tmax: time to maximal plasma 
concentration; AUC0-τ: area under the plasma concentration-time curve between two dosing 
intervals at steady state, with τ the dose interval of 12 h; Cpss: plasma concentration at 
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Fig. 1: Modelled individual plasma concentration-time curves for 2, 3 and 4 mg/kg BW of 
sotalol administered PO bid to 6 warmblood horses. Each horse was sampled on day 8 and 9 














Fig. 2: Visual evaluation of the population model of sotalol after 2, 3 and 4 mg/kg body 
weight dosing to horses: scatter plot of the population dependent variable (DV), namely 
observed plasma concentration (Cobs) versus the individually predicted plasma concentration 
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Electrocardiography 
Mean ± SD of the different electrocardiographic measurements are given in Table 2. 
Compared to baseline, sotalol significantly lengthened the QT interval with 49±5 (9%, 
P=0.001), 55±11 (10%, P<0.001) and 49±11 ms (9%, P=0.001) at 2, 3 or 4 mg/kg BW sotalol 
PO bid, respectively. P wave and QRS duration and PQ and RR interval did not change 
significantly (Table 2).   
Echocardiography and NIBP 
Mean ± SD of the different echocardiographic measurements and NIBP are given in Table 2. 
Sotalol treatment did not result in significant changes compared to baseline.  
Effective refractory period 
Mean ± SD of the AERPs and VERPs are given in Table 2. Stimulation threshold at 0.5 ms 
pulse duration was <1.5 volt for all measurements. In the right atrium, there was an increase 
in mean AERP1000 of 41±9 (15%), 64±8 (23%) and 65±6 ms (23%) and in mean AERP600 
of 38±4 (15%), 34±8 (13%) and 53±5 ms (20%) in horses on 2, 3 or 4 mg/kg BW sotalol bid, 
respectively. For the right ventricle there was an increase in mean VERP1000 of 64±11 
(17%,), 88±16 (24%) and 78±12 ms (21%) and in mean VERP600 of 17±4 (6%, ), 43±6 
(15%) and 19±4 ms (7%), respectively. Despite a consistent increase in all ERPs, these 
increases were not always statistically significant (Table 2).  
Monophasic action potential 
Mean ± SD of APD90 are given in Table 2. Despite changes in mean APD90 in both the 
atrium (+59 ms ±8 (23%), +22±6 ms (9%) and +31±6 ms (12%) at 1200 ms pacing cycle 
length and +65 ms±2 (27%), +61±6 ms (26%) and +98±13 ms (48%) at 600 ms pacing cycle 
length) and the ventricle (+53±8 ms (18%), +20±6 ms (4%) and +42±11 ms (9%) at 1200 ms 
pacing cycle length and -6±11 ms (-2%), -24±5 ms (-6%) and +8±9 ms (2%) at 600 ms pacing 
cycle length) in horses on 2, 3 and 4 mg/kg BW sotalol PO bid, only the 48% increase in atrial 








153 Electrophysiological effects of sotalol in horses 
 
Table 2: Mean±SD of electrocardiographic, echocardiographic and cardiac 
electrophysiological parameters in 6 warmblood horses receiving either 0, 2, 
3 or 4 mg/kg BW sotalol PO bid for 9 days. 
  Dose sotalol (mg/kg bwt, PO, bid) 
Parameter 0 2 3 4 
Mean arterial NIBP (mmHg) 81±2 80±2 80±2 79±1 
RR (ms) 1532±15 1555±12 1553±8 1564±15 
P (ms) 141±8 141±8 162±25 143±7 
PQ (ms) 338±13 323±15 334±8 330±12 










LVIDd (cm) 11.0±0.2 11.0±0.4 11.0±0.4 11.0±0.2 
FS (%) 38±2 38±2 38±1 41±2 
PEP (ms) 91±5 97±6 89±3 91±7 
ET (ms) 464±13 497±8 462±20 480±5 
PEP/ET 0.20±0.01 0.20±0.01 0.19±0.01 0.19±0.02 







AERP (600ms) (ms) 261±5
a
 299±6 295±6 314±5
b
 














Atrial APD90 (1200ms) (ms) 254±16 313±27 276±34 285±20 
Atrial APD90 (600ms) (ms) 237±29
a
 302±26 298±21 335±13
b
 
Ventricular APD90 (1200ms) (ms) 451±160 504±15 471±14 493±23 
Ventricular APD90 (600ms) (ms) 337±23 331±16 313±18 345±13 
NIBP: noninvasive blood pressure; LVIDd: left ventricular internal diameter during diastole; 
FS: fractional shortening; PEP: pre ejection period; ET: ejection time; AERP1000 and 
AERP600: atrial effective refractory period at 1000 and 600ms basic pacing cycle length; 
VERP1000 and VERP600: ventricular effective refractory period at 1000 and 600ms basic 
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Discussion 
This study demonstrated that the pharmacokinetics of sotalol remained linear as the oral dose 
was increased from 2 to 3 and then 4 mg/kg BW resulting in steady state plasma 
concentrations of 287, 409 and 543 ng/mL, respectively. Sotalol significantly increased the 
QT intervals and ERPs, but, despite increasing plasma concentrations, higher dosages did not 
result in a progressive increase in QT intervals or ERPs. Echocardiographic measurements, 
other electrocardiographic measurements and MAP durations at 90% repolarization were not 
significantly different with sotalol treatment.  
Little is known about pharmacokinetics and pharmacodynamics of sotalol in horses. For our 
study we chose to limit the number of blood samples drawn from each horse for ethical 
concerns as well as practical feasibility. Furthermore, the use of non-linear mixed effects 
modelling allows data analysis of sparse sampling protocols. We have previously described 
the PK of sotalol after single oral or intravenous administration in the horse, using a full 
sampling protocol for each subject 
8
. It was demonstrated that there was no double absorption 
peak nor enterohepatic recirculation. The sampling strategy was based on these data, namely 
to obtain peak values.  
In a previous study in fasted horses, the absolute oral bioavailability of sotalol was moderate 
(48%) and steady state plasma concentrations of 533±141 and 806±273 ng/mL for 2 and 3 
mg/kg BW sotalol PO bid were predicted 
8
. Average steady state concentrations and the AUC 
between dosing intervals in the present study in unfasted horses were about 50% lower than 
the values predicted by the previous study. Furthermore, plasma concentrations were more 
variable, not only between horses, but also within horses on the 2 different sampling days. 
These differences illustrate the effect of feeding on the bioavailability of sotalol. The horses in 
this study had free access to straw and hay during the day, so gastrointestinal filling might 
have interfered with drug absorption. Furthermore, sotalol tablets were given in a small 
amount of grain as opposed to crushing and administration by a nasogastric tube in the 
previous study. Together with our limited blood sampling point, this makes interpretation of 
our peak and steady state concentrations difficult. . Based on the PK results of a previous 
study, measurements were performed at day 8 and 9, at which point steady-state 
concentrations should have been reached 
8
. However, feeding of hay resulted in a more 
variable absorption and therefore probably a less stable steady state concentration. This 
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would be used. Time to reach maximal plasma concentrations ranged from 1.47 to 2.56 h, 
compared to 1 h in fasted horses 
8
, indicating that also the rate of absorption is decreased 
when administering the drug with food.  
Cpss in most horses in our study were below the therapeutic plasma concentration range of 
1000-3000 ng/mL aimed for in human medicine 
16
. However, concentrations were variable 
and in 1 and 3 horses peak concentrations above 1000 ng/mL were measured at a dose of 3 
and 4 mg/kg, respectively. Significant β-blockade in humans occurs at concentrations as low 
as 800 ng/mL, while class-III activity starts from 1200 ng/mL 
17
. In dogs, an oral dose of 5 
mg/kg bwt bid, leading to Cpss of 1100–1600 ng/mL, results in β-blockade, class-III activity 
and significant QT prolongation 
3
. If, in analogy with humans and dogs, a Cpss above 1000 
ng/mL would be aimed for in horses, 8 mg/kg sotalol bid would be necessary based on the 
predictions using the population PK model. However, because of the variability in plasma 
concentrations, using such a high dose would, in some horses, lead to even higher plasma 
concentrations and possibly adverse effects. Furthermore, in the current study in horses, 2 
mg/kg BW PO bid, with steady state plasma concentrations of 400-700 ng/mL, already 
resulted in class-III activity with a significant QT prolongation of about 9%.  
The class-III action potential prolonging effect of sotalol is important for its antiarrhythmic 
action. Aside from its β-adrenergic effects, sotalol is a potent competitive inhibitor of the 
rapid component of the delayed rectifier potassium current, Ikr 
18
. Blockade of Ikr by sotalol 
results in APD and ERP lengthening in both the atria and ventricles. In the ventricles, this 
results in QT prolongation, which is visible on the surface ECG. Excessive QT prolongation, 
however, increases the risk of ventricular proarrhythmia and the development of torsade de 
pointes, a life-threatening rhythm. In the present study in horses, a significant lengthening of 
the QT interval following sotalol administration was demonstrated. An oral dose of 2, 3 and 4 
mg/kg BW sotalol bid for 8 days resulted in an increase in QT interval of 9, 10 and 9%, 
respectively. In human medicine, an increase in QT interval of 15-20% is considered 
dangerous and an indication to reduce the sotalol dose. Moreover, a cumulative daily dosage 
of 320 mg, results in a sharp increase in the risk of proarrhythmia 
16,18
. Although the QT 
lengthening in the horses in the present study remained well below 20%, care should be taken, 
especially when sotalol is administered to horses with hypokalaemia, bradycardia or renal 
disease. Furthermore, sotalol dose reduction may be required when other QT prolonging 






156 Chapter 6 
Another consequence of sotalol’s class-III action, is the lengthening of ERPs and MAP 
durations in cardiac tissues. This has been demonstrated in humans, dogs and other mammals, 
but has not been studied in horses before 
22-24
. In this study in horses there was a significant 
increase in AERP (13-23%) and VERP (6-24%) when horses received sotalol. MAP durations 
also increased but did not reach significance, probably due to the moderate day-to-day 
variability in MAP measurements caused by variability in electrode position and electrode 
contact 
15
. In our study, the MAP catheter was usually placed at the level of the tuberculum 
intervenosum in the right atrium or in the right ventricular apex under ultrasonographic 
guidance. In some horses, right atrial free wall MAPs were acquired when tuberculum 
intervenosum recordings failed. As displayed in Table 2, there was a tendency for sotalol to 
increase MAP, but variations were large. Probably the day-to-day variability in this study was 
too large and the expected difference in APD90 (10-20%) too small, leading to insufficient 
study power to obtain significant results in this small population of 6 horses. 
A significant increase in QT interval and ERP was observed following sotalol administration 
but no clear dose-response correlation was observed. In human medicine, the concentration–
effect relationship between oral sotalol and QT duration showed a linear relationship 
18,25
. 
Why an increase in dosage did not further prolong QT interval or ERP in horses, is unclear. It 
might be hypothesized that, in horses, an oral dose of 2 mg/kg bwt could already lead to the 
maximal response achievable (Emax) and that increasing the dose did not lead to increased 
antiarrhythmic properties and might not or only have limited additional advantage over the 
dose of 2 mg/kg. However, further research is needed to confirm or refute this hypothesis. 
Furthermore, differences in distribution, density and regulation of the Ikr channels have been 
demonstrated, not only between species, but also within one species 
26
. These differences in 
channels may also partly explain the variability in electrophysiological effects between our 
horses. Electrocardiographic, echocardiographic and electrophysiological measurements were 
only performed once, approximately 2-3 hours after dosing. We chose to limit the number of 
procedures for ethical concerns as well as practical feasibility and cost limitations. The single 
time point for collection coincided with the theoretical peak plasma concentrations in order to 
assess maximal effects. Since only small effects were found, it is likely that the effects would 
have been smaller after several hours, when plasma concentrations decrease. 
Aside from class III effects, sotalol also has β-blocking effects. In this study, no bradycardia 
or other β-blocking effects were observed. This was in accordance with results from our 
previous study 
8
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intervals and echocardiographic variables concerning cardiac contractility were only 
measured once. Sweating was a common side effect in both this and our previous study on 
sotalol in horses. In human medicine, diaphoresis is a known side effect of sotalol and several 
other β-blockers, but the mechanism remains to be elucidated. 
Sotalol has been empirically used in horses, at different dosages and dose intervals, but no 
studies on its clinical antiarrhythmic properties have been published before. 
Electrophysiological studies on other antiarrhythmic drugs in horses are scarce. Quinidine 
lengthened ERP and QT intervals in healthy horses 
27
. Flecainide caused a QT prolongation 
without significant effects on ERP, but proved to be associated with life-threatening 
arrhythmias and even sudden death 
14,28-30
. In human medicine and dogs, sotalol is used both 
to treat ventricular and supraventricular arrhythmias and as a prophylactic drug to prevent 
recurrence of AF at an oral dose of 1-6 mg/kg bwt bid and 2 mg/kg bwt bid, respectively 
4,22,31,32
. The present study demonstrated that sotalol has promising antiarrhythmic effects in 
horses and that, in the 6 horses included in this study, it appeared safe up to a dose of 4 mg/kg 
bid for 9 days. However, further studies assessing its pro-arrhythmic potential in large groups 
of horses are necessary in order to confirm its safety for long-term use in the horse.  
We only included healthy animals in our study. However, if sotalol is to be used to suppress 
arrhythmias or to prevent AF recurrence, its effects might be different compared to healthy 
animals. AF induces electrical remodeling leading to AF stabilization, both in humans and in 
horses 
14,33
. This remodeling might alter the electrophysiological and anti-fibrillatory effects 
of class III antiarrhythmic drugs 
34
. A strong reduction in class III effects of sotalol was 




This study has several limitations. The limited blood sampling and single time point 
measurements were mentioned before and a consequence of ethical, practical and cost 
limitations. Another limitation was the feeding of hay. Food intake and timing of food intake 
were not continuously monitored, so important differences in gastrointestinal filling were 
likely present in the individual horses. However, this protocol was chosen to mimic the 
clinical circumstances in which sotalol would be used in horses. Furthermore our study 
population was small, making it difficult for small differences to become statistically 
significant and the variability in MAP catheter location and angle between electrode and 
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the entire study period in order to monitor for torsade de pointes, was not available and 
therefore conclusions regarding the safety of sotalol should be drawn carefully. We did, 
however, record the ECG on day 8 and 9 for 2-3 hours during the electrophysiological 
measurements, at 2 hours after sotalol administration. No torsade de pointes or ventricular 
ectopic activity was recorded in our small study population.   
In conclusion, this study demonstrated that sotalol at a dose of 2, 3 and 4 mg/kg bBW bid in 
unfasted horses does lead to class-III antiarrhythmic actions. It might therefore be a useful 
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Summary 
Background: Based on its pharmacokinetic profile and electrophysiological effects in healthy 
horses, sotalol could potentially be used as a long-term oral antiarrhythmic drug in horses. 
Objectives: To evaluate the effect of sotalol on the heart rate, QT interval and atrial 
fibrillatory rate in horses with naturally-occurring chronic atrial fibrillation (AF). 
Animals: 28 horses refer  ed for transvenous electrical cardioversion (TVEC) of AF were 
treated with 2 mg/kg sotalol bid PO for three days as part of the standard treatment protocol, 
while 13 horses underwent the same protocol without sotalol administration.  
Methods: Retrospective study. Before and after sotalol or placebo treatment, the heart rate 
was measured at rest and during a standardized exercise test. The QT interval and the atrial 
fibrillation cycle length (AFCL) using tissue Doppler velocity imaging were measured at rest.  
Results: In the control group, no significant differences were found between the two 
examinations. In the sotalol group, the heart rate at rest and during exercise was significantly 
lower after sotalol treatment, while the QT interval and the AFCL measured by tissue Doppler 
increased significantly. Compared to the control group, horses in the sotalol group showed a 
significantly lower resting heart rate, lower heart rate during trot and increased QT interval 
after treatment. Cardioversion to sinus rhythm was achieved by a TVEC procedure in 25/28 
horses in the sotalol group and all horses in the control group, but the median number of 
shocks required and median energy at cardioversion were significantly lower in the sotalol 
group. 
Conclusions and clinical importance: Sotalol shows potential as an oral antiarrhythmic drug 
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Introduction 
Atrial fibrillation (AF) is a relatively common condition in horses, which often presents as so-
called ‘lone AF’ without underlying structural cardiac disease. Pharmacological or 
transvenous electrical cardioversion (TVEC) to sinus rhythm is usually recommended in 
equine athletes as AF limits performance in horses performing rigorous work.  Even at lower 
levels of exercise intensity, horses may exhibit extremely high heart rates and collapse or 
rarely sudden cardiac death has been described 
1
. The success rate for both pharmacological 
cardioversion and TVEC is very high, however, AF recurrence after treatment is a frequent 
event with an overall rate of recurrence up to 43% at 1 year after cardioversion 
2-5
. The 
pathophysiology of AF initiation and perpetuation in horses has not yet been completely 
elucidated. Factors that might be associated with AF recurrence include structural changes to 
the atrial myocardium, atrial size and stretch, short atrial effective refractory period (AERP) 
and supraventricular ectopic foci 
2,6
.  
Long-term antiarrhythmic treatment could be used to prevent AF recurrence after 
cardioversion through different mechanisms, such as increasing AERP, decreasing 
supraventricular ectopy and reducing vulnerability to AF initiation. In addition, 
antiarrhythmic treatment might also be useful to decrease the heart rate during exertion in 
horses in AF. This rate control therapy could possibly reduce the risk of collapse and sudden 
cardiac death. However, long-term oral antiarrhythmic therapy is scarce in horses. Sotalol is a 
class III antiarrhythmic drug with nonselective β-blocking activity which can be safely 
administered in horses, with an intermediate oral bioavailability 
7
. In human medicine, sotalol 
is not commonly used for cardioversion of AF, but it is frequently used as an effective drug 
for prevention of recurrence after cardioversion 
8,9
. The electrophysiological effects of sotalol 
include an increase in QT interval, a decrease in heart rate and prolongation of the 
atrioventricular nodal refractory period and PQ interval. In veterinary medicine, sotalol is the 
most commonly used long-term treatment for hemodynamically significant ventricular 
arrhythmias in dogs and cats 
10
. The pharmacokinetics and electrophysiological effects of 
sotalol hydrochloride administered orally for 9 days have been investigated in healthy horses, 
demonstrating a prolongation of QT interval, AERP and ventricular refractory period at a 
dosage of 2 mg/kg bodyweight sotalol twice daily 
11
. However, the use of sotalol has not been 
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The objectives of this study were to assess the effect of sotalol on the heart rate, QT interval 
and atrial fibrillatory rate in horses with atrial fibrillation. We hypothesized that sotalol 
administration would result in a decreased heart rate at rest and during exercise, a prolonged 
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Material and Methods 
Study set-up 
The study population consisted of 41 horses admitted for treatment of atrial fibrillation to the 
Department of Large Animal Internal Medicine at the Faculty of Veterinary Medicine, Ghent 
University. All horses were examined by an ECG at rest of at least two hours duration, an 
ECG during a lunging exercise test and echocardiography to assess the atrial fibrillatory rate. 
After these initial measurements at admission, 28 horses were treated orally with 2 mg/kg 
sotalol hydrochloride bid for three days before cardioversion. Echocardiography was repeated 
just before TVEC, after 6 doses of sotalol hydrochloride had been administered. The ECG at 
rest was repeated after at least 5 doses of sotalol, and the exercise test after at least 4 doses of 
sotalol. Measurements during sotalol treatment were always performed approximately 2-3 
hours after sotalol administration. To exclude a placebo effect, the 13 remaining horses 
underwent the same protocol without sotalol administration. TVEC was performed according 
to the procedures described previously 
4,14
. Shocks were administered under general 
anesthesia using stepwise increases of the delivered energy (150, 200, 250, 300, and 360 J) 
until cardioversion. If cardioversion was not acquired after the 360 J shock, the catheters were 
repositioned and more high energy shocks were administered. 
Measurements 
The heart rate at rest was measured from the resting ECG
a
 as an average over a 30 minute 
period. The mean QT interval was measured at rest as an average from 10 RR intervals with a 
heart rate of 35 to 45 BPM. The lunging exercise test consisted of five minutes of walk, ten 
minutes of trot, four minutes of canter and one minute of gallop. The test was terminated early 
if the horse showed an excessively high heart rate or frequent QRS complexes with an R-on-T 
morphology. The heart rate at walk, trot and canter was measured over 2 minutes, starting at 
least 1 minute after the gait transition. The heart rate during gallop was measured over the 
entire gallop phase.  
The atrial fibrillatory rate was assessed from tissue Doppler velocity curves of the atrial 
myocardial walls, as described previously 
15,16
. In brief, tissue Doppler images were acquired 
from the left atrial free wall in a right parasternal four chamber view, from the right atrial 
dorsal wall at the level of the tuberculum intervenosum in a right parasternal view and from 
the left atrial free wall in a left parasternal long axis view. The probe frequency was 1.7/3.4 
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was +16/-16 cm/s
b
. This resulted in a frame rate of > 180 fps. From each view, 10 loops with 
a long RR interval (≥2 s) were stored. Tissue Dopper velocity curves were acquired off-line 
by positioning a 5x5 mm sample volume in the atrial myocardial wall
c
. The atrial fibrillation 
cycle length (AFCL) was measured from consecutive loops with a quality score ≥ 3, until at 
least 30 AFCL were measured from each view. These measurements were then averaged to 
obtain mean AFCL from each view. All measurements were performed with the observer 
blinded to the identity of the horse and treatment status. 
Statistics 
Statistical analysis was performed using dedicated software
d
. The number of horses that were 
administered sotalol was determined using a power calculation based on a paired comparison 
with a hypothesized increase of AFCL of 5 ms and a standard deviation within the population 
of 20 ms. Based on this calculation, a sample size of 28 horses could detect a significant 
difference with a two sided α of 5% and β of 20%. Normality of the data was checked using 
visual inspection, the Kolmogorov-Smirnov test and Shapiro-Wilk test. Heart rate, QT 
interval and AFCL were compared between each group (sotalol administration or control) and 
timing (pre-treatment or post-treatment) using a univariate analysis of variance with horse as 
the unit of repeated measure, with post-hoc Bonferroni correction for multiple comparisons. 
Height, body weight, age and cardioversion data of the sotalol group were compared using an 
independent t-test for normally distributed variables or the Mann-Whitney test for non-
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Results 
The sotalol group consisted of 23 Warmbloods, 3 trotters, 1 Paint and 1 Appaloosa, with a 
mean (± standard deviation SD) height of 169 ± 7 cm, weighing 565 ± 65 kg, aged 9 ± 3 
years. The control group consisted of 12 Warmbloods and 1 trotter, with a mean (± SD) 
height of 172 ± 6 cm, weighing 605 ± 60 kg, aged 10 ± 3 years. Height, body weight and age 
were not significantly different between groups (P ≥ 0.05). During exercise, 4/13 (30.8%) 
horses in the control group showed QRS complexes with an R-on-T morphology during the 
first test compared to 3/13 horses (23.1%) during the second test (Figure 1). In the sotalol 
group, 5/21 (23.8%) horses showed QRS complexes with an R-on-T morphology both pre- 
and post-treatment. R-on-T morphology was not consistently present in the same horses 
during both exercise tests. In total, 7 horses in the sotalol group and 5 horses in the control 
group showed R-on-T morphology during either the first or the second test. Cardioversion to 
sinus rhythm was achieved by the TVEC procedure in 25/28 horses in the sotalol group and 
all horses in the control group. One of the horses that did not convert underwent a successful 
second TVEC procedure with amiodarone premedication two weeks later. Two horses in the 
sotalol group showed early recurrence of AF immediately after the procedure, during 
anesthesia or recovery. Both horses could be converted to stable sinus rhythm on the same 
day.  The median number of shocks required for cardioversion to sinus rhythm was 1 (range 
1-4) in the sotalol group, compared to 3 (1-8) in the control group (P=0.016). The median 
energy of the shock at cardioversion was 150J (150-300J) in the sotalol group, and 250J (150-
360J) in the control group (P=0.023).   
Figure 1: High heart rate and QRS complexes with an R-on-T morphology in one horse in the 
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The resting heart rate, QT interval, heart rates during exercise and AFCL pre- and post-
treatment are summarized in Table 1 for the sotalol group and the control group. Within the 
sotalol group, the resting heart rate and the heart rates during exercise decreased post-
treatment compared to pre-treatment (Figure 2), while the QT interval and the AFCL (Figure 
3) measured in the right atrium and the left atrial free wall from the left parasternal view 
increased. In the control group, no significant differences were found between the two 
examinations. Compared to the control group, horses in the sotalol group showed a lower 
resting heart rate, lower heart rate during trot and increased QT interval post-treatment.  
Table 1: Resting heart rate, QT interval, heart rates during exercise and AFCL pre- 
and post-treatment for the sotalol group (n=28) and the control group (n=13) 
  
Sotalol_pre Sotalol_post Control_pre Control_post 
Mean SD N Mean SD N Mean SD N Mean SD N 
HR rest 50a 10 28 41b 6 28 49a 7 13 49a 7 13 
QT rest 513a 41 28 560b 52 28 521a 23 13 521a 40 13 
HR walk 97a 30 21 77b 20 21 80b 17 13 79b 17 13 
HR trot 152a 37 21 114b 24 21 140a 35 13 140a 25 13 
HR canter 204a 48 21 165b 34 21 190a 30 12 183a,b 32 12 
HR gallop 246a 29 18 215b 31 18 228a,b 30 11 213b 37 11 
AFCL4CH 138 13 28 144 16 28 145 12 11 138 18 11 
AFCLRA 171a 16 28 181b 13 28 179a,b 13 13 180b 16 13 
AFCLLLA 151a 13 28 161b 16 28 158a,b 11 13 160b 13 13 
HR_rest, heart rate at rest; QT_rest, QT interval at rest; HR_walk, heart rate during walk; 
HR_trot, heart rate during trot; HR_canter, heart rate during canter; HR_gallop, heart rate 
during gallop; AFCL4CH, atrial fibrillation cycle length measured in the left atrial free wall 
from the four chamber view; AFCLRA, atrial fibrillation cycle length from the right atrial 
dorsal wall at the level of the tuberculum intervenosum in a right parasternal view; 
AFCLLLA, atrial fibrillation cycle length measured in the left atrial free wall from the left 
parasternal long-axis view. Significant differences between groups are indicated by different 


















Figure 2: Mean and standard deviation (SD) of the heart rate at rest and during the exercise 
test in the sotalol group (left) and the control group (right). 
 
 
Figure 3: Tissue Doppler velocity curve of the left atrial free wall from a left parasternal long 
axis view with moderate quality (quality score = 3, the lowest quality still included in the 
study). The biphasic atrial velocity pattern can be distinguished but there is still presence of 
artifacts, indicated by green arrows. The blue line demonstrates one atrial fibrillation cycle 
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Discussion 
This manuscript describes the effects of sotalol administered orally to horses with atrial 
fibrillation. Sotalol treatment resulted in a decrease in heart rate at rest and during exercise, a 
prolongation of the QT interval and an increase in atrial fibrillation cycle length. Significantly 
less energy was required for electrical cardioversion in the sotalol group, although 
cardioversion could not be achieved in 3/28 horses, of which 1 horses converted during a 
second TVEC procedure.  
The increased AFCL after sotalol treatment indicates slowing of the atrial activation rate. 
During atrial fibrillation, the AFCL is directly related to the AERP, although the AFCL is 
somewhat longer than the AERP due to the presence of a small excitable gap 
17
. The 
prolongation of AFCL after sotalol administration can be attributed to an increase of the 
AERP or to widening of the temporal excitable gap. A previous study in goats described a 
24% increase of the AFCL during intravenous sotalol infusion at 0.2 mg/kg/minute 
18
. This 
mainly resulted from widening of the temporal excitable gap, while the AERP remained 
stable. Sotalol administration in our study resulted in a modest increase of AFCL by 
approximately 6%. In comparison, intravenous administration of the class III antiarrhythmic 
drug amiodarone caused the AFCL to increase up to 100% in horses with naturally occurring 
chronic AF 
19
. In another study, the class I drug flecainide administered intravenously to 
horses resulted in an AFCL increase of approximately 50% 
20
.  This is in line with the 
experimental study in goats, where administration of flecainide caused an AFCL increase of 
48% 
18
. This was attributed to widening of the temporal excitable gap and could be explained 
by a reduction in the average number of fibrillation waves through the atrium. Widening of 
the excitable gap results in reduced fragmentation of wavelets and fusion of waves, which 
causes a reduction of the number of wavelets in the atria and thus an increased chance of 
cardioversion 
20
. Compared to amiodarone or flecainide, the effect of 2 mg/kg oral sotalol bid 
on AFCL was limited and cardioversion of AF using sotalol therapy alone seems unlikely in 
horses.  
The limited effects of sotalol on AFCL can be explained by several factors. First, the sotalol 
plasma concentrations were probably below the therapeutic range described in human 
medicine. Plasma concentrations were not measured in our study, but the steady state plasma 
concentration was 287 ng/mL in horses receiving 2 mg/kg body weight sotalol orally twice 
daily for 9 days, while fed hay ad libitum during the day 
7
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plasma concentrations of 1000-3000 ng/mL described in human medicine 
21
. However, the 
significant QT prolongation indicates class III activity despite the low plasma concentrations. 
The limited effects on the AFCL can also be explained by the reverse use dependence of the 
effect of sotalol on atrial refractoriness, which results in reduced class III effects at more rapid 
atrial rates 
22
. Reverse use dependence of sotalol probably limits the efficacy of sotalol against 
naturally occurring chronic atrial fibrillation with short AFCL, compared to use dependent 
drugs such as propafenone. Finally, the effect of sotalol might also be affected by electrical 
remodeling of the atrial myocardium. Reduced electrophysiological actions of class III 
antiarrhythmic agents have been described in a goat model of chronic AF, and this was 




Sotalol administration resulted in a significantly lower heart rate at rest and during exercise. A 
12-25% reduction in heart rate was obtained post-treatment. Atrial fibrillatory rate decreased 
by 6% but this was unlikely to contribute to a decrease in heart rate. Rather,  the decreased 
heart rate was caused by the β-blocking activity of sotalol. As a competitive β-blocking agent, 
sotalol administration results in lower intracellular Ca2+ concentrations in the myocardial 
cells, causing a negative chronotropic effect by decreasing atrioventricular conduction  
24
. 
Sotalol could be a possible candidate drug for rate control therapy in horses with AF in which 
cardioversion is not possible or declined by the owner. Horses with AF often show no 
performance limitations during low-level exercise but are deemed at increased risk to ride if 
the average maximal heart rate during exercise exceeds 220 BPM, as high heart rates during 
exercise have been associated with collapse 
25
. Long-term rate control therapy could possibly 
reduce the heart rate during exercise in these horses. Based on our study, it is unclear whether 
sotalol therapy could permanently reduce the exercising heart rate in horses with AF and 
whether riding a horse on sotalol is safe. First, the presence of QRS complexes with an R-on-
T morphology was not reduced after sotalol treatment, while this may be associated with 
increased risk of ventricular fibrillation 
26
. Second, sotalol is not recommended for rate 
control therapy in human medicine because of the risk of torsade de pointes and sudden 
cardiac death associated with the QT prolongation 
27
. The QT prolongation in our study was 
limited to 9%, while in human medicine an increase of 15-20% is considered dangerous. 
Excessive QT prolongation might occur in horses when sotalol therapy is combined with 
other drugs, as has been described with general anesthesia 
28
. Finally, the β-blocking activity 
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exercise. However, the negative inotropic effect is counteracted by the class III activity and 
no alterations of blood pressure have been described at rest in horses receiving sotalol 
7
. 
In human medicine, sotalol is used to maintain sinus rhythm after cardioversion of AF, 
although proarrhythmogenic effects and a small increase of all-cause mortality have been 
associated with its use 
29
. Our study did not allow to evaluate whether sotalol reduces the risk 
of AF recurrence, as this would require a long-term follow-up study in which horses are 
randomly administered sotalol hydrochloride or placebo. The effect of sotalol on the presence 
of atrial premature depolarizations during a 24-hour ECG recording after cardioversion was 
also not assessed. The day-to-day variability of the number of arrhythmias on Holter ECGs in 
horses is unknown but probably relatively high, as has been described in dogs 
30
. Therefore, a 
large group of horses would be needed to find a significant difference in the number of atrial 
premature depolarizations in treated versus untreated horses. 
The main limitation of this study is that sotalol administration was not performed in a double 
blinded study design with random assignment of horses to either the treatment group or the 
control group. Instead, all horses admitted for AF treatment in the timespan of 1 year were 
administered sotalol before TVEC. The control group consisted of horses consecutively 
admitted for AF treatment in a different calendar year, during which no sotalol was 
administered prior to treatment but the same study protocol was followed. Therefore, no 
difference between the two groups was expected. 
In conclusion, sotalol administration resulted in a decrease of the atrial activation rate and 
heart rate at rest and during exercise in horses with atrial fibrillation. Further research is 
needed to investigate the potential of sotalol as a rate control drug in ridden horses or to 
prevent AF recurrence after cardioversion. 
 Manufacturer’s Details 
a Televet 100, Engel Engineering Services GmbH, Heusenstamm, Germany 
b Vivid 7, GE Healthcare, Diegem, Belgium 
c Echopac software version 11.2, GE Healthcare, Diegem, Belgium 
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180 General Discussion 
The purpose of this PhD research was to improve both the diagnosis and the outcome of atrial 
arrhythmias in horses. By better defining ECG characteristics of APDs, we highlighted some 
of the common mistakes and contradicted some general assumptions regarding ECG 
interpretation, in order to reduce erroneous diagnoses. Furthermore we introduced HRV as a 
novel diagnostic approach to AF. We have demonstrated that HRV parameters can distinguish 
AF from SR and that HRMs automatically calculating HRV can be used to monitor for AF in 
the field. In the future this should lead to the development of an easy-to-use, equine-specific 
home monitoring tool for AF.  
In order to improve the outcome of supraventricular arrhythmias we focused on the evaluation 
of a new oral antiarrhythmic drug in horses. We studied the pharmacokinetics and –dynamics 
of sotalol and have shown a moderate oral bioavailability in horses. Furthermore we have 
demonstrated both its β-blocking activity and its capacity to lengthen the cardiac 
repolarization phase. Therefore, we can assume that antiarrhythmic activity is obtained in the 
horse. Finally, we have shown that sotalol also exerts these effects in horses with AF, possibly 
facilitating their treatment and preventing early AF recurrence.  
This chapter discusses the challenges that were faced during and the overarching results of 
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The challenges of correctly diagnosing APDs 
Electrocardiography is of increasing importance in equine cardiology and is becoming more 
widely used, not only by experienced cardiologists but also by veterinarians in the field. 
Therefore, clear guidelines on equine ECG interpretation are necessary. Correct 
differentiation between APDs and other atrial and ventricular arrhythmias is important 
because of their different clinical relevance.  
Challenge 1: Optimal Electrode Configurations and Multiple Leads 
An important factor for correctly diagnosing arrhythmias is the use of different electrode 
positions and multiple lead recordings. The configuration we used in our studies is a vertical 
modification of a classic base-apex configuration using 3 recording electrodes and one 
reference electrode. Our system, as most ECG recorders, recorded 2 leads (I and II) and 
calculated the third lead (III) 
1,2
. The advantage of this configuration is that all electrodes can 
be placed underneath a girth or a saddle. This makes dislodging during exercise less likely 
and improves skin contact, reducing the number of artifacts 
2
. In addition, this specific 
positioning of the electrodes is less subject to movement artifacts. This configuration leads to 
large QRS complexes and optimal registration of the electrical activity of the ventricle. The 
mean electrical axis of the atrium, however, is not optimally aligned, leading to smaller P 
waves compared to a classic base-apex lead 
2
.  
Many studies and many veterinarians only use one single base-apex lead for ECG recording 
and interpretation. Although this is usually sufficient to record rate and rhythm, recording 
additional leads may be very useful in specific cases. Each lead measures the cardiac 
electrical activity from a different angle, so subtle, local changes in depolarization may be 
invisible in one lead while obvious in another. Therefore, the use of multiple lead recordings 
is advised, especially when arrhythmias are expected 
3
. During exercise, however, these 
additional leads may show a lot of movement artifacts. In the configuration we used in our 
studies, lead I (right arm – left arm) showed significantly larger P wave amplitudes compared 
with lead II or III and an amplitude comparable to that of a classic base-apex configuration 
4
. 
In this first lead, the positive electrode is placed 10-15 cm behind and above the left 
olecranon, while the negative electrode is positioned 15cm right of the withers. As such, this 
lead configuration is better aligned with the electrical axis of the atrium. This configuration 
has previously been shown to produce larger P waves in a study evaluating different electrode 
configurations 
4
. The fact that the best P wave visualization is obtained in a non-classical lead, 
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ECGs. However, the optimal electrode positions to perform multiple lead or even 12-lead 
recording in horses is not known yet.  
Challenge 2: Sinus Arrhythmia and Wandering Pacemaker 
An important problem in ECG interpretation is the correct differentiation between sinus 
arrhythmia and an APD. During sinus arrhythmia, a high vagal tone leads to an irregular 
discharge of the sinus node and an irregular RR interval on the ECG. Although sinus 
arrhythmia often occurs as a progressive increase and decrease in RR interval over successive 
beats, there might be confusion with APDs, especially when multiple successive APDs are 
present. There is currently no universal agreement on electrocardiographic differentiation 
between APDs and sinus arrhythmia. Specific studies on the ECG criteria of sinus arrhythmia 
are lacking, but, while from a clinical point of view P wave morphology changes seem likely,  
it is often stated that sinus arrhythmia does not lead to changes in ECG morphology. In our 
study in Chapter 1, APDs were significantly associated with singular positive P waves and 
larger S wave deflections and were more likely to have a single positive T wave. These 
findings may help in distinguishing APDs from sinus arrhythmia.  
Wandering atrial pacemaker is another ECG finding which may lead to confusion with APDs. 
Wandering pacemaker occurs when the natural cardiac pacemaker location shifts between 
the sinoatrial node and various locations along the internodal tracks, as a result of high vagal 
tone and slow heart rate. This shifting of the pacemaker is identifiable on ECG by 
morphological changes in the P wave, a subtle change in PQ interval and an irregular PP and 
RR interval, while the QRS and T wave are not altered. Also in dogs with high vagal tone, 
wandering pacemaker is a common finding. Since, in horses, wandering atrial pacemaker is 
an ill-defined arrhythmia and its ECG characteristics are largely unknown, care should be 
taken not to confuse this arrhythmia with others. In addition, it is still under debate whether or 
not internodal tracts exist in horses.  
Challenge 3: Atrial or Ventricular Origin? 
A second, clinically important error is an incorrect differentiation between APD and VPD. In 
most cases, the difference between atrial and ventricular premature depolarizations is clear, 
but when P waves are difficult to identify or only small changes in the QRS complex are 
present, errors may occur. In contrast to what has been described in current ECG guidelines, 
we have shown that APDs, especially short-coupled APDs, may lead to changes in QRS and 
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polarity and morphology may lead to confusion, especially when the P wave is buried in the 
preceding T wave. Furthermore, when a VPD arises close to the atrioventricular node and His 
bundle (junctional VPD), the ventricular depolarization may only be slightly altered with only 
very subtle changes in QRS and T wave morphology, making differentiation between sinus, 
atrial and ventricular origin difficult and sometimes almost impossible, especially when there 
is a preceding or unidentifiable P wave. Guidelines for ECG interpretation should 
acknowledge these pitfalls in order to prevent mistakes.  
Recent techniques as a solution?  
Recently, new techniques improving the visualization of the depolarization path in the equine 
heart have been explored.  
An alternative new 12-lead ECG for horses has been proposed 
5
. Six precordial, unipolar 
leads and 3 bipolar leads were used (Table 1). This ECG configuration aims for improved 
evaluation of the cardiac depolarization. With this modified 12-lead ECG, the largest P wave 
was obtained with a unipolar precordial electrode on the left side of the thorax in the 6
st
 
intercostal space at the level of the shoulder joint 
5
. In lead V2, a significant correlation 
between the P wave duration and left atrial size was found. A significant correlation between 
the QRS amplitude in lead V1 and V2 and the QRS duration in all leads and left ventricular 
mass was also found 
5
. These results suggest that this modified 12-lead ECG should be 
explored further to assess diagnosis of  atrial or ventricular hypertrophy, as well as arrhythmia 
detection in horses. 
Table 1: Electrode placement for an alternative 12-lead ECG configuration in horses. 
Adapted from Hesselkilde et al., 2016 
5
 
LA On the top of the left scapula spine 
RA On the top of the right scapula spine 
LF A little left to the midline and just caudal to the xiphoid process 
V1 Between the dorsal part of the two descending superficial pectoral muscles 
V2 On the left side, on the ventral part of the triceps muscle 
V3 On the left side of the thorax, in the 6th intercostal space, at the level of the shoulder joint 
V4 On the left side of the thorax, in the 6th intercostal space, at the level of the elbow joint 
V5 On the right side of the thorax, in the 6th intercostal space, at the level of the elbow joint 
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From human medicine, we know that the ultimate tool to unravel intracardiac impulse 
formation and conduction is intracardiac mapping. Results from multiple precisely positioned 
multi-electrode intra-cardiac catheters allow to derive the conduction pattern. Modern 
techniques, however, use sophisticated software algorithms and a multi-electrode exploring 
catheter to obtain more accurate results in a shorter time-frame. Recently, our research group 
performed the first successful 3D electroanatomical intracardiac mappings in adult horses 
6
. 
An automatic, high resolution mapping system was successfully used to identify not only the 
electrical activation patterns from the right and left heart, but also 3D cardiac geometry in 2 
adult warmblood horses (Fig.1) 
6
. In human medicine this technique has revolutionized the 
evaluation of specific arrhythmias, the identification of diseased myocardium and ectopic foci 
origin. Subsequently, these techniques have allowed to develop new treatments based upon 
ablation of these areas. As we showed that intracardiac mapping is feasible in horses, this 
technique could become a promising and powerful tool for electrophysiological research, for 
diagnosis in clinical patients and for development of new treatment strategies such as ablation 
in horses.  
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Conclusions 
We conclude that multiple lead recordings are useful for a correct diagnosis of atrial 
dysrhythmias and that care should be taken to choose an electrode configuration with optimal 
visualization of the P wave. Further research regarding optimal electrode placement is needed, 
but placement of one or more electrodes in the region of the atria seems useful to pick up 
optimal atrial electrical activity. Furthermore, one should be aware that sinus arrhythmia and 
wandering pacemaker might be challenging arrhythmias to differentiate from APDs and even 
differentiation between near junctional VPDs and APDs can sometimes be difficult. 
Guidelines for ECG interpretation acknowledging these pitfalls might improve diagnosis. 
Furthermore, the development of new techniques for a better evaluation of the depolarization 
pattern in the heart, such as 12-lead ECG or 3D electroanatomical intracardiac mapping may 
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Is AF Really That Important?  
An important part of this dissertation focused on the diagnosis and treatment of AF. AF is a 
relatively common condition and the most important clinically significant arrhythmia in 
horses with a prevalence ranging from 0.3 to 2.5% depending on the population 
7,8
. 
Warmblood horses, which constitute the largest part of our population, are probably 
predisposed due to their large heart size. At our equine clinic, at least 40-50 sport horses are 
treated for AF each year. In racehorses, several studies have identified cardiac arrhythmias as 




The clinical importance of AF and whether or not to treat the arrhythmia are still subject for 
debate amongst equine cardiologists. The clinical consequences of AF for horses with lone 
AF or mild cardiac abnormalities are sometimes difficult to estimate. AF usually causes poor 
performance when high level exercise is expected, but when used for less intense athletic 
work, some horses are able to perform to expectations. Therefore, also the intended level of 
activity of the horse should be taken into account. Horses that remain permanently at rest do 
not need to be cardioverted. Treatment decision is based on two factors, namely the intended 
exercise level of the horse but also the underlying cardiac health. Horses with severe 
underlying cardiac disease and congestive heart failure are not candidates for cardioversion 
and treatment should be directed towards the underlying condition. Significant left atrial 
dilatation reduces the likelihood of successful cardioversion and increases the chances of 
recurrence after treatment 
11
. Left ventricular dilatation may be an indication for underlying 
myocardial damage in horses with AF and decreases the chances of return to previous level of 
performance after AF treatment 
12
. If no or limited underlying cardiac disease is present, 
treating AF may be warranted.  
During exercise AF may lead to extremely high heart rates and occasionally collapse or rarely 
even sudden death have been reported. Collapse during exercise may not only lead to injury 
of the horse but is also dangerous for riders and bystanders. Several studies have reported 
collapse in horses with AF 
13,14
 and during our studies, several horses with lone AF collapsed 
during training at home or during canter exercise on the lunge. In some of these horses no 
signs of ventricular arrhythmia were observed on the ECG immediately before the collapse 
but heart rates were very high, often exceeding 300 BPM, probably causing an important 
decrease in cardiac output and hypotension, potentially leading to collapse. For this reason  
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is greater than 220 BPM, at an intensity at, or slightly exceeding the horse’s normal 
activities
11
. In human medicine, rate control is an important part in the treatment strategy of 
AF. Under specific circumstances, horses that are not or cannot be converted might also 
benefit from rate control therapy, but little is known so far.  Rate control therapy aims to 
reduce the heart rate at rest and during exercise and might reduce the risk of exercise-related 
collapse in some horses. Our study on sotalol and AF (Chapter 7) showed a decrease in heart 
rate both at rest and during exercise when horses were under sotalol treatment. Therefore 
sotalol might be a possible candidate drug for rate control therapy in horses with AF in which 
cardioversion is not possible or not preferred by the owner. However, further research into the 
potential risks of using sotalol, especially in exercising horses, is first needed. Indeed, in 
human medicine, sotalol is currently no longer advised for rate control therapy because of the 
risk of torsade de pointes and sudden cardiac death associated with QT prolongation 
15
. Such 
a mechanism might increase the risk for collapse or even sudden death in exercising horses 
when treated with sotalol.  
Abnormal ventricular activation during exercise and/or sympathetic stimulation (stress, pain) 
has been reported in AF horses. Especially short coupling intervals or R-on-T phenomenon 
are thought to increase the risk for ventricular tachyarrhythmia 
2,11,16
. R-on-T phenomenon is  
the superposition of a QRS complex on the T wave of the preceding beat whereby an irregular 
pattern is present and the isoelectric line is lost (Fig.2).  This rhythm has been associated with 
an increased risk for sudden death in human patients 
17
. During the sotalol and AF study 
(Chapter 7), R-on-T phenomenon was observed in 30% (11/37) of the horses and 24% (12/50) 
of the exercise ECGs during canter. This is in line with a previous publication regarding 
abnormal ventricular depolarizations in horses with AF 
16
. In 3 horses, the exercise test was 
terminated because of repeated R-on-T episodes. In our study, sotalol treatment did lead to a 
significant reduction in heart rate but not in number of R-on-T episodes.  
 
Figure 2: R-on-T phenomenon (arrow) during slow canter in a horse with AF. Heart rate 
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Sudden death associated with AF and exercise-induced ventricular tachyarrhythmias, has been 
reported 
2,11
. Therefore, treatment of AF is always recommended when concurrent ventricular 
arrhythmias are observed 
11
.  
Finally, pronounced ventricular dyssynchrony during stress was observed on ultrasound in our 
clinic population, in the absence of R-on-T phenomenon. This dyssynchrony is probably the 
result of aberrant intraventricular conduction (e.g. bundle branch block) and might contribute 
to hypotension during stress or exercise. It is important to notice that this abnormality is very 
difficult to diagnose and might go unnoticed as it does not always result in R-on-T on the 
ECG.  
It can be concluded that AF is an important and relatively common condition in horses. Since 
AF leads to performance problems and dangerous ventricular tachyarrhythmia at high 
intensity exercise and timely diagnosis increases treatment success, a rapid diagnosis and 




189 General Discussion 
Do HRV and HRMs Show Real Promise as a Diagnostic Test for AF? 
The purpose of this PhD thesis was to improve diagnosis of AF by introducing a user-
friendly, easy-to-interpret, diagnostic test. HRV was chosen based on examples and 
techniques from human medicine and the reasoning that in horses, because of their slow heart 
rate, differences in HRV should be larger and AF detection therefore even easier compared to 
human patients. These assumptions were confirmed in the studies reported in Chapter 2 and 3.  
Challenge 1: Correct Heart Rate Detection 
Large differences in HRV parameters between horses in AF and horses in SR were observed, 
provided that heart rate detection was correct. Therefore the most important factor in 
developing a reliable diagnostic test based on HRV is assuring correct heart rate detection. 
This is challenging, since all marketed devices, both ECG recorders and HRMs, are prone to 
identical types of errors. First, only a few RR detection software programs or algorithms are 
adapted to the horse’s unique ECG and overcome the problem of the large T wave sensing. To 
make RR detection even more difficult; the most reliable cut off values for differentiation 
between AF and SR in our studies were obtained during walk and trot. However, during 
exercise the QRS deflection enlarges but the T wave enlarges even more and horses in AF 
rapidly reach high heart rates, even at low level exercise. This may hamper the differentiation 
between QRS complex and T wave or artifacts, even for an experienced observer and 
especially when the trace quality is suboptimal. Therefore RR detection programs specifically 
adapted to the horse’s ECG should be designed.  
A few of the possible electrode – heart rate sensor – software combinations were studied in 
Chapter 3 of this dissertation. Heart rate detection using a commercially available electrode 
belt was unreliable in our study. This belt contains two built-in electrodes and was positioned 
according to the manufacturer’s guidelines, with one electrode a the lower left thorax, behind 
the olecranon and the second one halfway the left thorax. It is possible that the elasticity of 
the belt allowed the electrodes to move with the horse movements. However, even in the 
resting horse, RR detection with the belt was unreliable. According to the manufacturer, skin 
contact could be improved by clipping the horses or moisturizing the electrodes. In our study 
horses were not clipped but electrode gel was used, which should have resulted in sufficient 
contact between the electrodes and the skin. Electrode contact is an important issue 
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Apart from the systems evaluated in our study, there are various other heart rate detection 
systems available, most of them designed for use in humans. An ideal electrode system 
ensures good skin contact and stable positioning. Using adhesive electrodes, electrode gel, 
contact glue or ensuring stable positioning under a girth or saddle, is advised. In addition, the 
heart rate sensor should use an RR detection algorithm especially designed for analyzing 
equine ECGs. Finally, if data are not stored locally, the telemetric signal should be 
sufficiently strong to send data over a long distance so that recordings during exercise or work 
are possible without signal interruptions.  
Challenge 2: Ideal Artifact Correction 
Another important consideration when using HRV is the implementation of artifact correction 
methods. Artifact correction generally omits outliers that differ to some, variable extent from 
the other RR intervals, or replaces them by interpolated values. Devices used in human 
medicine to diagnose AF based on HRV use a very low level of artifact filtering of the RR 
intervals before HRV calculations are made. However movement artifacts in humans are less 
important compared to horses and arrhythmias such as 2
nd
 degree AVB (AVB2) are 
uncommon. AVB2 is very common in horses due to their high vagal tone. Since the RR 
interval is doubled compared to the other RR intervals, an AVB leads to a large increase in 
HRV, which may hamper differentiation between AF and SR, especially when short-term 
recordings are used 
18
. Ideal artifact correction in horses should omit all movement artifacts 
and AVB2s, but still allow the natural variability in heart rate caused by AF. Based on the 
results of our study (Chapter 3) we can conclude that low level artifact correction should be 
used. The low level artifact correction algorithm removed most AVBs and markedly 
improved the diagnostic capacity of the test. The use of PP intervals instead of RR intervals 
could be useful to circumvent the problem of AVBs 
18
, but automatic P wave detection is very 
difficult in horses. Another approach for the removal of AVBs is to increase sympathic and 
decrease vagal tone by exercising or stressing the horse, which we achieved by walking or 
trotting the horse. There are many heart rate sensors and software programs available, each 
with their own artifact correction algorithm. Sometimes the level of artifact correction can be 
manually adjusted, but often unknown algorithms are used. The artifact correction level 
should be taken into account where possible.  
The difference in artifact correction methods raises questions about other studies using HRV 
in horses. Especially when HRV is used to evaluate psychophysiological parameters such as 
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artifact correction algorithms. Most of the published HRV studies do not address the level of 
artifact correction and often systems with automatic, unadjustable and unknown correction 
algorithms are used. Considerations concerning the artifact correction method should be taken 
into account when interpreting the results of such studies.  
Challenge 3: Optimal Cut Off Values 
For the studies concerning HRV in Chapter 2 and 3 we aimed at choosing cut off values with 
maximal sensitivity whilst maintaining a good specificity. Since AF is a potentially dangerous 
condition in some horses and rapid detection improves outcome, we wanted to avoid false 
negative tests. As a consequence, some false positives may arise. In human medicine, a 
worldwide discussion concerning the obligatory ECG screening of athletes, is ongoing and led 
to the publication of an international consensus statement on cardiovascular care by the 
NCAA, the National Collegiate Athletic Association, to prevent sudden death in athletes 
19
. 
These guidelines ceased recommending heart tests for all college students, due to the high 
costs of standard screening combined with a small amount of false positives, with important 
economical and personal consequences. In horses, similar concerns may arise when standard 
screening of healthy horses for AF would be recommended. In our study in Chapter 5 a mean 
sensitivity and specificity of 1 and 0.93 was obtained when using RMSSD after low level 
filtering of RR intervals. This means that, if the total riding horse population in Flanders 
(130 000 horses registered) would be screened for AF, this would result in around 8000 false 
positive test results if every horse would be screened only once. Whether the detection of the 
‘diseased’ animals justifies the costs made for the screenings and the extra costs for the ECGs 
of the false positive horses, would be an interesting discussion but is beyond the scope of this 
dissertation. Heart rate monitors are, however, increasingly being used during training for a 
wide range of equine disciplines. In these cases including the registration of heart rate 
variability, which is already available on some of these devices, could be easy and cheap. 
However, when the risk of AF development is increased, such as in horses with a dilated 
atrium, frequent APDs or moderate to severe mitral valve regurgitation, a regular screening 
could be very useful. Particularly in horses that have already been treated for AF, regular 
screening in order to detect recurrence is mandatory. Chances of AF recurrence after 
treatment are reported to be between 35 and 45%, meaning that for 100 cardioverted horses, 
monitoring for AF recurrence using HRV would result in 35-45 true positive and only 4-5 
false positives. If this screening would be feasible with a cheap, home monitoring system, cost 
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Furthermore, false positive heart rate variability test results are caused either by artifacts or 
electrical interference or by the presence of other arrhythmias, requiring further investigation. 
Using low level filtering may help decrease the number of false positives. Therefore, when 
low level filtering is used, choosing cut off values with maximal sensitivity whilst 
maintaining an acceptable level of specificity, is advised. 
The cut off values obtained in our studies had moderate to high sensitivity and specificity, 
depending on which level of filtering was used. However, some horses may have a 
surprisingly regular heart rate in AF, while others may have an irregular heart rate in SR, due 
to frequent sinus arrhythmia or premature depolarizations. It is therefore important to use 
these cut off values not as rigid values, but rather as a rough guide, or, even better, determine 
individual-specific normal values for each horse in SR. In addition, especially in case of 
doubt, one should evaluate the combination of the resting, walking and trotting values and not 
the individual data of one gait, in order to fine tune the diagnosis.  
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Conclusion 
HRV parameters can be used as a screening tool for AF (Fig.3). When a HRM is used to 
obtain RR data, care should be taken to ensure correct RR detection by optimizing electrode 
skin contact and ensuring correct and stable electrode placement. Furthermore, R wave 
detection software should preferentially be specifically designed for horses. HRV parameters 
can be obtained from several software programs, smartphone or computer applications. 
Artifact correction should be set to a low level correction, if possible. In our studies, cut off 
values for RMSSD were established, but other parameters such as SD1 and SDNN might also 
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Pharmacokinetic Profile of Sotalol in Horses 
The pharmacokinetic profile of sotalol was less favorable in horses compared to humans or 
small animals, but better than most other antiarrhythmic drugs in horses (Chapter 4 and 6).  
Both oral bioavailability and oral absorption were considerably lower in horses compared to 
other monogastric species. Although horses have a monogastric digestive system, the lower 
availability of some drugs can be attributed to their herbivorous diet. Whereas horses do not 
maintain the full spectrum of cellulolytic gastric bacteria, as do ruminants, they do maintain 
some fermentative bacteria as part of the normal stomach flora due to their ingestion of a 
large volume of herbaceous feed. Although the effect of the equine gastric flora on oral 
stability of drugs is not yet fully understood, it has been shown that some drugs bind to equine 
ingesta, slowing down their rate of absorption and limiting their bioavailability 
20
. While a 
moderate oral bioavailability of 48% was found in fasted horses, administration of the drug 
with food led to an important decrease in steady state concentrations. Studies in humans 
showed variable but rather small effects of food on bioavailability of sotalol, ranging from a 
0-20% decrease in absorption 
21-23
. In horses however, the influence of feeding on the oral 
bioavailability of drugs in general is rather variable. Most often the rate of drug absorption is 
diminished with feeding, resulting in a slower drug uptake and an increase in Tmax, whereas 
the extent of absorption strongly depends on the formulation of the drug 
24,25
. Furthermore, 
sotalol plasma concentrations in our studies in unfasted horses were variable, not only 
between horses, but also within horses on different sampling days (Chapter 6). This variability 
illustrates once more the important effect of feeding and gastrointestinal filling on the oral 
bioavailability of sotalol. Horses had free access to straw and hay during the day for the entire 
study period and daily food intake was not monitored. Gastrointestinal filling therefore 
depended on the feeding behavior of the animals and was probably variable within and 
between horses. We chose this approach in order to mimic the clinical situation in which this 
drug would be used.  
With an oral bioavailability of 48% in fasted animals, sotalol is less absorbed in horses 
compared to other species. However, if we compare its bioavailability to other antiarrhythmic 
drugs in horses, results are promising. Only quinidine, administered by nasogastric tube in 
fasted horses, has a similar oral bioavailability (48±21%) 
26
. Phenytoin has a moderate oral 
absorption of 35±8% in fasted horses and amiodarone (F=6-33%) and propranolol (F=1-32%) 
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The steady state concentrations reached in our studies were well below the therapeutic 
concentrations aimed for in humans and small animals. In human patients, β-blocking activity 
starts from a plasma concentration of 0.8 µg/mL and concentrations above 1.4 µg/mL cause 
class III antiarrhythmic effects, while in dogs β-blocking and class III action were present 
from a concentration of 0.8 µg/mL and 6 µg/mL, respectively. When such plasma 
concentrations would be aimed for in horses, predictions using the population 
pharmacokinetic model indicate that 8 mg/kg bodyweight three times daily would be 
necessary. However, significant QT and atrial and ventricular ERP lengthening were already 
present at plasma concentrations around 0.3 µg/mL, indicating class III activity even at low 
plasma concentrations. Increasing the dose did not lead to significantly higher effects. 
Therefore, it may not be necessary or beneficial to adjust the dosing schedule and increase the 
plasma concentrations. In Chapter 7 of this dissertation, β-blocking activity, more specifically 
a decrease in heart rate, was present after an oral sotalol dose of 2 mg/kg twice daily. Plasma 
concentrations were not determined in this study, but were probably around 0.3 µg/mL based 
on the results of our previous studies 
30
.  
While in human medicine a near linear relationship between sotalol plasma concentrations 
and its electrophysiological effects was observed, this was not shown in our study (Chapter 
6). Surprisingly, the electrophysiological class III effects of sotalol, namely ERP and QT 
lengthening, did not appear to increase with increasing plasma concentrations (Chapter 6). 
This may possibly be explained by differences in K
+
 channels between species. The 
configuration and duration of the cardiac action potentials vary considerably among species
31
. 
This heterogeneity reflects differences in the type and/or expression patterns of the K
+
 
channels that contribute to the genesis of the cardiac potential. The main targets for sotalol are 
receptors from the rapidly activating component of the delayed rectifier K
+
 current, the IKr. 
Molecular studies have shown that the distribution, the amount and the regulation of the IKr 
channels are species specific and may differ markedly between species and even within 
species between individuals 
31
. In humans it has been shown that these individual variations in 
K
+
 channels may be caused by genetic mutations that may lead to a genetic susceptibility to 
long QT syndrome and torsade de pointes 
32
. Few studies on the distribution and regulation of 
IKr receptors in horses have been published. Finley et al. 
33
 confirmed the expression of K
+
 
channels and the presence of a delayed rectifier K
+
 current in horse heart, while Pedersen et 
al. 
34
 reported a high homology between the human and equine genes encoding the cardiac 
voltage-gated K
+
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studies suggest that, in horses, repolarizing currents and their genetic basis are similar to other 
species, and that horses are therefore susceptible to both acquired and congenital long QT 
syndrome. It is possible that horses possess less IKr receptors compared to humans and 
maximal saturation and clinical response are already obtained at low plasma sotalol 
concentrations. It is therefore uncertain whether an additional benefit is obtained by 
increasing the dose or decreasing the dosing interval. Furthermore, in some horses a dose of 2 
mg/kg bid already led to increases in QT interval beyond the 20% deemed at increased risk in 
human patients and the effects of doses higher than 4 mg/kg twice daily were not evaluated in 
our studies. Therefore, adjusting the dosing schedule in order to obtain plasma concentrations 
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Does Sotalol have Real Antiarrhythmic Potential in Horses? 
Challenge 1: How Can we Define Antiarrhythmic Effect? 
Assessing the antiarrhythmic potential of a drug is often challenging. While we can study the 
electrophysiological effects of an antiarrhythmic drug in vitro on cardiac myocytes and in vivo 
from surface ECG traces or from intracardiac electrophysiological studies, as in Chapter 4, 6 
and 7 of this dissertation, the actual potential to reduce arrhythmia is more difficult to assess. 
When, almost 40 years ago, the dual action of sotalol was first being discovered, a variety of 
in vitro studies were necessary to explain its unique antiarrhythmic properties and the large 
array of clinical applications this offered. In the following decades, a large number of cohort 
studies in animal models and later in large groups of human patients were performed. These 
studies compared groups on placebo, sotalol or other antiarrhythmic treatments for frequency 
of arrhythmic events, ease of AF cardioversion or recurrence of AF after treatment in order to 
obtain clinical evidence for the antiarrhythmic efficacy of sotalol 
23,35-37
. In horses, such large 
clinical studies are difficult, due to the smaller study population and practical (transportation, 
lack of follow-up) and legal (competition, drug approvals and registration) consequences. 
However, future studies, confirming the antiarrhythmic benefits of sotalol in horses, are 
necessary. A large prospective study comparing the recurrence rates of horses with and 
without sotalol treatment post cardioversion could not be included in this dissertation, but 
would be a valuable future study to assess the clinical antiarrhythmic properties of sotalol.  
Studying AF susceptibility by intracardiac pacing with and without sotalol, as was recently 
done for flecainide 
38
, would also be of clinical interest. The high variability in fibrillation 
threshold between and within horses, however, complicates this type of studies.  
Antiarrhythmic Effects of Sotalol in Horses 
Our studies on the electrophysiological effects of sotalol in horses (Fig.4) have shown its 
potential as an antiarrhythmic drug in horses. Our studies have consistently shown a 
lengthening of the QT interval on the surface ECG and an increase in both atrial and 
ventricular refractory periods, illustrating a lengthening of the repolarization phase of the 
action potential in cardiac tissues and confirming the class III antiarrhythmic action of sotalol. 
While our studies did not report differences in RR interval or blood pressure in healthy 
horses, sotalol caused a significant decrease in heart rate in horses with AF, demonstrating its 
β-blocking activity. In the studies in healthy horses, RR interval was calculated as the mean of 
10 measurements, while in the horses with AF the mean resting heart rate over a time frame 
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Figure 4: Flowchart of the findings obtained from the sotalol studies in Chapter 4, 6 and 7. 
HR: heart rate; AF: atrial fibrillation; FS: fractional shortening.                                                                    
Based on the above findings, sotalol exerted identical electrophysiological effects as in 
humans and small animals and is therefore expected to have antiarrhythmic activity against 
supraventricular arrhythmias in horses. Not only does sotalol reduce the sympathetic activity 
of the heart (β-blocker), thereby possibly decreasing the likelihood of abnormal discharges 
39
, 
it also increases the refractoriness of all cardiac tissues. Therefore premature impulses will be 
less likely to initiate re-entry loops. Furthermore, according to the multiple wavelet theory, 
AF is maintained through the presence of multiple re-entry circuits meandering chaotically 
through the atria. It is obvious that, due to an increase in refractoriness, the excitable gap will 
become smaller and/or the wavelength longer. If sufficient increase in refractoriness occurs, 
the number of wavelets reduces and/or the head of the depolarization wave will hit its own 
tail, thereby terminating the re-entry loop. In human patients, the role of sotalol is well 
established for the maintenance of sinus rhythm after successful conversion of AF, but even 
when sotalol is used for the pharmacological cardioversion of AF its efficacy was comparable 






199 General Discussion 
In our hospital population of horses treated for AF, we have noticed that early recurrence was 
often preceded by a short period of atrial tachycardia. Before we used sotalol, all the horses 
that presented periods of atrial tachycardia after cardioversion relapsed into AF in the first 
days after cardioversion. Since we started using sotalol, 2 horses have shown periods of atrial 
tachycardia on Holter ECG after cardioversion. Both were treated with sotalol, both remained 
in sinus rhythm. This could mean that sotalol does effectively reduce AF recurrence, but 
currently too limited data are available to draw firm conclusions.  
Finally, because sotalol, unlike other β-blockers, prolongs the refractoriness of cardiac tissues, 
it may decrease atrioventricular conduction and, as such, the ventricular response rate in AF 
patients 
35
. Indeed, our study in AF horses on sotalol treatment (Chapter 7) has shown a 
decrease in heart rate, illustrating its rate control properties. This might be a long-term 
treatment strategy for horses refractory to AF treatment in order to control heart rate and 
decrease the risk of collapse during sympathetic stimulation such as stress or exercise. In 
human medicine, however, sotalol is no longer advised for long-term rate control treatment, 
because of the risk of torsade de pointes and sudden cardiac death due to excessive QT 
lengthening. A similar risk might apply to horses and should be further studied.  
Challenge 2: Is Sotalol Dangerous in Horses?  
The most important side effect of all class III antiarrhythmic drugs is the occurrence of 
dangerous ventricular tachycardia, especially torsade de pointes, due to excessive QT 
prolongation. Torsade de pointes is a special form of polymorphic ventricular tachycardia 
with a characteristic twisting of the QRS complex around the isoelectric baseline (Fig.5). It 
causes a sudden drop in arterial blood pressure, leading to dizziness and collapse. Most 
individual episodes of torsade de pointes in humans revert to normal sinus rhythm within a 
few seconds; however, episodes may also persist and possibly degenerate into ventricular 
fibrillation, leading to sudden death in the absence of prompt medical intervention. Most pro-
arrhythmic events occur in the beginning of treatment, therefore hospitalization in a 
monitored setting is recommended for initiation of therapy and continued until a steady state 
drug level is reached 
23
. In human medicine the risk of torsade de pointes when on long-term 
sotalol treatment is estimated between 2 and 4%, increasing with higher dosage 
23
. For other 
drugs the reported risk of torsade de pointes ranges between approximately 0.001% for 
cisapride to approximately 8% for quinidine 
32
. Furthermore, in humans a genetic 
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shown 
32
. In experimental models in dogs, proarrhythmia has also been described during 
sotalol treatment, especially in bradycardic animals 
41
.   
The risk of proarrhythmia is often estimated based on the percentage of QT prolongation. In 
human medicine, an increase in QT interval of 15-20% is considered dangerous and an 
indication to reduce the sotalol dose. Moreover, a cumulative daily dose of 320 mg, or 4 
mg/kg, results in a sharp increase in the risk of proarrhythmia 
42,43
. In all our studies in horses, 
mean QT lengthening was between 8 and 10%, independent from the dose. Standard 
deviations were rather small, meaning individual variation was limited. Although the mean 
QT lengthening in the horses in our studies remained well below 20%, some individuals 
showed QT lengthening above 20% with one horse even exceeding 30% on a dose of 2mg/kg 
bid. Plasma concentrations of this particular horse were unfortunately not available. In the 
sotalol electrophysiology study (Chapter 6), QT intervals did not increase linearly with the 
sotalol plasma concentrations and horses with high plasma concentrations did not necessarily 
have the longest QT intervals. This might be explained by a variable individual susceptibility 
to sotalol, in which the IKr receptor distribution or regulation vary between animals 
31
 or a 
genetic susceptibility for long QT syndrome, as was shown in human patients 
32
 and has been 
suggested in horses before 
34
. In horses it is not known as from which increase in QT interval, 
the risk for proarrhythmia is significantly increased and no guidelines on cut off values exist.  
 
Figure 5: Torsade de Pointes in a horse. Note the QRS complexes turning around the 
baseline. 
 
During the course of our sotalol studies, no pro-arrhythmic events were noted for doses up to 
4 mg/kg two times daily. However, no continuous ECG follow-up was available nor exercise 
tests were performed in healthy horses, so drawing conclusions regarding safety, especially in 
horses with AF, is difficult. In analogy with human medicine, when sotalol is administered to 
horses with hypokalaemia, bradycardia or renal disease or when other QT prolonging drugs 
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is recommended 
44,45
. A preliminary study described an increase in QT interval of 38% in 
healthy horses under general anaesthesia 
46
. When these horses received sotalol, QT interval 
lengthened even more, with increases above 60% in individual animals 
46
. Special care should 
thus be taken when horses receiving sotalol undergo general anaesthesia and close ECG 
monitoring or dose reduction might be recommended. Strategies to decrease the chances of 
proarrhythmia or torsade de pointes include alternative pharmacotherapy, avoiding potentially 
aggravating drug-drug interactions, bradyarrhythmias or electrolyte abnormalities, and the 
supplementation of magnesium sulphate 
47,48
.   
During the course of our studies, other, less dangerous side effects were noted. Sweating was 
regularly encountered, at all dosages and one horse experienced an episode of colic after 1 
mg/kg sotalol intravenously. Colic was never observed during the studies with oral sotalol up 
to a dose of 4 mg/kg bid. Both sweating and abdominal discomfort are known side effects in 
human medicine and can be explained by the β-blocking activity of the drug. Sweating was 
most often noted at the start of the sotalol treatment, after the first or second dose. Other side 
effects often mentioned in human medicine as a reason for discontinuation of treatment are 
fatigue, bradycardia, dyspnea, weakness and dizziness. In dogs, sotalol is usually well 
tolerated, rare side effects being lethargy, dyspnea and vomiting 
41,49,50
. Dyspnea and 
bradycardia were not observed in the horses in our studies. However, owners from horses that 
were on sotalol after cardioversion in our clinic, did occasionally report that their horse was 
noticeably calmer when receiving sotalol.  
Conclusion 
Both the β-blocking activity of sotalol and its potential to increase the cardiac repolarization 
process were demonstrated in horses. Whether these electrophysiological effects also lead to a 
reduction in supraventricular arrhythmias and decrease the chances of AF recurrence, is 
likely, but remains to be elucidated in further clinical studies. The dosages used in our studies 
seemed safe, but care should be taken when sotalol is used concurrently with other QT 
prolonging drugs, during general anaesthesia or in hemodynamically unstable situations. The 
fact that sotalol shows β-blocking and class III antiarrhythmic activity, has a moderate oral 
absorption, is a cheap drug and was well tolerated by our study population, supports its use as 
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Future Prospects 
The ultimate goal of our studies concerning HRV and AF is the development of an easy-to-
use home monitoring tool for horses at risk of AF. In order to reach this goal, improvements 
should be made. Equine specific hardware should be developed with special focus on 
electrode design and placement. Efforts should be made to optimize skin contact and 
electrode positioning and retaining the electrodes in place during exercise. Furthermore 
software for RR detection should be adapted to the ECG wave forms of the horse and an 
adequate artifact correction filter should be developed in order to remove artifacts and AVB2 
whilst maintaining the variation in RR interval due to AF. Finally, when this device is 
functional, it should be validated, both in a healthy population, a population with various 
arrhythmias and an AF population, against the gold standard of manually analyzed ECG 
tracings.  
The efficacy of sotalol to prevent AF could be experimentally assessed by measuring AF 
susceptibility by intracardiac pacing with and without sotalol. However, the large day-to-day 
variability in burst pacing induced AF in horses makes interpretation of the results difficult.    
In analogy with human medicine, the efficacy of sotalol in reducing arrhythmia should be 
clinically evaluated in large cohort studies in groups of horses with various arrhythmias. 
These types of studies in horses are complicated due to difficulties in long-term follow-up and 
issues regarding owner compliance. Furthermore, the large day-to-day variability in 
arrhythmias on ECG recordings, complicates these types of studies. Drug legislation also 
hampers the use of sotalol in sport horses. Recently, sotalol was approved by the Fédération 
Equestre International (FEI) as ‘controlled’ medication instead of ‘banned’ medication, 
meaning that it can be used in competing horses, but only outside the competition period. 
Unfortunately, high performance horses are the population in which arrhythmias, and 
especially AF, cause their most important clinical effects and thus the study group in which 
sotalol treatment would be most indicated. Hopefully the improved legislation together with 
our study results will lead to further multicenter research in a sufficiently large study 
population to clinically evaluate the antiarrhythmic potential of sotalol in horses.  




203 General Discussion 
References 
1.  Verheyen TD, A.; De Clercq, D.; Deprez, P.; Sys, S.U.; van Loon, G. Electrocardiography 
in horses - part 1: how to make a good recording. Vlaams Diergeneeskundig Tijdschrift 
2010;79:331-336. 
2.  Young L, van Loon G. Equine sports medicine and surgery : basic and clinical sciences of 
equine athlete. Editors: Kenneth W Hinchcliff, Andris J Kaneps and Ray J Geor. 2nd Edition. 
. 2013:695-744. 
3.  van Loon G. Procedure and Techniques: Electrocardiography. In: Clinical Veterinary 
Advisor: The Horse Editor: Wilson DA Elsevier Saunders, Missouri, USA 2012:716-718. 
4.  De Clercq D, Broux B, Claasen S, et al. Effect of commonly used electrode configurations 
on electrocardiographic parameters in the standing horse: Preliminary results. . Proceeding of 
the 8th ECEIM congress, Helsinki, Finland 2014. 
5.  Hesselkilde EZ, Carstensen H, Vandso B, et al. Is ECG in horses only for dysrhyshmia 
diagnosis? Introducing a new method for 12-lead ECG. . Proceeding of the 2016 ACVIM 
Forum, Denver, Colorado, USA 2016. 
6.  van Loon G, Boussy T, Vera L, et al. Successful High Resolution 3D Electroanatomical 
Cardiac Mapping in Adult Horses in Sinus Rhythm. Proceedings of the 2017 ACVIM Forum, 
National Harbor, MD, USA 2017. 
7.  Slack J, Boston RC, Soma LR, et al. Occurrence of cardiac arrhythmias in Standardbred 
racehorses. Equine veterinary journal 2015;47:398-404. 
8.  Physick-Sheard P, Kraus M, Basrur P, et al. Breed predisposition and heritability of atrial 
fibrillation in the Standardbred horse: a retrospective case-control study. Journal of veterinary 
cardiology 2014;16:173-184. 
9.  Martin BB, Reef VB, Parente EJ, et al. Causes of poor performance of horses during 
training, racing, or showing: 348 cases (1992-1996). Journal of the American veterinary 
medical association 2000;216:554-558. 
10.  van Erck E, Jakesova V, Lekeux P, et al. Field evaluation of poor performance in 
Standardbred trotters. Pferdeheilkunde 2006;22:625-631. 
11.  Reef VB, Bonagura J, Buhl R, et al. Recommendations for management of equine 
athletes with cardiovascular abnormalities. Journal of veterinary internal medicine 
2014;28:749-761. 
12.  Marr CM, Reef VB, Reimer JM, et al. An Echocardiographic Study of Atrial-Fibrillation 
in Horses - before and after Conversion to Sinus Rhythm. Journal of veterinary internal 
medicine 1995;9:336-340. 
13.  Deem DA, Fregin GF. Atrial fibrillation in horses: a review of 106 clinical cases, with 
consideration of prevalence, clinical signs, and prognosis. Journal of the American Veterinary 
Medical Association 1982;180:261-265. 
14.  Reef VB, Levitan CW, Spencer PA. Factors affecting prognosis and conversion in equine 
atrial fibrillation. Journal of veterinary internal medicine 1988;2:1-6. 
15.  January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: executive summary: a report of the American 
College of Cardiology/American Heart Association Task Force on practice guidelines and the 
Heart Rhythm Society. Circulation 2014;130:2071-2104. 
16.  Verheyen T, Decloedt A, van der Vekens N, et al. Ventricular response during lungeing 
exercise in horses with lone atrial fibrillation. Equine veterinary journal 2013;45:309-314. 
17.  Engel TR, Meister SG, Frankl WS. The "R-on-T" phenomenon: an update and critical 
review. Annals of internal medicine 1978;88:221-225. 
18.  Eggensperger BH, Schwarzwald CC. Influence of 2nd-degree AV blocks, ECG recording 




204 General Discussion 
cardiology : the official journal of the European Society of Veterinary Cardiology 
2017;19:160-174. 
19.  Hainline B, Drezner J, Baggish A, et al. Interassociation Consensus Statement on 
Cardiovascular Care of College Student-Athletes. Journal of athletic training 2016;51:344-
357. 
20.  McKellar QA, Horspool LJ. Stability of penicillin G, ampicillin, amikacin and 
oxytetracycline and their interactions with food in in vitro simulated equine gastrointestinal 
contents. Research in veterinary science 1995;58:227-231. 
21.  Antonaccio MJ, Gomoll A. Pharmacology, pharmacodynamics and pharmacokinetics of 
sotalol. The American journal of cardiology 1990;65:12A-36A 
22.  Hanyok JJ. Clinical pharmacokinetics of sotalol. The American journal of cardiology 
1993;72:19A-26A. 
23.  Anderson JL, Prystowsky EN. Sotalol: An important new antiarrhythmic. American heart 
journal 1999;137:388-409. 
24.  Bouckaert S, Voorspoels J, Vandenbossche G, et al. Effect of drug formulation and 
feeding on the pharmacokinetics of orally administered quinidine in the horse. Journal of 
veterinary pharmacology and therapeutics 1994;17:275-278. 
25.  Lakritz J, Wilson WD, Marsh AE, et al. Effects of prior feeding on pharmacokinetics and 
estimated bioavailability after oral administration of a single dose of microencapsulated 
erythromycin base in healthy foals. American journal of veterinary research 2000;61:1011-
1015. 
26.  McGuirk SM, Muir WW, Sams RA. Pharmacokinetic analysis of intravenously and orally 
administered quinidine in horses. American journal of veterinary research 1981;42:938-942. 
27.  De Clercq D, Baert K, Croubels S, et al. Evaluation of the pharmacokinetics and 
bioavailability of intravenously and orally administered amiodarone in horses. American 
journal of veterinary research 2006;67:448-454. 
28.  Kowalczyk DF, Beech J. Pharmacokinetics of Phenytoin (Diphenylhydantoin) in Horses. 
Journal of veterinary pharmacology and therapeutics 1983;6:133-140. 
29.  Muir WW, Mcguirk S. Cardiovascular Drugs - Their Pharmacology and Use in Horses. 
Veterinary clinics of North America-Equine 1987;3:37-57. 
30.  Broux B, De Clercq D, Decloedt A, et al. Pharmacokinetics of intravenously and orally 
administered sotalol hydrochloride in horses and effects on surface electrocardiogram and left 
ventricular systolic function. Veterinary journal 2016;208:60-64. 
31.  Tamargo J, Caballero R, Gomez R, et al. Pharmacology of cardiac potassium channels. 
Cardiovascular Research 2004;62:9-33. 
32.  Drew BJ, Ackerman MJ, Funk M, et al. Prevention of Torsade de Pointes in Hospital 
Settings A Scientific Statement From the American Heart Association and the American 
College of Cardiology Foundation. Circulation 2010;121:1047-1060. 
33.  Finley MR, Li Y, Hua F, et al. Expression and coassociation of ERG1, KCNQ1, and 
KCNE1 potassium channel proteins in horse heart. American journal of physiology 
2002;283:H126-138. 
34.  Pedersen PJ, Thomsen KB, Olander ER, et al. Molecular Cloning and Functional 
Expression of the Equine K+ Channel KV11.1 (Ether a Go-Go-Related/KCNH2 Gene) and 
the Regulatory Subunit KCNE2 from Equine Myocardium. PloS one 2015;10:e0138320. 
35.  Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the 
maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 
1990;82:1932-1939. 
36.  Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. The 




205 General Discussion 
37.  McNamara RL, Tamariz LJ, Segal JB, et al. Management of atrial fibrillation: review of 
the evidence for the role of pharmacologic therapy, electrical cardioversion, and 
echocardiography. Annals of internal medicine 2003;139:1018-1033. 
38.  Haugaard MM, Pehrson S, Carstensen H, et al. Antiarrhythmic and electrophysiologic 
effects of flecainide on acutely induced atrial fibrillation in healthy horses. Journal of 
veterinary internal medicine 2015;29:339-347. 
39.  Gronefeld GC, Hohnloser SH. Beta-blocker therapy in atrial fibrillation. Pacing and 
clinical electrophysiology : PACE 2003;26:1607-1612. 
40.  Milan DJ, Saul JP, Somberg JC, et al. Efficacy of Intravenous and Oral Sotalol in 
Pharmacologic Conversion of Atrial Fibrillation: A Systematic Review and Meta-Analysis. 
Cardiology 2017;136:52-60. 
41.  Miller MW, Adams R. Antiarrhythmic Agents. From: Veterinary Pharmacology and 
TherapeuticsJohn Wiley & Sons, Inc. ; 2006. 
42.  Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. British 
journal of clinical pharmacology 1998;46:307-319. 
43.  Kpaeyeh JA, Jr., Wharton JM. Sotalol. Cardiac electrophysiology clinics 2016;8:437-452. 
44.  Kehoe RF, Zheutlin TA, Dunnington CS, et al. Safety and efficacy of sotalol in patients 
with drug-refractory sustained ventricular tachyarrhythmias. The American journal of 
cardiology 1990;65:58A-66A 
45.  Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with 
arrhythmias. The American journal of cardiology 1990;65:74A-83A 
46.  A. Dufourni BB, A. Decloedt, D. De Clercq, G. van Loon. . Influence of orally 
administered sotalol hydrochloride on QT intervals at rest and in anesthetized horses after 
transvenous electrical cardioversion (TVEC). Proceedings of the 9th congress of the European 
College of Equine Internal Medicine: abstracts 2016:104-104. 
47.  Hoshino K, Ogawa K, Hishitani T, et al. Successful uses of magnesium sulfate for torsade 
de pointes in children with long QT syndrome. Pediatrics international 2006;48:112-117. 
48.  Hoshino K, Ogawa K, Hishitani T, et al. Optimal administration dosage of magnesium 
sulfate for torsade de pointes in children with long QT syndrome. Journal of the American 
college of nutrition 2004;23:497S-500S. 
49.  Meurs KM, Spier AW, Wright NA, et al. Comparison of the effects of four 
antiarrhythmic treatments for familial ventricular arrhythmias in Boxers. Journal of the 
American Veterinary Medical Association 2002;221:522-527. 





























































































208 Summary / Samenvatting 
Summary 
Atrial arrhythmias, and especially atrial fibrillation, are  rather common disorders in horses. 
Because of large differences in clinical consequences of atrial arrhythmias, a correct diagnosis 
is crucial. An early diagnosis is, especially for atrial fibrillation, important in order to improve 
treatment success and decrease the chances of recurrence. For horses at risk for atrial rhythm 
disorders, such as horses with an enlarged atrium, moderate to severe mitral valve 
regurgitation or frequent atrial premature depolarization, regular follow-up is advised. The 
standard diagnostic tool for heart rhythm disorders is electrocardiography. However, this 
technique requires specialized equipment and a certain amount of expertise, making regular 
monitoring often time consuming and expensive. Therefore a cheap and easy to use 
monitoring tool for arrhythmias, especially atrial fibrillation, would be beneficial. Although 
short-term treatment of atrial arrhythmias is often successful, long-term success rates are often 
lower. Especially for atrial fibrillation, chances of relapse after successful treatment are 
relatively high. Horses at risk for recurrence could benefit from long-term antiarrhythmic 
treatment in order to suppress premature depolarizations while reverse remodeling takes 
place. Unfortunately, limited oral antiarrhythmic drugs are available for long-term use in 
horses. Furthermore, most of these drugs have poor oral availability or may cause important 
side effects.  
The purpose of this PhD thesis was to improve the diagnostic possibilities and 
pharmacological treatment of atrial rhythm disturbances in horses.  
The thesis has been divided into 2 large parts. Part 1 aims to improve the diagnosis of atrial 
arrhythmias. First we focused on a correct diagnosis of atrial rhythm disorders, especially a 
correct differentiation between premature depolarizations of an atrial or a ventricular origin 
(Chapter 1). Therefore the morphology of atrial premature depolarizations was studied in a 
group of 30 healthy horses. Although it is usually stated that atrial premature depolarizations 
do not cause changes in the morphology of the QRS complex and the T wave, our study has 
shown that sometimes they can cause significant changes in QRS complex and T wave 
morphology. This can make differentiation with premature depolarizations of a ventricular 
origin challenging. In chapter 2 and 3 the concept of heart rate variability is introduced. Heart 
rate variability describes and quantifies the variation in heart rate. This variation is larger 
when arrhythmias are present compared to normal, regular heart rhythms. Therefore, heart 
rate variability is used in human medicine for the diagnosis of several heart rhythm disorders 
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welfare studies assessing pain, stress and fear. In Chapter 2 and 3 of this thesis, heart rate 
variability is studied as a possible diagnostic tool for atrial fibrillation in horses. In a first 
study, 6 different heart rate variability parameters were studied in 20 horses before and after 
treatment of atrial fibrillation and for certain heart rate variability parameters there was a 
strongly significant difference between horses in sinus rhythms and horses in atrial 
fibrillation. A second study evaluated whether a commercial heart rate monitor could be used 
for the diagnosis of atrial fibrillation. In 14 horses, a heart rate monitor automatically 
calculating heart rate variability was able to differentiate between horses in atrial fibrillation 
and horses in sinus rhythm. Furthermore, the effect of different artifact correction algorithms 
was studied. These algorithms are applied before heart rate variability calculations and 
therefore have an important effect on their results. Artifact corrections levels differ between 
the different software programs and can sometimes be manually adjusted. Our study has 
shown that a very low level of filtering already eliminates the most important artifacts whilst 
maintaining the variability caused by arrhythmia.   
The second part of this thesis concerns the treatment of atrial arrhythmias and especially atrial 
fibrillation. Horses with rhythm disorders sometimes require long-term antiarrhythmic 
treatment and also horses recently treated for atrial fibrillation may require treatment in order 
to decrease the chances of recurrence. However, there are currently few antiarrhythmic drugs 
available for long-term oral use in horses. In human medicine and dogs, sotalol, a β-blocker 
with additional class III antiarrhythmic properties, is frequently used for the treatment of 
arrhythmias and the prevention of atrial fibrillation recurrence. Sotalol decreases the 
excitability of the cardiac tissue and lowers heart rate and blood pressure. Sotalol is already 
empirically used in horses for the prevention of atrial fibrillation recurrence, but little is 
known about its pharmacokinetic profile and efficacy in horses. In a first study (Chapter 4), 
the pharmacokinetics and – dynamics of 1 and 2 mg/kg sotalol were studied in 6 healthy 
horses. Sotalol had a moderate oral bioavailability in fasted horses and caused a significant 
prolongation of the QT interval on surface electrocardiogram.  This indicates that sotalol also 
has antiarrhythmic activity in horses. A second study (Chapter 6) revealed the 
pharmacokinetics, pharmacodynamics and electrophysiological effects of higher doses (3 and 
4 mg/kg bid) of sotalol for a longer period (9 days). Furthermore the influence of feeding on 
the absorption of sotalol could be assessed. Sotalol caused a significant prolongation of the 
QT interval and the refractory periods, both in the atrium as in the ventricle, indicating some 
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were registered in the standing horse (Chapter 5). This technique is often used in human 
medicine to study the electrical activity in the heart and the effects of medication. It was the 
first time this technique was described in horses. Finally, in Chapter 7 the effects of sotalol in 
horses with atrial fibrillation were studied. In 41 horses with atrial fibrillation, sotalol (2 
mg/kg bid for 9 days) caused a decrease in heart rate at rest and during exercise, a 
prolongation of the QT interval on the surface electrocardiogram and a decrease in atrial 
fibrillation cycle length. This confirms that sotalol has, aside from its class III effects, also β-
blocking action in horses.  
In the last chapter of this thesis the results of the different studies are discussed and 
conclusions are drawn. Which techniques show potential to improve the diagnosis and 
treatment of atrial rhythm disorders? A first important conclusion was that good guidelines 
need to be developed in order to improve the correct interpretation of equine 
electrocardiograms. This would decrease the chance of erroneous diagnoses and treatments. 
Furthermore, heart rate variability has shown potential as a future diagnostic parameter for 
atrial fibrillation. Large differences in heart rate variability between horses in sinus rhythm 
and horses in atrial fibrillation were found. This could lead to the development of an easy-to-
use monitoring tool using automatic heart rate variability parameters for an early diagnosis of 
atrial fibrillation. However, RR detection in horses is not always reliable and needs 
improvement and an optimal artifact correction algorithm needs to be developed. As a second 
conclusion we have shown that sotalol exerts both class III antiarrhythmic action and β-
blocking activity in the horse, without any clinically significant side effects in the horses in 
our studies. However, sotalol plasma concentrations were often variable between horses and 
even within horses on different study days. Furthermore electrophysiological effects were 
often small and of minor clinical importance and treatment duration was limited to 9 days 
maximum. Finally, our small population of horses was not permanently monitored for 
proarrhythmia. For these reasons it is important that further clinical studies assess the efficacy 
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Samenvatting 
Atriale hartritmestoornissen, en in het bijzonder atriale fibrillatie zijn relatief frequent 
voorkomende aandoeningen bij het paard. Omdat de klinische implicaties van de 
verschillende mogelijke atriale ritmestoornissen sterk kunnen verschillen, is een correcte 
diagnose van groot belang. Bovendien is, voornamelijk voor atriale fibrillatie, een vroege 
diagnose belangrijk om het succes van de behandeling te verbeteren en de kans op herval te 
verminderen. Het regelmatig opvolgen van risicopaarden, zoals paarden met een vergroot 
hart, matig tot ernstige mitraalklepinsufficiëntie of een grote hoeveelheid atriale extrasystolen, 
wordt daarom steeds aangeraden. Electrocardiografie is de standaard diagnostische techniek 
voor hartritmestoornissen. Deze techniek vereist echter gespecialiseerde apparatuur en de 
nodige expertise zodat regelmatige opvolging al snel arbeidsintensief en duur wordt. Er is dus 
nood aan een eenvoudige, goedkope techniek voor het opsporen van hartritmestoornissen, en 
in het bijzonder atriale fibrillatie. Hoewel veel ritmestoornissen op korte termijn goed 
behandeld kunnen worden, is de lange termijn behandeling soms moeilijk. Vooral bij atriale 
fibrillatie is de kans op herval na een succesvolle behandeling relatief groot. Paarden met een 
verhoogd risico op herval zouden baat kunnen hebben bij een lange termijn antiaritmische 
behandeling om de kans op atriale extrasystolen te verminderen terwijl het myocard de kans 
krijgt zich te herstellen. Er zijn echter zeer weinig orale antiaritmica beschikbaar voor 
langdurig gebruik bij het paard. De meeste producten hebben een lage orale biologische 
beschikbaarheid of veroorzaken belangrijke neveneffecten bij het paard.  
Het doel van dit doctoraat is daarom het verbeteren van de diagnostische modaliteiten en de 
farmacologische behandeling van atriale hartritmestoornissen.  
De resultaten van dit doctoraat zijn opgedeeld in 2 grote delen. In deel 1 wordt de diagnose 
van atriale ritmestoornissen van naderbij bekeken. Eerst wordt aandacht besteed aan een 
correcte diagnose van atriale ritmestoornissen, meer bepaald een correcte differentiatie tussen 
premature depolarisaties van atriale en van ventriculaire oorsprong (Hoofdstuk 1). De 
morfologie van atriale premature depolarisaties werd bestudeerd in een studiegroep van 30 
paarden. Hoewel steeds werd gedacht dat atriale premature depolarisaties de morfologie van 
het QRS complex en de T golf niet veranderen, toonde deze studie aan dat er wel degelijk 
veranderingen in QRS en T golf morfologie kunnen optreden. Dit maakt de differentiatie met 
premature depolarisaties van ventriculaire origine soms moeilijk. Vervolgens wordt het begrip 
heart rate variability geïntroduceerd. Heart rate variability parameters kwantificeren de 
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een normaal, regelmatig ritme, wordt heart rate variability in de humane geneeskunde 
gebruikt voor de diagnose van verschillende hartritmestoornissen, in het bijzonder atriale 
fibrillatie. Bij het paard werd heart rate variability tot dusver voornamelijk gebruikt voor het 
bestuderen van stress en angst bij paarden. In Hoofdstuk 2 en 3 van dit doctoraat wordt het 
gebruik van heart rate variability voor de diagnose van atriale fibrillatie bij het paard 
bestudeerd. In een eerste studie werden 6 verschillende heart rate variability parameters 
bestudeerd bij 20 paarden voor en na behandeling van atriale fibrillatie. Deze studie toonde 
een sterk significant verschil in bepaalde heart rate variability parameters aan bij paarden met 
atriale fibrillatie vergeleken met gezonde paarden. In een tweede studie werd vervolgens 
gekeken of ook een commercieel beschikbare hartslagmonitor kan gebruikt worden voor de 
detectie van atriale fibrillatie. Bij 14 paarden werd aangetoond dat een hartslagmonitor die 
automatisch heart rate variability berekent, bruikbaar is voor detectie van atriale fibrillatie. 
Tevens werd het effect van verschillende artefact correctie filters bestudeerd. Deze filters zijn 
algoritmen die worden toegepast op de verkregen data betreffende hartritme, alvorens de heart 
rate variability parameters berekend worden en hebben op die manier een belangrijke invloed 
op hun resultaat. Ze zijn variabel voor de verschillende beschikbare software programma’s en 
kunnen soms handmatig ingesteld worden. Er werd aangetoond dat een zeer laag niveau van 
filtering reeds zorgt voor het verwijderen van storende artefacten terwijl de variatie verkregen 
door de aritmie grotendeels behouden werd.  
Het tweede deel van dit doctoraat behelst de behandeling van atriale ritmestoornissen en in 
het bijzonder atriale fibrillatie. Paarden met ritmestoornissen hebben soms langdurig 
medicatie nodig en ook paarden behandeld voor atriale fibrillatie kunnen nood hebben aan 
antiaritmica om de kans op herval te verlagen. Momenteel zijn er weinig antiaritmica 
beschikbaar voor langdurig, oraal gebruik bij het paard. Bij de mens en de hond wordt sotalol, 
een β-blocker met klasse III antiaritmische activiteit, frequent gebruikt voor de behandeling 
van hartritmestoornissen en de preventie van herval bij atriale fibrillatie. Sotalol vermindert 
de prikkelbaarheid van het hartweefsel en zorgt voor een verlaging van de hartslag en de 
bloeddruk. Steeds vaker wordt sotalol ook bij het paard gebruikt ter preventie van 
ritmestoornissen. Er is echter weinig informatie beschikbaar over zijn farmacologisch profiel 
en zijn werking bij het paard. In een eerste studie (Hoofdstuk 4) werd de farmacokinetiek en -
dynamiek van 1 en 2 mg/kg sotalol bij 6 gezonde paarden bestudeerd. Er werd aangetoond dat 
sotalol een matige orale beschikbaarheid heeft bij uitgevaste paarden. Bovendien veroorzaakte 




215 Summary / Samenvatting 
heeft dus ook bij het paard mogelijks antiaritmische activiteit. In Hoofdstuk 6 werden de 
farmacokinetiek en –dynamiek van hogere doseringen (3 en 4 mg/kg tweemaal daags 
gedurende 9 dagen) en de elektrofysiologische effecten van sotalol bekeken, opnieuw bij 6 
gezonde paarden. In deze studie werd ook het effect van voeding op de absorptie van sotalol 
bestudeerd. Sotalol veroorzaakte een significante verlenging van het QT interval en de 
refractaire perioden, hetgeen zijn klasse III antiaritmische werking op het hartspierweefsel 
bevestigt. Tijdens deze studie werden ook voor het eerst monofasische actiepotentialen 
(Hoofdstuk 5) geregistreerd op het staande paard. Deze techniek wordt in de humane 
geneeskunde hoofdzakelijk gebruikt om de elektrische activiteit in en het effect van medicatie 
op de verschillende hartkamers te bestuderen. In Hoofdstuk 7 tenslotte, werd het effect van 
sotalol bij paarden met atriale fibrillatie bekeken. Bij 41 paarden met atriale fibrillatie 
veroorzaakte sotalol (2 mg/kg tweemaal daags) een daling van het hartritme tijdens rust en 
inspanning, een verlenging van het QT interval op oppervlakte elektrocardiogram en een 
daling van de atriale fibrillatie cycluslengte. Sotalol heeft dus, naast de reeds aangetoonde 
klasse III effecten, ook β-block werking bij het paard.   
Tenslotte worden in de discussie van dit doctoraat de resultaten van de verschillende studies 
samengelegd en besproken. Welke conclusies kan men trekken? Welke technieken hebben 
potentieel om de diagnose en prognose van atriale ritmestoornissen te verbeteren? Vooreerst 
is het van belang goede richtlijnen op te stellen voor een correcte interpretatie van het 
elektrocardiogram bij paarden. Hierdoor kan de kans op foute diagnoses en behandelingen 
verminderd worden. Voorts is heart rate variability een veelbelovende tool om in de toekomst 
de diagnose van hartritmestoornissen, in de eerste plaats atriale fibrillatie, op een snelle en 
gemakkelijke manier te kunnen stellen. Er werden grote verschillen vastgesteld tussen 
paarden in atriale fibrillatie en paarden in sinusritme. Dit kan er in de toekomst toe leiden dat 
eenvoudige tools die gebruik maken van automatische heart rate variability berekeningen 
gebruikt zouden kunnen worden om de diagnose van atriale fibrillatie vroegtijdig te stellen. 
Echter, RR detectie is bij het paard nog niet optimaal en ook de zoektocht naar een correcte 
filter methode is lopende. Voorts werd aangetoond dat sotalol ook bij paarden over 
antiaritmisch potentieel beschikt. Onze verschillende studies toonden zowel de β-block 
werking als de klasse III antiaritmische werking van sotalol aan bij paard, zonder dat er 
klinisch belangrijke neveneffecten optraden. De bereikte plasmaconcentraties waren echter 
vaak variabel zowel tussen de verschillende dieren als binnen één dier op verschillende dagen 




216 Summary / Samenvatting 
eerder klein, de behandeling vrij kort en werd er geen permanente elektrocardiografische 
opvolging uitgevoerd. Het is daarom belangrijk dat er verdere, klinische studies gebeuren om 
de efficiëntie en veiligheid van sotalol als lange termijn antiaritmische behandeling bij het 
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En nu…. We zullen wel zien. Alles komt goed! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
